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2 ABBREVIATIONS 
 
 
 
AP1  activator protein 1 
Akt  alpha serine/threonine-protein kinase 
BDV  Borna disease virus 
CARD  caspase activation and recruitment domain 
Cardif  CARD adapter inducing interferon-beta 
CBP  cAMP-responsive-element-binding protein (CREB)-binding protein 
CNS  central nervous system 
CpG  cytidine-phosphate-guanosine 
CRM1  chromosome region maintenance 1 
dsRNA  double stranded RNA 
dsDNA  double stranded DNA 
GAF  gamma-activated factor 
GAS  gamma-activated sequence 
IFN  interferon 
IFNAR  interferon alpha receptor 
IFNGR  interferon gamma receptor 
IKK  IκB kinase 
IL  interleukin 
IPS-1  interferon-beta promoter stimulator 1 
IRAK  IL-1 receptor associated kinase 
ISG  interferon stimulated gene 
ISGF3  IFN-stimulated gene factor 3 
ISRE  interferon stimulated response element 
IRF  interferon regulatory factor 
JAK  Janus kinase 
Lgp2  probable ATP-dependent helicase 
MAVS  mitochondrial antiviral signaling protein 
MDA5  melanoma differentiation-associated gene 5 
MHC   major histocompatibility complex 
MyD88  myeloid differentiation primary response protein 88 
NFκB  nuclear factor kappa-B 
NNSV   non-segmented negative strand RNA viruses 
2’-5’OAS 2’-5’oligoadenylate synthetase 
pDC   plasmacytoid dendritic cell 
PAMP  pathogen-associated molecular patterns 
PI3K  phosphoinositide-3 kinase 
PKR  protein kinase R 
PML  promyelocytic leukemia protein 
RIG-I  retinoic acid inducible gene-I 
RNP  ribonucleoprotein 
RSV  respiratory syncytial virus 
RV  rabies virus 
ssRNA  single strand RNA 
SOCS  suppressor of cytokine signaling 
STAT  signal transducer and activator of transcription 
TANK  TRAF-associated NFκB kinase 
TBK-1  TANK-binding kinase 1 
TIR  Toll/IL-1 receptor 
TNF  tumour necrosis factor 
TRAF  TNF Receptor-Associated Factor 
TRIF  Toll/IL-1R domain-containing adaptor inducing IFN-β 
ABBREVIATIONS 
TRAM  TRIF-related adaptor molecule 
TLR  Toll-like receptor 
VISA  virus-induced signaling adaptor 
VSV  vesicular stomatitis virus 
VV  vaccinia virus 
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3 INTRODUCTION 
 
3.1 Rabies virus (RV) 
 
3.1.1 Pathogenicity 
 
 Rabies belongs to one of the oldest known infectious diseases. Already first 
known reports that are found in Egyptian writings, associate the consequences of a 
contact with a “mad” dog with an acute, progressive and incurable encephalitis 
(Hemachudha et al., 2002; Rupprecht et al., 2002). Rabies is caused by a neurotropic 
RNA virus of the Rhabdoviridae family, genus Lyssavirus. Bites and scratches represent 
the typical transmission route of this virus. After initial replication in the peripheral wound 
RV is transported in a retrograde way to the central nervous system (CNS). The 
incubation period ranges from one week to several months. The neurotropism of RV is 
at least in part caused by the use of several receptors in the CNS to facilitate virus entry 
into neurons: the neural cell adhesion molecule (Thoulouze et al., 1998), the p75 
neurotrophin receptor (p75NTR) (Tuffereau et al., 2001; Tuffereau et al., 1998) and the 
acetylcholine receptor (Lentz et al., 1982). Rabies is characterized by very little neuronal 
pathology and mild CNS inflammation. Clinical presentation of rabies disease comes in 
two major forms, encephalitic (furious) and paralytic (dumb), but there is no clear 
explanation for this dysfunction of the limbic system. Direct post exposure treatment 
encompasses wound treatment, vaccine administration and inoculation of rabies virus 
neutralizing immunoglobulins. This treatment is mostly effective when applied in time, 
but once first symptoms of rabies encephalitis occur, the outcome of the disease is 
almost always fatal and the management of the disease is palliative (Jackson et al., 
2003; Warrell and Warrell, 2004).  
Recent studies addressed the question of rabies virus pathogenicity and 
activation of the immune response system. Inflammation and production of neutralizing 
antibodies, which depend on B lymphocytes and CD4+ T cells, are crucial for clearance 
of RV from the CNS (Dietzschold, 1993; Dietzschold et al., 1992; Perry and Lodmell, 
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1991; Hooper et al., 1998). As mature neurons are relatively resistant to either cell or 
cytokine induced cytolysis, the role of cytotoxic CD8+ T cells in RV clearance is 
considered minor. A major role can be attributed to cytokine production, mainly IFN-γ. 
Infection with pathogenic rabies virus results in chemokine production and infiltration of 
the CNS by mononuclear inflammatory cells (NK cells, T and B lymphocytes). In contrast 
to attenuated RV, no or only slight activation of innate immune response was observed 
(Wang et al., 2005; Nakamichi et al., 2004; Nakamichi et al., 2005; Lafon, 2005). 
Additionally, rabies virus infected neurons retain their integrity but upregulate FasL 
levels, and  thereby induce apoptosis of T-cells, shortly after the T-cells cross the blood-
brain barrier (Baloul et al., 2004).  
3.1.2 Virus structure and replication 
  
RV is a prototypic virus of the Mononegavirales order, the nonsegmented 
negative strand RNA viruses (NNSV). The RV single strand RNA genome of 
approximately 12 kb is packed into a bullet-shaped, enveloped virion of approximately 
250 nm length and 70 nm width (Figure 1). It comprises five genes encoding 
nucleoprotein (N), phosphoprotein (P), matrixprotein (M), glycoprotein (G) and 
polymerase (L) in the order 3’-N-P-M-G-L-5’. All the five proteins are structural proteins 
of the virion and are essential for virus replication and spread. 
The viral RNA is tightly enwrapped by the highly conserved nucleoprotein N and 
forms a ribonucleoprotein complex (RNP). The RNP serves as a template for the viral 
polymerase which is composed of a large catalytic subunit L and the polymerase 
cofactor P. The RNA synthesis, as well as the whole replication cycle, takes place in the 
cytoplasm. In the transcription mode, a gradient of monocistronic, capped- and 
polyadenylated mRNAs is synthesized using genomic RNA (“-“strand) as a template. In 
this model, the mRNAs of the genes most proximal to the 3’ leader promoter are the 
most abundant ones and the amounts of transcribed mRNAs decrease with the distance 
from the leader sequence due to dissociation of the polymerase at the gene borders. In 
the replication mode, full-length RNA is synthesized on both genomic and anti-genomic 
RNPs (Finke and Conzelmann, 2005). Recombinant rabies viruses can be created from 
cDNA using a “reverse genetics” approach. Co-transfection of cDNA expressing the viral 
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anti-genome RNA together with support plasmids expressing rabies virus N, P and L 
proteins into stable cell line constitutively expressing T7 polymerase (BSR T7/5 cells) 
results in production of virus particles (Schnell et al., 1994; Buchholz et al., 1999). 
Recovery of genetically engineered rabies viruses with defined changes in the genome 
greatly facilitated studies on the different steps of virus life cycle, the determination of 
viral pathogenicity factors, and on host-virus interactions. The balance between RNP 
replication and mRNA transcription is regulated by the structural matrix (M) protein 
(Finke and Conzelmann, 2003; Finke et al., 2003). The M protein, together with the 
spike glycoprotein (G), is also essential for budding of virus particles. The glycoprotein is 
the major viral antigen and pathogenicity factor of rabies virus, as shown by in vivo 
experiments, involving the exchange of glycoproteins of pathogenic and attenuated 
rabies virus. Infection with a chimeric virus expressing G protein of an apathogenic strain 
resulted in abortive infection and increased the survival rate of infected mice (Morimoto 
et al., 2000; Finke and Conzelmann, 2005). High levels of glycoprotein expression were 
found to be responsible for induction of apoptosis in infected cells. Downregulation of G 
expression prevents induction of apoptosis and correlated with virus pathogenicity 
(Faber et al., 2002; Morimoto et al., 1999; Prehaud et al., 2003; Sarmento et al., 2005). 
 
nucleoprotein N
phosphoprotein P
matrix protein M
glycoprotein G
viral polymerase L
A
B
 
Figure 1.  (A) Rabies virus belongs to the 
family of ssRNA enveloped viruses. The 
mature rabies virion has a characteristic 
bullet-shaped appearance of 
approximately 80 nm diameter and length 
varying between 130 and 300 nm. (B) 
Negative stranded RNA genome codes for 
5 proteins; nucleoprotein (N),  
phosphoprotein (P), matrix protein (M), 
glycoprotein (G) and polymerase (L).  All 
proteins are structural and can be divided 
in two groups: a helical ribonucleoprotein 
core (RNP) and a surrounding envelope. 
In the RNP, the viral RNA-dependent RNA 
polymerase consisting of P and L proteins 
is associated with genomic RNA tightly 
encased by the N protein. The M protein is 
associated with both RNP and the 
envelope and plays an essential role in 
rabies virus assembly. The rabies 
glycoprotein forms approximately 400 
trimeric spikes which are tightly arranged 
on the surface of the virus.  
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3.1.3 Multifunctional phosphoprotein P 
 
 The multifunctional phosphoprotein P (Figure 2) of rabies virus is an essential and 
structural protein of 297 aa length.  P-deficient rabies viruses are unable to replicate 
(Shoji et al., 2004; Finke et al., 2004), as RV P serves as a scaffold protein that 
associates with nucleoprotein (N) and the large subunit of vital polymerase (L). The very 
N-terminus of RV P is responsible for binding to L protein, with the 19 first aa residues 
being crucial for interaction with the C-terminal domain of L protein (Chenik et al., 1998). 
There are two independent N-binding domains, one is localized between aa 69-177 and 
most likely serves as a chaperone for non-RNA bound N protein, and the other in the C-
terminus (aa 268-297) is essential for transcriptional activity of P (Chenik et al., 1994; 
Jacob et al., 2001; Mavrakis et al., 2004; Mavrakis et al., 2003). Phosphoprotein P 
contains an internal homooligomerization domain (Gigant et al., 2000; Jacob et al., 
2001), and is phosphorylated by two cellular kinases, a yet uncharacterized rabies virus 
protein kinase (RVPK) and four isomers of protein kinase C (PKC) (Gupta et al., 2000). 
An interaction between RV P and a component of the microtubular transport complex, 
the dynein light chain (LC8), was suggested to play a role in axonal retrograde transport 
of rabies virus (Raux et al., 2000; Jacob et al., 2000). The importance of this interaction 
in rabies pathogenicity has been questioned by in vivo experiments, where mutant 
viruses that lack the LC8 binding domain were only slightly attenuated in comparison to 
wt virus (Mebatsion, 2001; Rasalingam et al., 2005).  
Several N-terminally truncated forms of RV P are generated due to a ribosomal 
leaky scanning mechanism (Chenik et al., 1995; Eriguchi et al., 2002). Three such forms 
are detectable in RV SAD L16 infected cells, starting form internal AUG methionine 
codons in position 20, 53 and 83, called P2, P3 and P4, respectively. As shown by our 
own work, mutant SAD L16 with these internal methionine residues substituted by 
isoleucine (SAD P1xxx) could be “rescued” and showed only minor growth attenuation. 
This indicated that mutated P protein is able to support viral transcription and replication 
and the presence of truncated P forms is not required for RV replication in vitro (Brzózka 
et al., 2005).  
 In the present work, a new important role of RV P, namely in antagonizing specific 
functions of the innate immune system has been discovered. As RV is a rather slowly 
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replicating virus, it is of immense importance that initial steps of RV infection remain 
undetected by the host. This work shows that RV P is able to inhibit the activation of a 
crucial transcription factor IRF3 (interferon regulatory factor 3), thereby preventing 
production of interferon beta (IFN-β), a cytokine that regulates antiviral response 
(Brzózka et al., 2005). In addition, I was able to show that RV P is also responsible for 
preventing IFN-α/β as well as IFN-γ signaling. This occurrs by binding of RV P to 
activated STATs (signal transducer and activator of transcription) and their retention in 
the cytoplasm (Brzózka et al., 2006). Whereas 10 aa residues of the C-terminal domain 
of P were crucial for counteracting Janus kinase - signal transducer and activator of 
transcription (JAK-STAT) signaling, another stretch of 10 aa (residues 176-186)  was 
required for inhibition of IFN-β production (unpublished data). This demonstrates that P 
possesses two independent functions in antagonizing the IFN system.  
phosphorylation: RVPK at S(63) and S(64)
PKC isomers phosphorylate 
at S(162), S(210), and S(271)PP P P P
L binding site aa 1-19
N binding sites aa 69-177 and aa 268-297
LC8 binding site aa 143-149
IRF3 inhibition domain aa 171-186 (this work)
STAT binding domain aa 288-293 (this work)
PML binding domain aa 288-293
homooligomerization domain aa 52-189
191
69 177 268 297
189
143-149
223 297
52
1 297
171-186
288-293
P2 (aa 20-297)
P3 (aa 53-297)
P4 (aa 83-297)
 
Figure 2. Schematic representation of rabies virus phosphoprotein domains. For 
abbreviations and detailed description see text. P2, P3 and P4 stand for short 
forms of RV P created by ribosomal leaky scanning mechanism from internal AUG 
codons.  
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3.2 Innate immunity: Interferon 
 
Innate immunity is the first line of defense against viral and bacterial pathogens. 
Already minutes and hours after invasion of the pathogen can decide on the infection 
outcome – death or survival. For many years this response was underestimated and 
presented as basic and crude, in contrast to the sophisticated adaptive immunity. The 
situation changed during the last decade, with the discovery of a range of specialized 
receptors recognizing foreign molecular patterns and links to the adaptive immunity. 
Activation of the innate immune response plays a crucial role in the survival of the 
infected host as it occurs long before adaptive immune responses like activation of 
cytotoxic T lymphocytes or production of neutralizing antibodies. 
 
3.2.1 Interferon induction 
 
Among cytokines involved in innate immune response, interferons play a key role 
in turning on mechanisms of antiviral defense and shaping adaptive immunity. Initially 
discovered by Isaacs and Lindenmann in 1957, the family of interferons consists of two 
main types. The mammalian type I interferons comprise a single IFN-β protein and a 
dozen of IFN-α  subtypes, whereas type II interferon consists of the single IFN-γ. Time 
course and interferon types produced vary between cell types. Whereas IFN-γ is 
produced only by certain cells like natural killer (NK) cells, CD4+ and CD8+ T 
lymphocytes, macrophages and also by neurons, the type I interferons can be produced 
by most cell types. A specialized cell type, the plasmacytoid dendritic cell (pDC) is the 
main source of IFN-α in humans. 
Invading pathogens can be recognized by extracellular or intracellular receptors. 
Membrane associated Toll-like receptors (TLRs) recognize a broad spectrum of 
pathogen-associated molecular patterns (PAMPs), presented by viruses and bacteria. 
TLRs are present on many cell types, in particular on hematopoetic cells. There are 
twelve different TLRs, all of them capable to trigger nuclear factor κB-dependent (NFκB-
dependent) cytokine production. Among them, five TLRs are known to stimulate type I 
11 
    INTRODUCTION 
IFN synthesis (TLR3/4 and TLR7/8/9). Recognition of PAMPs leading to IFN production 
also occurs by poorly characterized cytoplasmic receptors, expressed in virtually all cell 
types. The transcription of interferon genes is tightly controlled by latent transcription 
factors, which are activated upon PAMPs recognition by TLRs or the cytoplasmic 
receptors (Figure 3).  
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Figure 3. Cellular pathways, leading to interferon production. TLR7/9 signaling is a 
MyD88- and IRAK1-dependent pathway in which IRF7 is phosphorylated by IRAK1 
in a complex with TRAF6 and IRAK4. TLR3/4 utilize a MyD88-independent 
pathway for downstream signaling. The adaptor protein TRIF binds to TLR3 upon 
ligand recognition. Recruitment of TBK1 or IKKε leads to phosphorylation of IRF3 
or IRF7, their nuclear translocation and activation of type I IFN production. Binding 
of double stranded RNA (dsRNA)  to the cytoplasmic receptors RIG-I and MDA5 
triggers downstream signals via a CARD-domain containing protein IPS-1 (MAVS, 
VISA, Cardif). This complex recruits TBK1 or IKKε and leads to phosphorylation of 
IRF3 (for details and abbreviations see text). 
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3.2.1.1 Interferon regulatory factors 
 
Two transcription factors are essential for IFN-α/β gene expression, the 
ubiquitously expressed interferon regulatory factor 3 (IRF3) that regulates expression of 
IFN-β (Yoneyama et al., 2002; Yoneyama et al., 1998; Lin et al., 1998; Lin et al., 1999), 
and interferon regulatory factor 7 (IRF7) that controls production of IFN-α subtypes. 
IRF7 is constitutively expressed only in pDCs (plasmacytoid dendritic cells), in other 
cells its expression is induced by IFN (Lin et al., 2000; Honda et al., 2005b; Caillaud et 
al., 2005; Civas et al., 2005; Sato et al., 2000). A hallmark of the IRF family is a highly 
conserved N-terminal DNA binding domain with five characteristic tryptophan repeats 
and a C-terminal serine-rich domain. IRF3 and IRF7 form hetero- or homodimers after 
activation by phosphorylation. Following nuclear translocation, IRFs bind to the IFN 
promoter sequence and transcription of IFN is switched on. Other transcription factors 
and co-factors like AP1, NFκB, or p300/CBP (directly interacting with IRFs) further 
support activation of IFN-β mRNA transcription. As shown recently, the critical IRF3 
phosphorylation step is executed by kinases of the IKK family (see below). Activation by 
phosphorylation of IRF3 and IRF7 seems to be a bottle neck where all the pathways 
leading to IFN production converge.  
IKKε (called also IKK-i) and TBK1 (known also as NAK) are members of the IKK 
kinase family and show structural and functional homology to IKKα and IKKβ which are 
involved in activation of NFκB. The overall topology of the kinase domain, a leucine 
zipper-like domain and helix-loop-helix region is similar within the family. Although both 
IKKε and TBK1 are able to activate NFκB via Ser36 phosphorylation of IκBα, their main 
and essential role is activation of IRF3 and IRF7 factors (Kishore et al., 2002; Huynh et 
al., 2002; Tojima et al., 2000; Sharma et al., 2003; Fitzgerald et al., 2003a). In contrast 
to the constitutively and ubiquitously expressed TBK1, IKKε is mostly expressed in 
immune cells, but can be also induced in other cells. Both kinases phosphorylate 
specific C-terminal serine residues of IRF3 and IRF7, leading to IRF dimerization, 
nuclear translocation and transcriptional activation of IFN-α/β promoters. Whereas the 
critical phosphorylation residues of IRF7 are still unclear (tenOever et al., 2004; Caillaud 
et al., 2005), IRF3 phosphorylation was extensively studied in the past years. A 
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sequential activation model has been proposed, in which a serine cluster containing 
Ser396 and Ser402 is phosphorylated by TBK1 or IKKε (Servant et al., 2001; tenOever 
et al., 2004; Qin et al., 2003). This leads to partial IRF3 activation and structural 
rearrangement that allows phosphorylation of Ser385/386 residues in another serine 
cluster, by TBK1 or an additional kinase, that has not yet been characterized. This step 
is essential for dimerization and transcriptional activity of IRF3 (Mori et al., 2004).  
3.2.1.2 RNA-helicase pathway 
 
 Two molecules, retinoic acid inducible gene-I protein (RIG-I) and melanoma 
differentiation associated gene 5 protein (MDA5, known also as Helicard) serve as 
intracellular receptors binding dsRNA and activate IFN production (Yoneyama et al., 
2004; Andrejeva et al., 2004). RIG-I and MDA5 are cytosolic proteins containing a 
carboxy-terminal DExD/H-box RNA helicase domain and two amino-terminal caspase 
activation and recruitment domains (CARDs). After binding of dsRNA an adaptor protein 
IPS-1 (interferon-beta promoter stimulator 1, called also MAVS (mitochondrial antiviral 
signaling protein), VISA (virus-induced signaling adaptor) or Cardif (CARD adapter 
inducing interferon beta)) associates with both RIG-I and MDA5 via CARD domain 
interactions (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005). 
The mitochondrial localization of IPS-1 is essential for its function in IFN induction  
providing an interesting link between innate immunity and mitochondria (Seth et al., 
2005). Most probably, the adaptor protein binds to the activated form of the RNA-
helicases, as suggested by co-precipitation of RIG-I ∆C and MDA5 ∆C lacking the auto-
inhibitory carboxy-terminal domains. Thus, virus infection stimulates formation of 
macromolecular signaling complexes consisting of RIG-I or MDA5 with IPS-1 and 
signaling effectors. However, the recruitment of IRF3 and TBK-1 or IKKε  to this complex 
remains still to be clarified.  
A negative feedback regulator of this pathway has been described recently 
(Yoneyama et al., 2005; Rothenfusser et al., 2005). Like RIG-I and MDA5, the Lgp2 
(probable ATP-dependent helicase) protein binds dsRNA with a very high affinity 
competing with RIG-I/MDA5 for dsRNA. However, Lgp2 lacks the caspase recruitment 
and activation domain. It is therefore not able to signal downstream via CARD-adaptor 
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protein and functions as a negative regulator of IFN induction by preventing recognition 
of viral RNA. 
 
3.2.1.3 Toll-like receptor 3 pathway 
 
Toll like receptor 3 is involved in recognition of exogenous dsRNA. In contrast to 
other members of the TLR family, downstream signal transduction of this receptor is 
independent of the common Toll/IL-1 receptor (TIR) - adaptor protein MyD88 (myeloid 
differentiation primary response protein 88). Stimulation of macrophages and DCs with 
dsRNA leads to recruitment of an adaptor protein called TRIF (Toll/IL-1R domain-
containing adaptor inducing IFN-β)  to the receptor via TIR domain interactions (Sato et 
al., 2003; Yamamoto et al., 2003a). TRIF binds to TBK-1 and IKKε, which in turn 
phosphorylate IRF3 to activate IFN-β production. Similarly to TLR3, signaling of TLR4 
after binding to its ligand LPS (lipopolysaccharide), involves TRIF, but requires an 
additional adaptor protein called TRAM (TRIF-related adaptor molecule) (Yamamoto et 
al., 2003b; Fitzgerald et al., 2003b). Recent studies revealed a pivotal role of TNF 
receptor associated factor-3 (TRAF3) in TLR signaling. Two groups showed that TRAF3 
binds to both TRIF and the kinases TBK1 and IKKε (Oganesyan et al., 2006; Hacker et 
al., 2006). The indispensability of TRAF3 in TLR3 signaling suggests that it serves as a 
critical link between the TLR adaptor proteins and effector kinases, enabling 
downstream signaling. Moreover, TRAF3-deficient fibroblasts were defective in IFN 
production in response to vesicular stomatitis virus (VSV) infection, indicating a role of 
TRAF3 in TLR-independent virus recognition as well. Another member of the TRAF 
family proteins, TRAF1, is a negative regulator of the TLR3 signaling pathway. Caspase-
dependent cleavage of TRAF1, somehow induced by TRIF adapter protein, leads to 
interaction of TRIF and TRAF1 that results in inhibition of TRIF-dependent signaling (Su 
et al., 2006). 
A two-step mechanism of IRF3 activation in TLR3 downstream signaling was 
suggested. Full phosphorylation and activation of IRF3 can be achieved if the 
phosphoinositide-3 kinase-alpha serine/threonine-protein kinase (PI3K-Akt) pathway is 
also activated (Sarkar et al., 2004; Spiegel et al., 2005). According to the model, IRF3 is 
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not completely phosphorylated when PI3K is not recruited to TLR3 after dsRNA binding, 
or the pathway is blocked by a specific inhibitor. IRF3 then translocates to the nucleus 
but is unable to drive transcription from the target gene promoter. Most probably, a 
nuclear kinase different from TBK-1 or IKKε can phosphorylate IRF3 at the crucial S386 
residue, allowing its dimerization and DNA binding. 
 
3.2.1.4 Toll-like receptor 7/9 pathway 
 
Plasmacytoid dendritic cells are responsible for production of the majority of type I 
IFN in vivo in response to viral infection. This is due to constitutive expression of TLR7 
and TLR9 on the cell surface, and of IRF7 in pDCs (Asselin-Paturel and Trinchieri, 
2005). Ligand recognition by TLR7 (ssRNA and synthetic imidazoquinoline-like 
molecules like imiquimod (R-837) and resiquimod (R-848)) or TLR9 (unmethylated 
2’deoxyribo (cytidine-phosphate-guanosine) (CpG) DNA motifs) activates signaling 
dependent on the TIR adaptor MyD88. An important observation regarding TLR3, TLR7 
and TLR8 ligand recognition was made by Kariko et al., indicating that innate recognition 
of RNA is dependent on its modifications, like methylation, which allows selective 
recognition of foreign RNA. Unlike cytoplasmic receptors, TLRs do not require viral 
infection of the cells. The association of MyD88 with TLR7/9 recruits members of IL-1 
receptor associated kinase (IRAK) family, namely IRAK4 and IRAK1, that bind to TRAF6 
and IRF7 (Kawai et al., 2004; Honda et al., 2004). This leads to phosphorylation of IRF7 
by IRAK1 and its translocation to the nucleus to induce production of IFN-α (Uematsu et 
al., 2005). In contrast to other cell types, pDCs are able to produce abundant amounts of 
interferon upon TLR7/9 activation. As shown by Honda et al., in pDCs but not in 
conventional dendritic cells, ligand bound TLR9 is retained for long periods in the 
endosomal vesicles, instead of being rapidly transferred to lysosomal vesicles (Honda et 
al., 2005a). This retention was suggested to be responsible for the robust type I 
interferon production by stimulated pDCs.  
Better understanding of the TLR7/9 signaling mechanisms included also the 
discovery of a whole range of negative regulators, that target different signaling 
components (reviewed in (Liew et al., 2005)). For example, IRAKM, an inactive member 
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of the IRAK kinase family proteins, is induced upon TLR stimulation and prevents 
IRAK4/IRAK1 dissociation from the MyD88 complex, disrupting downstream signaling 
(Kobayashi et al., 2002). SIGIRR (single immunoglobulin interleukin-1 receptor-related 
protein), a constitutively expressed protein is down-regulated when TLR signaling is 
activated, binds to both TRAF6 and IRAK, thereby preventing their actions (Wald et al., 
2003). Interestingly, also SOCS (suppressors of cytokine signaling), described initially as 
inhibitors of the JAK-STAT pathway (see below), are also upregulated by TLR ligands 
independent of type I interferon signaling. Although the mechanism of TLR inhibition by 
different SOCS are still unclear, recent publication linked SOCS1 mediated degradation 
of the adaptor Mal to inhibition of TLR2/4 signaling (Kinjyo et al., 2002; Mansell et al., 
2006). 
 
3.2.2 Interferon signaling 
  
IFN-α/β and IFN-γ act through binding to ubiquitous receptors, the IFNAR 
(interferon alpha receptor) and the IFNGR (interferon gamma receptor), respectively. 
IFN-α/β binding to IFNAR results in receptor dimerization and recruitment of two Janus 
kinases (JAK) that activate themselves by autophosphorylation. Those activated JAKs, 
directly or indirectly turn on several downstream signaling pathways (for review see 
(Platanias, 2005; Aaronson and Horvath, 2002)). The classical and best known signaling 
pathway involves phosphorylation of STAT1 and STAT2 at the specific tyrosine 
residues, Y701 and Y689, respectively. Activated STATs form a heteromeric complex 
containing STAT1, STAT2, and IRF9 (p48), also known as IFN-stimulated gene factor 3 
(ISGF3), that enters the nucleus, where it binds to a specific DNA sequence called ISRE 
(IFN-stimulated response element) initiating gene transcription of interferon stimulated 
genes (Figure 4). STAT dephosphorylation by nuclear phosphatases causes disruption 
of the complex and allows STAT reshuttling to the cytoplasm via the CRM1 
(chromosome region maintenance 1) export system. Inactivated STATs are shuttling 
between cytoplasm and nucleus with different speed (for review see (Vinkemeier, 2004; 
Meyer and Vinkemeier, 2004)). In contrast to IFN-α/β inducing predominantly STAT1/2 
heterodimers, IFN-γ signaling involves tyrosine phosphorylation of only STAT1 by the 
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kinases JAK1 and JAK2. This leads to the formation of STAT1 homodimers, also known 
as gamma-activated factor (GAF). GAF drives the expression of genes that are 
controlled by another specific promoter sequence, the gamma activated sequences 
(GAS). Tyrosine phosphorylation of STATs is the crucial step in IFN mediated signaling, 
required for nuclear import of the STAT complexes. Serine phosphorylation of STAT1 in 
the S727 position may further augment transcriptional activity via enhancement of STAT 
interaction with other co-activators, like p300/CBP. S727 phosphorylation is performed 
for example by protein kinase Cδ (PKCδ) kinase, the activation of which is PI3K 
dependent (Deb et al., 2003; Uddin et al., 2002).  
One group of IFN-induced proteins acts as feedback inhibitors. It is the family of 
suppressors of cytokine signaling (SOCS) consisting of eight members (SOCS1-SOCS7 
and CIS) that share structural homologies like a central SH2 domain and C-terminal 
SOCS box (for review see (Ilangumaran et al., 2004; Larsen and Ropke, 2002)). There 
are several mechanisms by which SOCS inhibit JAK-STAT signaling. They can bind 
through their SH2-domain to the phoshotyrosine residues of the target protein, either 
preventing JAK kinase activity or STAT recruitment to the IFN receptor. Another 
possibility is SOCS-box mediated proteosomal degradation of the target protein. 
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Figure 4. Downstream signaling of interferons. IFN binding to the receptor recruits 
members of the Janus kinase family, that cross-activate each other STAT proteins, 
by phosphorylation. Tyrosine phosphorylated STAT homo- and heterodimers 
translocate to the nucleus and drive transcription of interferon stimulatory genes 
controlled by the ISRE and GAS sequences (see text for details and 
abbreviations).  
 
3.2.3 Interferon stimulated genes (ISGs) 
 
Proteins produced upon IFN stimulation include several that exert direct antiviral 
effects, and others, which cause indirect antiviral effects (for review see (Sarkar and 
Sen, 2004; Samuel, 2001; Nisole et al., 2005)). For example, 2’-5’oligoadenylase (2’-5’ 
OAS) is an enzyme capable to synthesize short adenosine oligomers that bind latent 
endoribonuclease and cause its dimerization and activation. Active RNase L degrades 
cellular and viral RNA. Protein kinase R (PKR) is a kinase capable of binding dsRNA 
and phosphorylating the  α subunit  of the translation initiation factor 2 (eIF2), thus 
causing inhibition of translation. Similarly, a family of P56 proteins blocks different steps 
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of the translation initiation process by binding to the eIF3 factor. Mechanisms of actions 
of other antiviral proteins like Mx protein, PML (promyelocytic leukemia protein) or p200 
protein family are less clear and may involve direct interaction with viral proteins.  
The second group of IFN stimulated genes consists of proteins like IRF7, which  
control transcription of the “late” IFN-α genes, or other members of the IFN induction 
and signaling pathways. Increasing their levels sensitizes non-infected cells to invading 
pathogens. Additionally, a number of cytokines and chemokines are produced as a 
result of IFN signaling, stimulating mechanisms of the adaptive immune response, 
including expression of major histocompatibility complex (MHC), activation of NK cells, 
maturation of dendritic cells, and promoting the T helper cell response toward Th1 type. 
Taken together, all described mechanisms restrict virus replication and amplification via 
different means. 
 
 
3.3 Viral inhibitors of innate immune respose 
 
3.3.1 Viral inhibitors of IFN induction 
  
A broad range of viral IFN inhibitors, employing different strategies in 
counteracting IFN induction, was described in the past years (extensively reviewed in 
(Hengel et al., 2005; Conzelmann, 2005; Weber et al., 2004; Katze et al., 2002)). To 
date however, only two inhibitors of TBK-1 mediated phosphorylation of IRF3 have been 
reported, borna disease virus phosphoprotein (BDV P) and rabies virus P (RV P) 
(Unterstab et al., 2005; Brzózka et al., 2005). Another member of the negative strand 
RNA viruses family, Ebola virus, encodes a protein VP35, that blocks IRF3 activation 
upstream of TBK1 and IKKε (Basler et al., 2000; Basler et al., 2003; Conzelmann, 2005). 
Similarly, nonstructural proteins (NS) of respiratory syncytial virus are responsible for 
IRF3 pathway inhibition, whereas NFκB and AP1 activation remains unchanged 
(Bossert et al., 2003; Spann et al., 2005; Spann et al., 2004).  
Viruses like influenza and vaccinia virus encode for proteins (NS1 and E3L, 
respectively) that directly bind to dsRNA, therefore preventing its recognition by 
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intracellular receptors. Andrejeva and colleagues identified MDA5 as a direct target of 
the V proteins from Paramyxovirinae (Andrejeva et al., 2004). V proteins are expressed 
from the multicistronic P genes Paramyxovirinae by a RNA editing mechanism. P and V 
have therefore identical N-terminal domains, and specific C-terminal domains. The V 
proteins bind specifically to the RNA helicase MDA5, but not to RIG-I, reducing its IFN-β 
inducing activity. A serine protease NS3/4A of hepatitis C virus (HCV) causes specific 
proteolysis of two adaptor proteins, TRIF (Ferreon et al., 2005; Li et al., 2005) and IPS-1 
(Meylan et al., 2005), therefore disabling both TLR3 and RIG-I signaling pathways. The 
vaccinia virus A46R protein is so far the only TIR-domain containing viral protein that 
targets TLR adaptor molecules, like MyD88, TRAM and TRIF disrupting IRF3 activation 
(Stack et al., 2005).  
With regard to IFN gene expression, also other, unspecific mechanism like 
general transcription shut down, can be interpreted as developed by viruses to evade 
host innate immunity. For example, the matrix protein (M) of vesicular stomatitis virus 
(VSV) is responsible for blocking cellular mRNA transcription by binding to a TFIID RNA 
polymerase II cofactor (RNAPII) and influencing nuclear transport (Ahmed and Lyles, 
1998; Ahmed et al., 2003; Yuan et al., 2001; Yuan et al., 1998). Similarly, the small 
nonstructural protein (NSs) of Rift Valley Fever virus targets another component of the 
RNAPII  complex, namely the p44 subunit of the TFIIH factor (Le May et al., 2004).  
 
3.3.2 Viral inhibitors of interferon signaling 
 
The mechanism of RV P used to interrupt IFN JAK-STAT signaling is unique 
among viruses. The related Paramyxoviruses have developed a variety of “weapons of 
STAT destruction”, which are in particular represented by their V proteins. The V 
proteins of most Rubulaviruses bind to DDB1 (DNA-damage binding protein 1) which is 
a component of E3 ubiquitin ligase complexes, and then mediate proteasomal 
degradation of either STAT1 or STAT2 (Andrejeva et al., 2002; Parisien et al., 2002a; 
Parisien et al., 2002b; Ulane et al., 2005). Depletion of STAT2 or STAT1 from the 
infected cells is therefore responsible for the interference with IFNGR and/or IFNAR 
signaling. Notably, degradation of either STAT requires the presence of the other STAT, 
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suggesting that hetero(di)meric complexes of STAT1 and STAT2 with V, are required for 
degradation. The common direct and/or primary binding partner of some V proteins 
appears to be STAT2. Importantly, however, activation or tyrosine phosphorylation of 
STAT is not required for binding and degradation. The V proteins of other 
Paramyxoviruses like measles virus of the Morbillivirus genus or Nipah and Hendra 
viruses (Henipavirus genus) do not lead to degradation of STATs, but rather interfere 
with signaling mechanisms. Henipaviruses prevent phosphorylation of STATs and 
sequester STAT1 and STAT2 in high molecular mass complexes in the cytoplasm 
(Rodriguez et al., 2002; Rodriguez and Horvath, 2004; Rodriguez et al., 2004; Shaw et 
al., 2004). The V protein of Measles virus (Morbillivirus genus) V protein, was reported to 
co-precipitate with STAT1, STAT2, STAT3, and IRF-9, to bind to the IFNAR, and to 
recruit STATs to viral inclusion bodies, while Tyr-phosphorylation of STATs was possible 
(Palosaari et al., 2003; Takeuchi et al., 2003; Yokota et al., 2003). The phenotypes 
caused by measles virus V and RV P seem to be therefore similar. However, measles 
virus applies a constitutive binding of STATs, and RV P binding occurs on demand when 
STATs are activated (this thesis).  
Also the large poxviruses developed mechanisms of IFN signaling inhibition. They 
express soluble chemokine receptors (so called viroceptors), like B8R of vaccinia virus, 
that intercept soluble, secreted IFN and prevent its binding to the cellular receptors 
(Alcami and Smith, 1996). Other sophisticated mechanisms discovered among large 
DNA-viruses, are for example STAT2 degradation by m27 protein of CMV 
(cytomegalovirus) (Zimmermann et al., 2005) or  the VH1 phosphatase of vaccinia virus 
that is able to bind and dephosphorylate STAT1 (Najarro et al., 2001). 
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4 DISCUSSION 
 
 
4.1 Inhibition of interferon beta induction by Rabies virus P protein 
 
In this study I present evidence that the phosphoprotein P of RV is an IFN 
antagonist preventing transcription of IFN β in virus-infected cells (Brzózka et al, 2005). 
An initial finding pointing towards a role of RV P in inhibition of host cell defense was the 
observation that SAD eGFP-P rabies virus was severely attenuated in certain tissue 
cultures ((Finke et al., 2004) and Finke, unpublished data). This recombinant virus 
expressed an eGFP-P fusion protein instead of wt RV P. Attenuation of SAD eGFP-P 
was correlated with the presence of interferon and antiviral response in infected cells, in 
contrast to the wt SAD L16. Further experiments indicated that reduced levels of the P 
fusion protein and a possible impediment of P functions by the N-terminal eGFP moiety 
might be responsible for the inability of GFP-P to prevent IFN production. Indeed, from 
previous experiments involving complementation of P-deficient RV it appears that the 
eGFP-P fusion protein has severe defects in mRNA synthesis, while virus formation is 
well supported.  
To further address the role of the essential phosphoprotein P in rabies virus 
growth, I generated a recombinant virus, SAD ∆PLP, expressing very little of the RV P 
protein (Brzózka et al., 2005). Since viruses lacking the P gene are not able to replicate, 
I applied a reverse genetics approach making use of the typical transcription gradient of 
non-segmented negative strand viruses (NNSV) (Conzelmann, 2004). The P gene was 
moved from its second position in the genome (that allows abundant transcription of P 
mRNAs), to the most 3’-end promoter distal position. This resulted in a large decrease in 
the levels of P mRNA and of P protein in cells infected with SAD ∆PLP, in comparison to 
wt SAD L16. SAD ∆PLP was only slightly attenuated in the BSR T7/5 cell line  with titers 
approximately one log10 lower than wt, but failed to replicate in HEp-2 cells. This failure 
was due to efficient transcription of IFN-β upon virus infection. A substantial contribution 
of the M protein to preventing IFN production, as observed for VSV (Ferran and Lucas-
Lenard, 1997), could be excluded since RV replicons encoding N, P, and L did not 
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induce any IFN response. IFN-induction by SAD ∆PLP was correlated with the activation 
of the critical transcription factor IRF3, whereas the activity of NFκB and AP1 was 
unchanged (Figure 5A). This demonstrated that the IRF3 activation pathway is 
specifically blocked in wt RV-infected cells. In the presence of sufficient P, IRF3 is not 
activated as demonstrated by the absence of Ser386 phosphorylation and dimerization. 
In contrast, in SAD ∆PLP-infected cells the crucial phosphorylation at the Ser386 
residue of IRF3 dimers was readily detectable, and IRF3-dependent expression of 
reporter genes was possible (Figure 5B).  
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Figure 5. Rabies virus targets the IRF3 activation pathway. (A) Vero cells were 
transfected with reporter plasmids harbouring the firefly luciferase gene under the 
control of different promoter sequences and were infected at a MOI of 3 with SAD 
L16 or SAD ∆PLP. Cell lysates were analyzed using the Dual Luciferase reporter 
system (Promega) for luciferase activity at 48 hrs p.i.. In contrast to SAD ∆PLP, 
SAD L16 is able to prevent expression of firefly luciferase from plasmids containing 
the IFN-β promoter (p125luc) and the IRF3 binding site (p55C1Bluc). In contrast to 
IRF3, the activity of NFκB and AP-1 is not further stimulated in SAD ∆PLP-infected 
cells as compared to SAD L16-infected cells. Incubation of cells with tumor 
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necrosis factor α (TNF-α) was used as a positive control. (B) Dimerization and Ser 
386-phosphorylation of IRF3 in SAD ∆PLP infected cells. HEp-2 cells were infected 
at a MOI of 1 and cell extracts were analyzed at 24 hrs p.i. by native PAGE and 
Western blot. In contrast to SAD  ∆PLP, wt SAD L16 prevents IRF3 dimerization 
and phosphorylation on Ser386. The same cell lysates were analyzed by SDS 
PAGE for expression of viral N and P proteins. 
 
Since overexpression of TBK-1 in cells is sufficient for IRF3 activation, I have 
utilized this feature to demonstrate that the IFN inhibitory activity of RV involves a 
downstream target within the IRF3 activation pathway. In cotransfection experiments, 
RV P alone was sufficient for inhibiting TBK1-mediated IRF3 activation and IFN-β 
production (Figure 6A). The same effect was observed after expression of RV P with 
upstream TBK1 activators, TRIF and IPS-1. On the other hand, RV P did not show any 
effect on constitutively active forms of both IRF3 and IRF7 (unpublished data). Analysis 
by native PAGE revealed that P precludes not only the critical S386 phosphorylation of 
IRF3 by TBK-1, but also phosphorylation of IRF7, such that IRF dimerization and 
transcriptional activity is prevented (Figure 6B and C). A direct interaction between P 
and IRF3 or IRF7 is unlikely, since in co-immunoprecipitation experiments no 
association has been observed (data not shown). 
 
 
 
Figure 6. Expression of P is sufficient to prevent TBK1 mediated IFN-β induction. 
(A) HEK 293 cells were transfected with expression plasmids encoding the 
indicated genes and reporter plasmids harboring the firefly luciferase gene under 
control of the IFN-β promoter (p125luc). Luciferase activities were determined at 48 
hrs p.t. using the Dual Luciferase reporter system (Promega). Co-transfection of P, 
but not of P∆162-186 with TBK1 almost completely inhibited activation of the IFN-β 
promoter. (B) Expression of RV P inhibits TBK1-mediated dimerization of 
endogenous IRF3 and phosphorylation of IRF3 in position Ser386. Cell extracts 
were harvested 24 hrs p.t. of TBK1 or TBK1 and P-encoding plasmids and were 
analyzed by native PAGE and Western blot. Expression of Flag-tagged TBK1 (fl-
TBK1), RV P and β-actin was confirmed by SDS PAGE and Western blot analysis 
of the same lysates. (C) Expression of RV P inhibits TBK1-mediated 
phosphorylation of IRF7. Cell extracts were harvested 24 hrs p.t. of indicated 
expression plasmids. The typical mobility shift of IRF7, that could be detected upon 
phosphorylation of IRF7 by TBK1, was not detected in the presence of RV P. 
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To address which domains of RV P are important for inhibition of IFN induction, I 
generated a series of P mutants. An internal RV P domain consisting of the aa residues 171-186 
was found to be required since a corresponding deletion mutant failed in preventing TBK1-
mediated interferon induction (Fig. 6A). Notably, as found later, this domain is not important for 
another function of P, namely, the binding of STATs and inhibition of JAK-STAT signaling (see 
below). Therefore, inhibition of IFN induction is a function of RV P that is independent and 
genetically separable form other functions of P. In future experiments, such P mutants lacking 
individual functions will be used to identify the cellular interaction partners of P and to dissect the 
mechanisms of inhibition. 
In case of IFN induction, a potential molecular target of P is TRAF3, which was very 
recently described as part of the protein complex in which IRF-3 is phosphorylated by TBK-1. 
Binding of P to TRAF3 would provide an elegant explanation for the specific inhibition of the 
TBK1 pathway and the failure of RV P in inhibiting IRAK-dependent IFN induction. As we could 
show, RV P is not able to interfere with the TLR7/9 signaling pathway that involves 
phosphorylation of IRF7 by IRAK1 kinase ((Schlender et al., 2005) and Ch.Pfaller, personal 
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communication). Therefore infection of pDCs, in which TLR7/9 pathway is active, with rabies 
virus, in contrast to infection with respiratory syncytial virus (RSV) and Measles virus, results in 
the efficient production of IFN-α (Fig. 7). 
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Figure 7. Inhibition of the IFN induction pathway by the rabies virus 
phosphoprotein P. RV P prevents phosphorylation and activation of the crucial 
transcription factors IRF3 and IRF7 by the upstream TBK1 and IKKε kinases. 
Unphosphorylated IRF3 and IRF7 are unable to dimerize and enter the nucleus to 
switch on transcription of the IFN mRNA. In contrast, the TLR7/8/9 signaling 
pathway involving phosphorylation of IRF7 by IRAK is not influenced by the RV P. 
 
4.2 Inhibition of interferon signaling by Rabies virus P protein 
 
In the second part of my thesis work I could demonstrate that RV P is responsible 
for protecting the virus from the effects of IFN, by abolishing IFN-mediated JAK-STAT 
signaling (Brzózka et al, 2006). The existence of RV proteins able to counteract IFN 
signaling was first suggested by the observation that IFN treatment of cells previously 
infected with RV had no detectable effects on virus gene expression and infectious virus 
titers, whereas pre-treatment of cells with IFN completely prohibited RV replication. In 
RV-infected cells an almost complete inhibition of ISRE- and GAS-controlled luciferase 
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activity was observed after stimulation with IFN-α/β or IFN-γ (Fig. 8). In striking contrast, 
the recombinant RV expressing low P amounts was not able to prevent the induction of 
ISRE- and GAS-controlled genes, and was sensitive to the antiviral activities induced by 
IFN. This suggested the P protein as the inhibitory factor and was verified by expression 
of P from transfected plasmids (Brzózka et al, 2006).  
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Figure 8. Inhibition of IFN 
signaling by wt RV SAD L16 but 
not by a mutant virus expressing 
low amounts of P protein (SAD 
∆PLP). Virus-infected cells 
expressing firefly luciferase under 
the control of the ISRE sequence 
were stimulated with IFN-α as 
indicated.Only wt RV is able to 
abolish IFN-induced luciferase 
activities (top) and prevent 
upregulation of the IFN responsive 
STAT1 (bottom). SAD ∆PLP is not 
able to prevent IFN signaling and 
is therefore sensitive to IFN effects 
as indicated by decreased 
accumulation of virus proteins (G). 
The following experiments revealed that in the presence of P, STAT1 and STAT2 
was correctly phosphorylated by Janus kinases at the critical tyrosine residues after 
stimulation with IFN-α/β or IFN-γ. Nevertheless, neither activated STAT1 nor STAT2 was 
able to enter the nucleus as shown by confocal microscopy (Fig. 9). 
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Figure 9. Cytoplasmic retention of IFN-activated STAT1 (A) and STAT2 (B) in RV 
infected (SAD L16) or P-expressing (RV P) HEp-2 cells. Cells were stimulated with 
IFN-γ or IFN-α for 45 min at 24 h post infection or transfection, and stained with the 
indicated antibodies. In contrast to RV, or authentic RV P protein, a deletion mutant 
lacking the carboxyterminal 10 aa (RV P∆288-297) is not able to prevent nuclear import 
of STATs following IFN treatment. 
 
 
Surprisingly, a direct association of P with STAT1 or STAT2 was not apparent in 
RV-infected cells or in cells expressing P from transfected plasmids. Since nuclear 
shuttling of non-activated STATs was not affected, in contrast to IFN-induced nuclear 
import of STATs, the hypothesis emerged that P might bind selectively to the tyrosine-
activated isoforms of STAT1 and STAT2. I could verify this hypothesis by co-
precipitation experiments involving cell extracts from IFN-stimulated and non-stimulated 
cells. Precipitation of STATs was only possible after activation through IFN (Figure 10). 
The presence of tyrosine-phosphorylated STATs in the precipitates strongly argues in 
favor of P binding exclusively to tyrosine-phosphorylated STATs. I could further show 
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that recognition of activated STAT2 is independent of STAT1, as shown by co-
precipitation experiments using U3A cells that lack STAT1 (McKendry et al., 1991). 
Recognition and precipitation of pY689-STAT2 with RV P appears to be very specific, as 
suggested by the precipitation of these molecules from cell extracts of IFN-γ-stimulated 
cells, in which they were not detectable by Western blot, or were present in very low 
amounts among a bulk of non-phosphorylated STAT2. The possibility of a basic low 
level affinity of P to STATs was recently suggested by a paper (Vidy et al., 2005) in 
which an interaction of P and STAT1 was indicated in yeast-two-hybrid experiments. 
Under physiological conditions, however, interaction of RV P with non-phosphorylated 
STATs was not detectable. This is therefore the first example of a viral IFN antagonist 
acting in a “conditional” manner and targeting the activated isoform of a transcription 
factor (Brzózka et al, 2006) (Figure 11).  
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Figure 10. RV P interacts with 
STATs in an IFN-dependent 
manner. HEK293 cells were 
transfected with plasmids encoding 
immunoglobulin (Ig)-tagged P 
(pCR3-IgP), or the Ig moiety alone 
(pCR3-Ig). Prior to extraction and 
precipitation with Ig-binding 
Sepharose-A beads, cells were 
treated with IFN-α or IFN-γ as 
indicated, or were mock-treated. 
Precipitates (IP) and 3% of cell 
extracts (input) were analyzed by 
Western blot with the indicated 
antibodies. Only from IFN-treated 
cells STATs were co-precipitated 
with Ig-P. 
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Figure 11. Inhibition of IFN signaling 
by RV P. Binding of IFNs to IFN 
receptors results in phosphorylation 
of tyrosine residues in STAT1 and 
STAT2 by Janus kinases. RV P 
specifically binds to the tyrosine-
phosphorylated isoforms of STAT1 
and STAT2 and precludes their 
nuclear import. 
Additionally, the C-terminal 10 aa residues of RV P are responsible for STAT1 
and STAT2 binding, as I could show by analysis of P deletion mutants, whereas the 
above described internal “TBK1-inhibiting” domain is not important. These findings 
further confirm that the inhibition of IFN induction and of IFN signaling are two 
genetically independent functions of RV P. Interestingly, the 10 aa residues responsible 
for STAT binding lie within a domain that has been described to interact with 
promyelocytic leukemia protein (PML) (Blondel et al., 2002). Although not suggested by 
the authors, interaction of PML with RV P could be one of the means to constrict virus 
growth by the host. A competition between PML and STAT in binding to the C-terminal 
domain of P could result in lack of IFN signaling inhibition, establishment of the antiviral 
state and elimination of RV from the cell.  
The inability of rabies virus to prevent early IFN synthesis triggered by the IRAK 
pathway in certain tissues or cell types (Nakamichi et al., 2005; Nakamichi et al., 2004; 
Prehaud et al., 2005; Wang et al., 2005; Lafon, 2005) has to be compensated by the 
capability to preclude IFN signaling, in order to support virus growth. The outcome of the 
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rabies disease seems to depend on both innate and adaptive immune response. The 
group of Fu proposed that pathogenic rabies viruses evade host innate immune and 
antiviral response (Wang et al., 2005). In vivo experiments using different knock-out 
mice revealed that the rabies virus specific antibody response is an absolute 
requirement for recovery upon infection with attenuated strains, as shown by a lethal 
outcome of infection in mice lacking B cells (Hooper et al., 1998). Also inflammation and 
infiltrating T cells have been reported to play a role in controlling RV spread in the CNS 
(Camelo et al., 2000; Baloul and Lafon, 2003). Interestingly, IFNAR-/- or IFNGR-/- mice 
(lacking either IFN-α/β receptor or IFN-γ receptor), did not succumb to infection with a 
highly attenuated rabies strain, but the virus could be detected for a longer period in the 
brain, in comparison to wt mice. In vivo experiments in knock-out mice lacking IFNAR, 
IFNGR or both, are currently being performed with recombinant viruses generated in this 
work. Especially interesting is the outcome of the SAD ∆PLP infection in single and 
double IFN receptor knock-out mice. Since IFN-β, and in particular IFN-γ has a major 
role in the non-cytotoxic clearance of viruses from neurons and the CNS (Griffin, 2003; 
Burdeinick-Kerr and Griffin, 2005), it is expected that the ability of the wt SAD L16 RV to 
counteract IFN-α/β and IFN-γ signaling is crucial for RV infection in wt mice. This 
working hypothesis, can be verified by showing that SAD ∆PLP is able to establish 
successful infection only in IFN receptor knock-out mice, but not in wt mice.  
 
4.3 Concluding remarks 
 
The work presented here reveals a previously not appreciated role of the RV P 
protein. RV P was identified as an effective inhibitor of the host interferon system, which 
is not only the critical first line of defense against viruses but also, as it turned out more 
recently, a central stimulator and modulator of the adaptive immune response. 
RV P is the first specific IFN antagonist of a rhabdovirus described. The closely 
related and intensely investigated VSV, which is a fast growing virus, causes an early 
general host cell shut down, thereby killing all host cell responses. This is due to the 
activity of the VSV matrix (M) protein. The more slowly growing RV depends on the 
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integrity of cells to reach its final destination, the CNS and therefore must have means to 
specifically target the antiviral host response. 
With respect to the need to specifically counteract IFN, RV is therefore more 
similar to the more distantly related paramyxoviruses. Paramyxoviruses may afford 
separate proteins for counteracting IFN, either by encoding proteins from extra genes, or 
from polycistronic P genes encoding a variety of “accessory” proteins which are active in 
either counteracting IFN induction or IFN signaling. The combination of polymerase-
cofactor, N/RNA chaperone-, IRF inhibition, and STAT inhibitory functions as shown 
here for the authentic P protein is unique and demonstrates that even viruses with a 
small coding capacity may encode the full set of functions required for successfully 
counteracting the host response. 
The inhibitory activities of RV P were demonstrated in the context of recombinant 
viruses, using reverse genetics. The availability of viable recombinant viruses deficient 
for IFN escape functions will allow to dissect the RV P functions and their importance for 
RV virulence and pathogenicity in vivo.  
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5 SUMMARY 
 
 
Interferons are the key cytokines of innate immunity and represent the first line of 
defense against invading viruses. By activating immediate antiviral mechanisms and 
stimulating the adaptive immune response, interferon signaling is decisive for the 
outcome of disease and virus clearance. The work presented in this thesis reveals a 
central role of the phosphoprotein P of rabies virus (Rhabdoviridae family), known as a 
polymerase cofactor, as an inhibitor of the host interferon system.  
Counter-mechanism to escape form recognition by the immune system were 
previously unknown for the neurotropic rabies virus, which is characterized by the 
highest case-fatality ratio. In my work I have shown that rabies virus (strain SAD L16) is 
able to prevent both the production IFN-α/β and the effector functions of IFN-α/β and 
IFN-γ. The factor responsible is the viral phosphoprotein P. P interferes with 
transcriptional activation of IFN-α/β by preventing phosphorylation of the essential 
transcription factors IRF3 and IRF7 by their kinases TBK1 and IKKε. Unphosphorylated 
IRFs are unable to dimerize and fail to enter the nucleus. In addition, rabies virus P 
prevents IFN-mediated JAK/STAT signaling and the expression of IFN-stimulated genes 
which include a broad spectrum of antiviral and immune regulatory genes. The inhibition 
of JAK/STAT signaling by P involves a unique mechanism, namely, specific binding of 
the tyrosine-phosphorylated STAT1 and STAT2 isoforms and their retention in the 
cytoplasm. The inhibitory activities of RV P on IFN induction and signaling are 
independent functions, as shown by site-directed mutagenesis of P and identification of 
different short amino acid stretches required for either function. 
Importantly, the inhibitory activities of P were demonstrated in the context of 
recombinant viruses. Using reverse genetics, a rabies virus was constructed, in which P 
expression was “knocked down” by moving the P gene to a promoter-distal position of 
the genome (SAD ∆PLP). This virus caused efficient IFNα/β production in infected cells 
and upregulation of interferon stimulated genes. The IFN sensitivity of SAD ∆PLP was 
confirmed in cell culture and is now being studied in animal experiments including IFN 
receptor knock of mice, to verify the relevance of P functions in vivo. The described work 
contributes to the understanding of host responses to virus infections in general and of 
34 
    SUMMARY 
rabies virus pathogenicity in particular. In addition, viruses with modified IFN antagonists 
provide interesting opportunities for development of attenuated vaccines and vectors.      
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6 ZUSAMMENFASSUNG 
 
 
Interferone sind Schlüssel-Zytokine des angeborenen Immunsystems und stellen 
die erste Hürde für eindringende Viren dar. Durch die Aktivierung von direkten 
antiviralen Mechanismen und die Stimulierung des adaptiven Immunsystems ist die 
Funktion der Interferone entscheidend für die Ausbildung der Krankheit oder die 
Eliminierung der Viren. In der vorgelegten Arbeit wird die zentrale Rolle des 
Phosphoproteins des Tollwutvirus (Rabies virus, Fam. Rhabdoviridae) als Modulator des 
Interferonsystems aufgeklärt. 
Bisher waren die Mechanismen unbekannt, mit deren Hilfe das neurotrope  
Tollwutvirus der Erkennung durch das Immunsystem entgegenwirken kann. In dieser 
Arbeit konnte ich zeigen, dass das Tollwutvirus (Stamm SAD L16) sowohl die 
Produktion von Interferon a/b als auch die Effekte von Interferon a/b und Interferon g 
hemmen kann. Der verantwortliche virale Faktor ist in beiden Fällen das Phosphoprotein 
P. Das P Protein verhindert die Serin-Phosphorylierung und damit der Aktivierung der 
entscheidenden IFN Transkriptionsfaktoren IRF3 und IRF7 durch deren Kinasen TBK1 
und IKKε. Nicht phosphorylierte IRFs sind nicht imstande zu dimerisieren und in den 
Zellkern zu gelangen. Darüber hinaus ist P in der Lage, IFN-vermittelte JAK-STAT 
Signalübertragungswege zu blockieren und damit die Expression von IFN-stimulierten 
Genen mit antiviraler und immunmodulierenden Funktionen zu verhindern. Die 
Hemmung der JAK-STAT Signalübertragung durch P erfolgt durch einen bisher 
einzigartigen Mechanismus, die spezifische Bindung der tyrosin-phosphorylierten 
STAT1 und STAT2 Isoformen und deren Retention im Zytoplasma. Die inhibitorische 
Aktivität des P Proteins auf die IFN Induktion und die JAK-STAT Signaltransduktion sind 
genetisch unabhängige Funktionen. Dies konnte durch ortsgerichtete Mutagenese und 
die Identifizierung von P Mutanten mit Defekten in jeweils einer der Funktionen bestätigt 
werden. 
Die inhibitorischen Funktionen von P konnten darüber hinaus im Viruskontext 
bestätigt werden. Mit Hilfe der "reversen Genetik" konnte ein rekombinantes Tollwutvirus 
hergestellt werden (SAD ∆PLP), in dem die Expression des P Proteins durch die 
Translokation des P Gens an eine Promotor-distale Position wesentlich reduziert war 
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(SAD ∆PLP; Genomorganisation 3'-N-M-G-L-P-5'). Dieses Virus verursachte eine 
effiziente Induktion von IFN in infizierten Zellen sowie die Induktion von IFN-stimulierten 
Genen. Die in der Zellkultur bestätigte Sensitivität von SAD ∆LP gegenüber IFN wurde 
in der Zellkultur bestätigt und wird jetzt in Tierexperimenten, u.a. in wt und IFN 
Rezeptor-KO Mäusen, weiter analysiert, um die Relevanz der Funktionen von P in vivo 
zu bestätigen. Die vorliegende Arbeit trägt zum Verständnis der Immun-Antwort 
gegenüber Viren bei, insbesondere gegenüber neurotropen Viren wie dem Tollwutvirus. 
Viren mit modifizierten IFN Antagonisten wie hier beschrieben stellen darüber hinaus 
attraktive Kandidaten zur Entwicklung von attenuierten Lebendvakzinen und Vektoren 
dar. 
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Rabies virus (RV) phosphoprotein P is an interferon (IFN) antagonist counteracting transcriptional acti-
vation of type I IFN (K. Brzo´zka, S. Finke, and K. K. Conzelmann, J. Virol 79:7673–7681, 2005). We here show
that RV P in addition is responsible for preventing IFN-/- and IFN--stimulated JAK-STAT signaling in
RV-infected cells by the retention of activated STATs in the cytoplasm. Expression of IFN-stimulated response
element- and gamma-activated sequence-controlled genes was severely impaired in cells infected with RV SAD
L16 or in cells expressing RV P protein from transfected plasmids. In contrast, a recombinant RV expressing
small amounts of P had lost the ability to interfere with JAK-STAT signaling. IFN-mediated tyrosine phos-
phorylation of STAT1 and STAT2 was not impaired in RV P-expressing cells; rather, a defect in STAT recycling
was suggested by distinct accumulation of tyrosine-phosphorylated STATs in cell extracts. In the presence of
P, activated STAT1 and STAT2 were unable to accumulate in the nucleus. Notably, STAT1 and STAT2 were
coprecipitated with RV P only from extracts of cells previously stimulated with IFN- or IFN-, whereas in
nonstimulated cells no association of P with STATs was observed. This conditional, IFN activation-dependent
binding of tyrosine-phosphorylated STATs by RV P is unique for a viral IFN antagonist. The 10 C-terminal
residues of P are required for counteracting JAK-STAT signaling but not for inhibition of transcriptional
activation of IFN-, thus demonstrating two independent functions of RV P in counteracting the host’s IFN
response.
The interferon (IFN) systems represent powerful defense
elements of higher organisms that integrate innate and adap-
tive immunity. Type I IFN (IFN-/) is produced in response
to virus infection in most tell types, including neurons, and
upon recognition of conserved exogenous pathogen-associated
molecular patterns by several Toll-like receptors (2, 4, 14).
Expression of IFN- is mostly confined to T cells and NK cells;
however, some neurons can also produce IFN- (32).
IFN-/ and IFN- act through binding to ubiquitous
receptors, the IFN-/ receptor (IFNAR) and the IFN-
receptor (IFNGR), respectively, and activation of two vari-
ants of the Janus kinase-signal transducer and activator of
transcription (JAK-STAT) pathway (44). IFN-/ binding to
IFNAR results in TYK2- and JAK1-mediated tyrosine phos-
phorylation of the latent transcription factors STAT1 and
STAT2 and formation of a heteromeric complex (IFN-stimu-
lated gene factor 3 [ISGF3]) containing STAT1, STAT2, and
IFN regulatory factor 9 (IRF-9; p48). IFNGR signaling in-
volves tyrosine phosphorylation of STAT1 by JAK1 and JAK2
and formation of STAT1 homodimers, known as gamma-acti-
vated factor. ISGF3 and gamma-activated factor drive the ex-
pression of two big sets of genes that are controlled by specific
promoter sequences, the interferon stimulated response ele-
ments (ISRE) and the gamma-activated sequences (GAS), re-
spectively (reviewed in references [1, 34, and 44]). Expression
of interferon-stimulated genes (ISG) leads to establishment of
a powerful antiviral status and supports the development of an
adequate adaptive Th1-biased immune response.
IFN expression and IFN effector functions are therefore
vital targets of viruses (14, 17, 20, 51). It turns out that even
small viruses with a limited coding capacity, including nonseg-
mented negative-strand RNA viruses (order Mononegavirales),
which comprise the important Paramyxoviridae and Rhab-
doviridae families, have evolved multiple mechanisms to target
different functions of the IFN networks (10, 13, 29). Members
of the Paramyxoviridae family are well known for their effective
“weapons of STAT destruction,” represented, for example, by
the nonessential V protein, which lead to depletion of STATs
from virus-infected cells and thereby demolish the IFN JAK-
STAT signaling pathway (18, 52).
In contrast, interference with IFN signaling has not been
shown so far for members of the Rhabdoviridae family in-
cluding the prototypic neurotropic rabies virus (RV) of the
Lyssavirus genus. RV encodes merely five viral proteins, all
of which are essential for virus amplification, namely the
nucleoprotein (N), phosphoprotein (P), matrix protein (M),
glycoprotein (G), and a large (L) RNA-dependent RNA poly-
merase (gene order: 3-N-P-M-G-L-5). We have previously
identified the RV phosphoprotein P as an IFN-/ antagonist
preventing expression of IFN- in RV-infected cells by inter-
fering with the phosphorylation of the critical IFN transcrip-
tion factor IRF-3 (5). Although RV P is essential for viral
RNA synthesis, we could generate a recombinant IFN--in-
ducing RV (SAD PLP) by shifting the P gene to a promoter-
distal position of the genome. The low levels of P expressed
were sufficient to support viral RNA synthesis but not to block
activation of IRF-3.
* Corresponding author. Mailing address: Max von Pettenkofer In-
stitute and Gene Center, Feodor Lynen Str. 25, D-81377 Munich,
Germany, Phone: 49 89 2180 76851. Fax: 49 89 2180 76899. E-mail:
conzelma@lmb.uni-muenchen.de.
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We show here, by analysis of SAD PLP and wild-type (wt)
RV and by expression of P from cDNA, that RV P is also
effective in preventing IFN-/- and IFN--mediated signaling
and expression of ISGs. Inhibition of JAK-STAT signaling and
IFN induction are two separate functions of RV P since a
deletion mutant lacking the C-terminal 10 residues has lost the
ability to counteract JAK-STAT signaling but retained activity
in preventing IFN induction by TBK-1. The STAT inhibitory
activity of RV involves a unique mechanism among viral IFN
antagonists, in that it targets STAT1 and STAT2 exclusively
after activation by IFN-/ or IFN-. Such a purposive activity
only on demand may stem from a limited coding capacity of the
virus and the busy nature of P, allowing P to perform its many
other functions in virus replication.
(This work represents part of the doctoral thesis of K.
Brzo´zka in fulfillment of the requirements for a Ph.D. de-
gree from L-M-University, Munich, Germany, 2006)
MATERIALS AND METHODS
Cells, viruses, and reagents. HEp-2 cells (ATCC CCL-23) were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 5% fetal calf serum and
antibiotics. HEK 293 and U3A cells (25) were propagated in Dulbecco’s modi-
fied Eagle’s medium with 10% fetal calf serum, L-glutamine, and antibiotics, and
BSR-T7/5 cells (7) were propagated in minimal essential medium supplemented
with 10% newborn calf serum.
Recombinant RV SAD L16 (42) comprising the consensus sequence of the
attenuated vaccine strain SAD B19 (11) was used as wt RV. Cloning and recov-
ery of SAD PLP was described previously (5). Mouse monoclonal antibodies to
RV N (W239) were kindly provided by J. Cox (Tu¨bingen, Germany), and mono-
clonal antibodies and polyclonal anti-P serum (9, 37) were provided by D.
Blondel (Gif-sur-Yvette, France). Anti-STAT1 p84/p91 (sc-392), anti-STAT2
(sc-476), anti-ISGF- p48 (IRF-9) (sc-496), and anti-NFB p65 (sc-109) anti-
bodies were obtained from Santa Cruz Biotechnology; anti-pY701-STAT1 and
anti-pS727-STAT1 were obtained from Cell Signaling; anti-pY689-STAT2 was
obtained from Upstate Biotechnology; and anti-actin was obtained from Sigma.
Cytokines were purchased from Sigma (tumor necrosis factor alpha [TNF-])
and PBC Biomedical Lab (IFN- A/D and human IFN-).
Plasmids and transfection. The plasmid encoding RV P (pCR3-RVP) was
described previously (5). Similarly, the pCR3-RVPD288–297 expression vector
was created by PCR using an alternative antisense primer, P288–297NotI3
(5-ATGCGGCCGCTTACATGATTTTACTCAG-3), leading to a deletion of
the 10 C-terminal amino acids of P. The pCR3-Ig (where Ig is immunoglobulin)
vector (6) was used to create an N-terminally Ig-tagged P fusion protein. PCR
primers (5-ATATGAATTCATGAGCAAGATCTTTGTCAATCC-3 and 5-
ATATGCGGCCGCTTAGCAAGATGTATAGCGATTCAA-3) were used for
amplification of P cDNA and cloning into EcoRI/NotI restriction sites.
For reporter gene assays in virus-infected cells, 2  105 cells (HEp-2 or
BSR-T7/5) were seeded in 24-well plates and infected at multiplicities of infec-
tion (MOIs) of 1 or 3. After 16 h, cells were transfected with 0.5 	g of pISRE-luc
or 0.5 	g of pGAS-luc (Stratagene) per well using Lipofectamine 2000. In all
experiments, 10 ng of pCMV-RL encoding Renilla luciferase were cotransfected
as an internal control. Medium was changed 6 h later, and the cells were
stimulated with either universal IFN type I (IFN- A/D) or human IFN-. After
an additional 24 h, cell extracts were prepared and subjected to the reporter gene
assay using a Dual Luciferase Reporter system (Promega). Luciferase activity
was measured in a Luminometer (Berthold) according to the supplier’s instruc-
tions. For reporter gene assays using P cDNA transfection, 2  105 HEp-2 cells
were seeded in 24-well plates, and after 16 h cells were transfected with 0.8 	g
of DNA (0.4 	g of pISRE-luc or 0.4 	g of pGAS-luc cotransfected with 0.4 	g
of empty vector or RV P expression construct) per well using Lipofectamine
2000. At 24 h posttransfection, the medium was changed, and cells were treated
with the amounts of IFN indicated in the figures. At 24 h poststimulation, cell
lysates were subjected to the ISRE and GAS reporter gene assays. The reporter
gene assays for monitoring IFN- promoter activity (p125luc) upon TBK-1
expression were performed as described previously (5).
Precipitation assays. HEK 293 cells were transfected using a calcium phos-
phate mammalian transfection kit (Stratagene), and U3A cells were transfected
using Lipofectamine 2000 (Invitrogen). Precipitation was performed 48 h post-
transfection. Briefly, cells were lysed in lysing buffer (50 mM NaCl, 150 mM Tris,
1 mM Na-vanadate, 1 mM EDTA, and protease inhibitor cocktail [Roche]), and
after centrifugation (14,000 rpm for 10 min) protein A Sepharose (Amersham
Biosciences) was used to pull down Ig-tagged complexes from the supernatant
(2h at 4°C). After the incubation and washing steps, beads were resuspended in
lysis buffer (62.5 mM Tris, 2% sodium dodecyl sulfate [SDS], 10% glycerol, 6 M
urea, 5% -mercaptoethanol, 0.01% bromophenol blue, 0.01% phenol red) and
incubated at 95°C for 10 min in order to destroy bead-bound complexes.
Western blotting. Cell extracts were prepared by treatment with cell lysis
buffer (62.5 mM Tris, 2% SDS, 10% glycerol, 6 M urea, 5% -mercaptoethanol,
0.01% bromophenol blue, 0.01% phenol red). Proteins were resolved by 10%
SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose mem-
brane (Schleicher and Schuell) using a semidry blotter (Peq-Lab). Membranes
were incubated overnight at 4°C with primary antibodies. Protein signals were
visualized with horseradish peroxidase-conjugated secondary antibodies and an
ECL system (Perkin Elmer).
Immunofluorescence microscopy. HEp-2 cells were seeded on glass coverslips
and were infected with RV at an MOI of 1 or were transfected with plasmid
cDNA using Lipofectamine 2000. The cells were fixed using 3% paraformalde-
hyde for 20 min at room temperature and were permeabilized in 0.5% Triton
X-100 in phosphate-buffered saline (PBS). After incubation with primary anti-
bodies (1:100 in PBS for 45 min at 37°C), the specimens were incubated with
fluorescence-labeled secondary antibodies at a dilution of 1:200 in PBS for 1 h at
37°C (goat anti-rabbit Alexa Fluor 488 and anti-mouse tetramethylrhodamine,
both from Molecular Probes). Nuclear chromatin was stained by adding TO-
PRO-3-iodide (Molecular Probes) to the secondary antibodies (final concentra-
tion, 0.5 	M TO-PRO-3-iodide).
Confocal laser scanning microscopy was performed with a Zeiss LSM510 Meta
laser system using a Zeiss Axiovert 200 microscope. Excitation of Alexa Fluor
488, tetramethylrhodamine, and TO-PRO-3-iodide occurred at wavelengths of
488 nm, 543 nm, and 633 nm, respectively. To avoid cross talk, the individual
channels were scanned sequentially.
RESULTS
RV infection inhibits production of ISGs. RV is not able to
replicate in cells activated by IFN-/ or IFN-, i.e., in cells in
which an antiviral state has been established (data not shown).
We noticed, however, that IFN had no obvious effect on viral
replication and gene expression when cells were treated after
RV infection. This suggested that RV encodes proteins to
interfere with the establishment of an antiviral state by IFN or
to counteract the antiviral activity of ISGs.
To explore whether RV is able to interfere with the produc-
tion of ISGs, HEp2 cells were infected at a MOI of 1 with RV
SAD L16 for 18 h and were then transfected with plasmids
encoding firefly luciferase under the control of ISRE or GAS
sequences (pISRE-luc or pGAS-luc). At 6 h posttransfection,
cells were treated with IFN- or IFN-. Cell lysates were
prepared 24 h after IFN stimulation and processed for lucif-
erase assays and for Western blotting.
In mock-infected cells, stimulation with 1,000 U of IFN-
resulted in a more than 20-fold induction of luciferase activity
from the ISRE plasmid, whereas in SAD L16-infected cells
induction of luciferase activity was almost completely pre-
vented. Indeed, luciferase activity was comparable to mock-
infected nontreated cells (Fig. 1A). Similarly, IFN- stimula-
tion of luciferase from the GAS-controlled plasmid was greatly
impaired in RV-infected cells (Fig. 1B).
To check the expression of some individual ISGs upon
IFN treatment, cell extracts were also analyzed by Western
blotting with antibodies to IRF9, STAT1, and STAT2. In
mock-infected cells, a conspicuous accumulation of these
proteins, in particular, STAT2 and IRF9, was noticed al-
ready upon stimulation with 100 U of IFN- (Fig. 1C) or 10
ng/ml IFN- (Fig. 1D). In contrast, in RV-infected cells the
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upregulation of STAT1, STAT2, and IRF9 was evidently im-
paired, confirming the luciferase reporter gene assays. Only at
a high dose of 1,000 U of IFN- was some increase of protein
levels apparent, though levels remained below those of mock-
infected IFN-stimulated cells. Notably, the basic levels of
STAT1 and STAT2 were not reduced in RV-infected cells.
This indicated that the observed inhibition of ISG expression
by RV was not due to depletion of STATs.
STAT tyrosine phosphorylation is not affected. STATs are
activated by Janus tyrosine kinases associated with the cytoplas-
mic domains of IFNAR and IFNGR. To analyze the phosphory-
lation status of STAT1 and STAT2 in RV-infected cells, Western
blot experiments with phospho-specific STAT antibodies were
performed. HEp-2 cells infected for 24 h with SAD L16 were
treated with IFN, and cell extracts were prepared 30 min and
120 min after the IFN stimulation (Fig. 2A). As observed
previously, the total levels of STAT1 and STAT2 were similar
in mock- and virus-infected cells. As in mock-infected cells,
tyrosine-phosphorylated STAT2 (pY689-STAT2) and STAT1
(pY701-STAT1) were readily detected in RV-infected cells at
30 min poststimulation with IFN-. Similarly, IFN- stimula-
tion resulted in comparable amounts of pY701-STAT1 in
mock-infected and RV-infected cells at 30 min poststimulation
(Fig. 2A). Thus, activation of STAT1 and STAT2 by tyrosine
phosphorylation is not impaired in RV-infected cells.
To follow the long-term fate of phosphorylated STATs, cells
were allowed to grow for 24 h following IFN treatment (Fig.
2B). At this late time point, only trace amounts of pY701-
STAT1 and pY689-STAT2 were left in mock-infected cells
treated with IFN-, while total levels of STAT1 and STAT2
were increased as a result of IFN stimulation. In striking con-
trast, abundant amounts of pY689-STAT2 were present in
FIG. 1. RV inhibits induction of ISGs by IFN- and IFN-. (A and B)
HEp-2 cells were infected with RV SAD L16 (MOI of 1), transfected with
pISRE-luc (A) or pGAS-luc (B) at 18 h postinfection, and IFN- or
IFN- was added at 6 h posttransfection. Twenty-four hours later firefly
luciferase activities were measured and corrected to the Renilla lucif-
erase activity from a cotransfected control plasmid to normalize for
variations in the transfection efficiency. Transfection experiments were
repeated at least three times and averages and error bars are shown. (C
and D) Expression of individual ISGs STAT1, STAT2, and IRF9 was
analyzed by Western blot analysis of extracts from HEp-2 cells infected
at an MOI of 1 for 24 h and a subsequent 24-h stimulation with IFN-
(C) or IFN- (D). In contrast to mock-infected cells, RV-infected cells
do not upregulate ISRE- or GAS-controlled luciferase or STAT1,
STAT2, and IRF9 upon IFN stimulation.
FIG. 2. RV infection does not prevent tyrosine phosphorylation of
STAT1 and STAT2 (A) but leads to accumulation of tyrosine-phos-
phorylated STAT1 and STAT2 over time (B). Mock-infected and
RV-infected HEp-2 cells (MOI of 1) were stimulated at 24 h postin-
fection with IFN- or IFN-. After 30 or 120 min (A) cell extracts were
processed for Western blotting and probed with phospho-specific an-
tibodies as indicated. Tyrosine phosphorylation of STAT2 (pY689-
STAT2) and STAT1 (pY701-STAT1) was similar in mock- and RV-
infected IFN-stimulated cells, whereas serine phosphorylation of
STAT1 (pS727-STAT1) by IFN was more effective in mock-infected
cells. Tyrosine-phosphorylated STAT1 and STAT2 accumulate. As
shown in panel B, at later stages after IFN stimulation (24 h poststimu-
lation), abundant amounts of tyrosine-phosphorylated STATs are still
detectable only in RV-infected cells but not in mock-infected cells,
suggesting a defect in STAT recycling.
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RV-infected cells at this late time point, as well as increased
levels of pY701-STAT1 (Fig. 2B, left panel). In line with these
findings, IFN- treatment resulted in the most pronounced
accumulation of pY701-STAT1 and a less prominent accumu-
lation of pY689-STAT2 in RV-infected cells during the 24-h
period following IFN treatment. These results further con-
firmed that the initial tyrosine phosphorylation of STATs is
unimpaired and pointed toward a defect in recycling of cor-
rectly activated STATs.
In contrast to tyrosine phosphorylation of STAT1, serine
phosphorylation, which is not required for the transcriptional
activity of STATs, appeared to be somewhat less efficient in
RV-infected cells. Lower levels of pS727-STAT1 were ob-
served both at early (Fig. 2A) and late time points after IFN
stimulation (Fig. 2B).
RV prevents nuclear import of activated STAT1 and STAT2.
As STATs were found to be correctly activated by tyrosine
phosphorylation in RV-infected cells, we examined by confo-
cal laser scanning microscopy the subcellular localization of
STAT1 and STAT2 proteins after stimulation with IFN. For
this purpose, HEp-2 cells were infected at an MOI of 1 for
24 h, stimulated for 45 min with 100 ng/ml of IFN- or 1,000
U/ml of IFN-, and immunostained for STAT1 and STAT2,
respectively. In noninfected HEp-2 cells, IFN- treatment led
to a redistribution of STAT1 from the cytoplasm to the nucleus
(Fig. 3A), whereas IFN-treated RV-infected cells maintained
the phenotype of nontreated cells, with the major portion of
STAT1 in the cytoplasm (Fig. 3A). Stimulation of noninfected
cells with IFN- led to an almost complete relocalization of
STAT2 from the cytoplasm to the nucleus. This translocation
was precluded when cells were previously infected with RV
(Fig. 3B). To exclude the possibility that RV causes a general
block of nuclear import or an increase in nuclear export, we
investigated the nuclear localization of another transcription
factor, NF-B p65, on stimulation with TNF- (Fig. 3C). In
contrast to STAT1 and STAT2, nuclear accumulation of
NF-B p65 was not affected in RV-infected cells, indicating
that RV specifically interferes with the nuclear import of
STAT1 and STAT2 (see Discussion).
Failure of the RV SAD PLP to interfere with JAK-STAT
signaling. To identify the viral protein(s) responsible for inter-
ference with JAK-STAT signaling, we compared wt RV SAD
L16 with the previously described SAD PLP. Due to a change
in the gene order from 3-N-P-M-G-L-5 to 3-N-M-G-L-P-5,
SAD PLP virus expresses very low amounts of P and is there-
fore unable to prevent activation of IRF-3 and IFN- produc-
tion (5). Reporter gene assays were therefore performed in
BSR-T7/5 cells, which do not produce endogenous IFN on
SAD PLP infection. Cells infected at an MOI of 3 with SAD
L16 and SAD PLP virus for 18 h were transfected with
pISRE-luc and stimulated with IFN-, and luciferase activity
was determined 24 h after stimulation. An approximately 60-
FIG. 3. RV infection prevents IFN-mediated translocation of
STAT1 (A) and STAT2 (B) to the nucleus. RV-infected (MOI of 1)
and mock-infected Hep-2 cells were stimulated with IFN- or IFN-
for 45 min at 24 h postinfection, fixed with 3% paraformaldehyde, and
stained with STAT1 or STAT2 antibodies as indicated. The import of
both STATs on IFN-treated cells is prevented in RV-infected cells,
whereas import of NF-B p65 on TNF--treated cells is not (C).
Nuclei of cells were visualized by staining with TO-PRO-3 dye; RV P
was visualized by using P-specific polyclonal mouse serum.
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fold induction of luciferase activity was observed for mock-
infected cells. While infection with wt RV completely abol-
ished luciferase activity, SAD PLP infection was not able to
prevent IFN signaling (Fig. 4A), suggesting that the RV P
protein is involved in or responsible for counteracting IFN
signaling. Indeed, SAD PLP showed an increased sensitivity
to the antiviral effects of IFN. Treatment of virus-infected BSR
T7/5 cells with IFN- caused a clear and dose-dependent in-
hibitory effect of protein expression of SAD PLP, in contrast
to wt RV SAD L16 (Fig. 4B). Microscopic examination of
STAT localization in HEp2 cells infected with SAD PLP or
SAD L16 further confirmed that SAD PLP has a defect in
preventing nuclear accumulation of STAT1 and STAT2 (Fig.
4C and D). Thus, it appears that insufficient levels of P protein
expressed from SAD PLP are responsible for the failure of
this virus in preventing JAK-STAT signaling.
Rabies virus phosphoprotein P is responsible for interfer-
ence with STAT functions. In order to clarify whether P alone
is able to prevent ISG expression, HEp-2 cells were transfected
with an empty vector (pCR3) or an RV P-encoding plasmid
(pCR3-RVP), stimulated with IFN, and assayed for GAS- and
ISRE-directed luciferase expression. Expression of RV P was
sufficient to considerably reduce both IFN-- and IFN--in-
duced luciferase activity (Fig. 5A, top and middle panels). In
striking contrast to full-length P, a P deletion mutant lacking
the 10 C-terminal residues (P288-297) did not show an in-
hibitory effect on either GAS- or ISRE-driven reporter gene
expression. Notably, however, P288-297 has retained the abil-
ity to prevent TBK-1-mediated activation of IRF-3 and IFN-
induction. Compared to HEK 293 cells transfected with empty
vector plasmids, cotransfection of both P-encoding plasmids
FIG. 4. SAD PLP fails in inhibiting JAK-STAT signaling. (A) BSR-
T7/5 cells infected at an MOI of 3 with wt RV SAD L16 and a mutant
expressing low levels of P (SAD PLP) were transfected with pISRE-
luc and were stimulated with IFN- 18 h postinfection. In contrast to
wt RV, SAD PLP is not able to abolished luciferase activities.
(B) BSR T7/5 cells infected at an MOI of 1 with RV SAD L16 and
SAD PLP were treated with IFN- at 24 h postinfection. Cell lysates
were prepared 24 h after stimulation (48 h postinfection) and were
analyzed by Western blotting. Accumulation of viral proteins in SAD
PLP-infected cells was decreased after IFN induction. (C) HEp-2
cells infected with SAD L16 or SAD PLP at an MOI of 1 were
immunostained for STAT1 and STAT2 24 h postinfection as described
in the legend of Fig. 3. In contrast to wt SAD L16, SAD PLP-infected
HEp-2 cells allow nuclear accumulation of both STAT1 and STAT2.
RV N was visualized using N-specific mouse monoclonal antibodies.
FIG. 5. Expression of P alone prevents STAT signaling. (A) pISRE-
luc or pGAS-luc reporter constructs were cotransfected with plasmids
encoding wt P (pCR3-RVP), a C-terminally truncated protein, P288-297
(pCR3-RVP288-297), or with empty vector (pCR3) into HEp-2 cells.
After 24 h, IFN- or IFN- was added, and luciferase activities were
analyzed after an additional 24 h (top and middle panels). A reporter gene
construct controlled by the IFN- promoter (p125luc) was cotransfected
with RV P and TBK-1 expression plasmids into HEK 293 cells as indi-
cated. Luciferase activities were determined at 48 h posttransfection
(lower panel). The average of at least two independent experiments is
shown with error bars. (B to D) RV P prevents nuclear accumulation of
STATs. HEp-2 cells were transfected with the indicated expression con-
structs. After 24 h cells were stimulated for 45 min and were subsequently
stained for STAT1 (B), STAT2 (C), and NF-B p65 (D) as described in
the legend of Fig. 3. In contrast to P288-297, expression of wt P prevents
nuclear import of STAT1 and STAT2 by IFN but not of NF-B p65 by
TNF-.
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with a TBK-1-encoding plasmid reduced expression of lucifer-
ase from the IFN- promoter (p125luc) considerably (Fig. 5A,
bottom panel).
To verify the results from the reporter gene assays and to
address the question of how expression of RV P and P288-
297 affect the nuclear import of STATs, transfected HEp-2
cells were treated with IFN and processed for confocal micros-
copy as described above. In cells expressing P, neither STAT1
nor STAT2 could accumulate in the nucleus upon IFN stimu-
lation. In contrast, cells expressing even abundant P288-297
showed efficient nuclear accumulation of STAT1 and STAT2
(Fig. 5B and C). As observed previously for RV-infected cells,
nuclear import of NF-B p65 was not impaired in P-expressing
cells (Fig. 5D). Thus, RV P alone is sufficient to specifically and
efficiently prevent STAT1 and STAT2 nuclear import and ISG
induction by IFN JAK-STAT signaling.
Activation-dependent binding of STATs by RV P. To assay
whether RV P is able to physically associate with STATs and
thereby preclude their nuclear import, precipitation assays were
performed using a P in which an Ig tag was fused to the N
terminus of P (pCR3-IgP) or of P288-297 (pCR3-Ig P288-
297). As we considered the possibility that activated STATs rep-
resent the targets of P (see Discussion), the experiments were
designed in a way to include IFN-treated cells. HEK 293 cells
were transfected with pCR3-IgP or a control plasmid expressing
the Ig tag alone (pCR3-Ig) and were stimulated with 1,000 U/ml
of IFN- or 100 ng/ml of IFN- after 48 h for 45 min. Ig-contain-
ing complexes were precipitated from cell extracts using Sepha-
rose A beads (Amersham Biosciences), and precipitates were
analyzed by Western blotting.
Notably, neither STAT1 nor STAT2 was coprecipitated with
IgP from nonstimulated cells (Fig. 6A, left panel). However, when
cells were pretreated with IFN-, both STAT1 and STAT2
molecules were effectively pulled down with IgP but not by
the Ig control construct (Fig. 6A, middle panel). The presence
of activated, tyrosine-phosphorylated STAT2 (pY689) and
STAT1 (pY701) in the precipitates was confirmed by phospho-
specific antibodies.
After treatment of cells with IFN-, pY701-STAT1 was
readily detected in the cell extracts in contrast to pY689-
STAT2 (Fig. 6A, right panel, input). Again, IgP coprecipitated
STAT1 exclusively and effectively from stimulated cells. Fur-
thermore, not only STAT1 (pY701-STAT1) was present in the
IgP precipitates but also STAT2 (pY689-STAT2), although
pY689-STAT2 was below the detection limit in the input cell
extracts (Fig. 6A, lower panel). Coprecipitation of STATs with
IgP288-297 was not observed in either IFN-stimulated or
nonstimulated cells (data not shown).
These experiments confirmed that RV P associated with
STAT2 and/or STAT1 only after IFN activation; however, they
did not reveal whether the interaction with STAT2 occurs via
STAT1 or independently of STAT1. We therefore repeated
the precipitation experiments with cell extracts of U3A cells
that lack STAT1. IgP clearly coprecipitated pY689-STAT2
from cell extracts of IFN--stimulated U3A cells, as well as
from nonstimulated cells, in which low amounts of pY689-
STAT2 were already detectable (Fig. 6B). Again, no precipi-
tation was observed with the C-terminally truncated IgP288-
297 (data not shown). Thus, full-length RV P is able to
independently interact with pY-STAT1 and pY-STAT2 in
IFN-stimulated cells.
DISCUSSION
In this work, we have demonstrated that RV has the ability
to interrupt the IFN-stimulated JAK-STAT signaling pathways
and thereby to prevent the detrimental effects of type I and
type II IFN. This activity could be attributed entirely to the P
protein. The mechanism by which RV P interrupts IFN JAK-
STAT signaling involves a specific association of P with STAT1
and STAT2 exclusively after activation by IFN, which is unique
for viral IFN antagonists.
The existence of RV proteins able to counteract IFN signal-
ing was first suggested by the observation that treatment of
cells previously infected with RV had no detectable effects on
virus gene expression and infectious virus titers, whereas pre-
treatment of cells with IFN completely prohibits RV replica-
tion. The resistance of RV to both IFN-/ and IFN- further
pointed toward STAT1 as a target, since it is a common factor
of the IFNAR and IFNGR/JAK-STAT pathways. In RV-in-
FIG. 6. RV P interacts with STATs in an IFN-dependent manner.
(A) HEK 293 cells were transfected with constructs encoding Ig-tagged
P (pCR3-IgP) or the Ig moiety alone (pCR3-Ig). Precipitation was
performed using Sepharose A beads binding the Ig tag at 48 h postin-
fection from extracts of cells that were treated for 45 min with 1,000
U/ml IFN- or 100 ng/ml IFN- or were not treated. Precipitates (IP)
and 3% of cell extracts (input) were analyzed by Western blotting with
the indicated antibodies. Only from IFN-treated cells were STATs
coprecipitated with Ig-P. (B) The experiment shown in panel A was
performed with U3A cells that lack STAT1. STAT2 is precipitated
from IFN-treated cells independent of STAT1.
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fected cells an almost complete inhibition of ISRE-controlled
luciferase activity was observed, consistent with the later ob-
servation that RV P binds both STAT1 and STAT2. The ob-
served residual leakiness of RV-infected cells for IFN--stim-
ulated and GAS-mediated reporter gene expression may be
due to different reasons, e.g., activation of STAT3 in addition
to STAT1 at the IFN- receptor (44).
Upon stimulation of the IFN receptors by IFN, STATs are
phosphorylated by the receptor-associated Janus kinases at
tyrosine residues 689 (STAT2) and 701 (STAT1) (19, 22, 23,
46). The STATs then dimerize through SH2-phosphotyrosine
interactions, translocate to the nucleus, and bind to ISRE or
GAS sequences. Additional phosphorylation of C-terminal Ser
residues by kinases such as protein kinase C 
 may improve the
transcriptional activity of tyrosine-phosphorylated STATs by
facilitating binding of nuclear factors, such as CBP/p300, but
this is not a requirement for STAT transcriptional activity (12,
47). The analysis of STAT proteins with phospho-specific an-
tibodies revealed that the critical tyrosine phosphorylation of
STATs is not precluded in RV-infected cells. Rather, an accu-
mulation of tyrosine-phosphorylated STATs was observed over
time, whereas in mock-infected cells these molecules rapidly
disappeared (Fig. 2B). In contrast to the initial tyrosine phos-
phorylation, however, the following serine phosphorylation of
STATs appeared to be somewhat hampered in RV cells, as
suggested by poor accumulation of pS727-STAT1 (Fig. 2B).
These observations pointed toward an interference of RV P
with a step following the initial receptor-mediated STAT acti-
vation.
Indeed, in spite of correct tyrosine phosphorylation, neither
STAT1 nor STAT2 was able to accumulate in the nucleus of
RV-infected cells. A very clear-cut alternative distribution was
observed for STAT2. IFN- treatment of mock-infected cells
led to a rapid and almost complete relocalization of STAT2
from the cytoplasm to the nucleus, whereas in RV-infected or
RV P-expressing and IFN-treated cells, virtually no STAT2
was detectable in the nucleus (Fig. 3 and 5). In case of STAT1,
a readily detectable portion of the protein showed nuclear
localization even in nonstimulated cells. This reflects the well-
known shuttling of nonactivated STAT1 between the cyto-
plasm and nucleus (24, 28) and indicated that cycling of non-
activated STAT1 is not affected by RV P. Nevertheless, an
efficient inhibition of IFN-triggered nuclear accumulation of
STAT1 by RV was obvious, indicating that RV P retains acti-
vated STAT1 in the cytoplasm and prevents its nuclear import.
It should be noted that pY-STAT1 is incapable of nuclear exit
and has to be dephosphorylated first by nuclear phosphatases
(26–28). Confocal live microscopy experiments involving photo-
bleaching of cytoplasmic STAT1-GFP (where GFP is green
fluorescent protein) revealed that the nuclear export rate of
nonphosphorylated STAT1-GFP is not changed in the pres-
ence of RV P (not shown). The lack of nuclear import of
activated STATs and of their dephosphorylation in the nucleus
therefore explains the overall accumulation of pY-STATs over
time in RV-infected cells.
Direct evidence for activation-dependent binding of STAT1
and STAT2 by P was obtained from precipitation assays with
Ig-tagged P protein. Effective coprecipitation of both STATs
with RV P was dependent on stimulation of cells with IFN. We
were unable to detect substantial coprecipitation of STAT1 or
STAT2 in nonstimulated HEK 293 cells, suggesting that non-
phosphorylated STATs are not recognized, or only poorly rec-
ognized, and bound by P. After submission of this work, Vidy
et al. published a report on binding of the RV P of the CVS
strain to STAT1 (49). These authors were able to coprecipitate
STAT1 from cell extracts using a glutathione transferase-P
fusion construct. It was not revealed whether this represented
activated or nonactivated STAT1. However, the observation
that STAT1 and P coexpression was able to activate gene
transcription in a yeast two-hybrid system indicates some basic
association of P with STAT.
Only IFN stimulation, however, resulted in effective copre-
cipitation of both STAT1 and STAT2 in our hands. The pres-
ence of tyrosine-phosphorylated STATs in the precipitates
strongly argues in favor of the idea that P binds exclusively to
tyrosine-phosphorylated STATs, although we cannot formally
exclude some coprecipitation of nonphosphorylated STATs via
pY-STATs, due to the lack of antibodies that positively identify
nonphosphorylated STATs. Recognition and precipitation of
pY689-STAT2 by P appear to be very specific, as suggested by
the precipitation of these molecules from cell extracts of IFN-
-stimulated cells, in which they were not detectable by West-
ern blotting or were present in very small amounts (53) among
a bulk of nonphosphorylated STAT2 (Fig. 6A and B). We
could further show that recognition of activated STAT2 is
STAT1 independent, as shown by coprecipitation experiments
using U3A cells that lack STAT1 (25) (Fig. 6B). Thus, RV P
interacts with both STAT1 and STAT2 only upon activation,
either directly or in a complex with other proteins, and this
interaction explains the retention of activated STATs in the
cytoplasm of infected cells.
The described conditional, activation-dependent targeting
of STAT1 and STAT2 by RV P to interrupt IFN JAK-STAT
signaling is unique among viruses. Constitutive targeting of
bulk nonactivated STATs is a common strategy of the related
paramyxoviruses and is due to the activities of their nonessen-
tial V proteins (for review see references 13, 14, 18, and 29).
Rubulavirus V proteins assemble STAT-specific ubiquitin-li-
gase complexes from cellular components and target either
STAT1 or STAT2 for proteasomal degradation (35, 48). The V
proteins from other paramyxovirus genera do not lead to deg-
radation of STATs. Henipaviruses, for example, in fact prevent
phosphorylation of STATs and sequester STAT1 and STAT2
in high-molecular-mass complexes (39, 40). For Nipah virus it
has been shown that the V, W, and P proteins, which are all
encoded by the same viral gene and share an identical 407-
amino-acid N-terminal region but have distinct C-terminal se-
quences, have anti-STAT function. This confirmed the finding
that the common N-terminal domain is involved in the antag-
onist activity (38, 43). However, it was also found that activity
of the P protein is not as strong as that of V or W, perhaps
explaining why Nipah virus has evolved to express additionally
two edited products (43). The V protein of measles virus was
reported to copurify with STAT1, STAT2, STAT3, and IRF-9,
to bind to the IFNAR, and to recruit STATs to viral inclusion
bodies (33, 45).
We have here identified RV P as an inhibitor of IFN signal-
ing and have previously shown that RV P is active in counter-
acting transcriptional induction of type I IFN (5). As demon-
strated by P288-297, these are independent functions of P. A
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region within the 10 C-terminal amino acid residues of RV P is
required for counteracting STAT signaling but not for inhib-
iting TBK-1. Interestingly, paramyxovirus V proteins also com-
bine inhibitory activities in IFN signaling and in IFN induction
(16) but with different targets in either function. Whereas V
C-terminal domains bind and inhibit the double-stranded
RNA receptor mda-5 which relays signals to activation of
IRF-3 and NF-kB (3), RV P acts farther downstream and
specifically prevents phosphorylation of IRF-3 by TBK-1 (5).
This finding stresses the importance for a virus of having
means to target different steps within the powerful host IFN
response. In particular, it is obvious that viral IFN antagonists
are insufficient to prevent some early IFN synthesis or to pre-
vent synthesis in certain tissue or cell types. Indeed, we have
identified a variety of cell types in which active IFN is being
expressed upon RV infection with SAD L16, though at lower
magnitudes than the “IFN-inducing” SAD PLP. In particular,
and in striking contrast to measles virus and respiratory syn-
cytial virus (41), RV SAD L16 is not able to prevent IFN
induction in human plasmacytoid dendritic cells (unpublished
data), which represent the major IFN producers in vivo. Con-
sistent with these observations, IFN has been detected upon
RV infection in vitro and in vivo (21, 30, 31, 36, 50). Since
IFN- and, in particular, IFN- have a major role in the non-
cytotoxic clearance of viruses from neurons and the central
nervous system (8, 15), it is predicted that the ability of RV to
counteract IFN-/ and IFN- signaling is crucial for RV
infection in vivo. Further experiments should be directed to
further dissociate RV P functions in IFN induction and re-
sponse. The use of recombinant RV with defined defects in
either function should help to study the contribution of the
innate immune response to the control of RV and to reveal a
possible correlation of IFN antagonistic activities with viral
pathogenicity. Viral antagonists targeting particular functions
of the JAK-STAT pathways, such as RV P, may further help in
studying details of STAT signaling.
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Rabies virus (RV) of the Rhabdoviridae family grows in alpha/beta interferon (IFN)-competent cells, sug-
gesting the existence of viral mechanisms preventing IFN gene expression. We here identify the viral phos-
phoprotein P as the responsible IFN antagonist. The critical involvement of P was first suggested by the ob-
servation that an RV expressing an enhanced green fluorescent protein (eGFP)-P fusion protein (SAD eGFP-P)
(S. Finke, K. Brzo´zka, and K. K. Conzelmann, J. Virol. 78:12333–12343, 2004) was eliminated in IFN-com-
petent HEp-2 cell cultures, in contrast to wild-type (wt) RV or an RV replicon lacking the genes for matrix
protein and glycoprotein. SAD eGFP-P induced transcription of the IFN- gene and expression of the IFN-
responsive MxA and STAT-1 genes. Similarly, an RV expressing low levels of P, which was generated by moving
the P gene to a promoter-distal gene position (SAD PLP), lost the ability to prevent IFN induction. The
analysis of RV mutants lacking expression of truncated P proteins P2, P3, or P4, which are expressed from
internal AUG codons of the wt RV P open reading frame, further showed that full-length P is competent in
suppressing IFN- gene expression. In contrast to wt RV, the IFN-inducing SAD PLP caused S386 phos-
phorylation, dimerization, and transcriptional activity of IFN regulatory factor 3 (IRF-3). Phosphorylation of
IRF-3 by TANK-binding kinase-1 expressed from transfected plasmids was abolished in wt RV-infected cells
or by cotransfection of P-encoding plasmids. Thus, RV P is necessary and sufficient to prevent a critical IFN
response in virus-infected cells by targeting activation of IRF-3 by an upstream kinase.
The alpha/beta interferon (IFN) system, comprising IFN-
and the IFN- family, represents a crucial defense element of
higher organisms that activates both innate and adaptive im-
munity (for reviews, see references 2, 3, 26, and 35). IFN
expression is tightly controlled by latent transcription factors,
which are activated upon recognition of intruding viruses by
cytoplasmic receptors that sense viral double-stranded RNA
(dsRNA) such as retinoic acid-inducible gene I (RIG-I) (58) or
through Toll-like receptors sensing exogenous ligands (2). The
key factor for initiating an IFN response is interferon regula-
tory factor 3 (IRF-3), which is constitutively expressed in the
cytoplasm of most cell types. Latent IRF-3 is activated by
phosphorylation at C-terminal serine residues and then can
form dimers that are recruited to the IFN- enhancer as part
of a protein complex that includes the transcription factors
ATF-2/c-Jun and NF-B and coactivators p300/CBP (38, 57,
59). As shown recently, the critical IRF-3 phosphorylation step
is executed by kinases of the IKK family, i.e., TANK-binding
kinase 1 (TBK-1) which is constitutively expressed, and the
inducible IKK-i (22, 30, 41, 49).
Binding of the secreted early IFNs, predominantly IFN-, to
the IFN- receptor in an autocrine or paracrine fashion acti-
vates JAK/STAT-mediated signal transduction pathways that
culminate in the expression of a huge set of IFN-stimulated
genes (ISGs). Among these is IRF-7, which is activated like
IRF-3 and which allows transcription of the “late” IFN-
genes. Several of the ISGs encode enzymes with antiviral func-
tion, such as Mx proteins, 2-5 oligoadenylate synthetase,
PKR, or factors that inhibit cell growth and promote apoptosis,
thereby restricting viral spread. Moreover, IFN signaling stim-
ulates mechanisms of the adaptive immune response, including
expression of major histocompatibility complex, activation of
NK cells, maturation of dendritic cells, and promotion of the
T-helper cell response toward the Th1 type.
For members of most virus groups, including negative-strand
RNA viruses, specific antagonists of IFN have been identi-
fied during the past years. These may interfere with IFN gene
induction, IFN signaling, or the activity of ISGs (for recent
reviews, see references 3 and 24). Members of the Paramyxo-
virinae subfamily encode small nonessential proteins, such as V
and C, which are expressed from the phosphoprotein (P) gene
through alternative translation initiation and mRNA editing. V
and C proteins interfere with IFN JAK/STAT signaling, ren-
dering the viruses IFN resistant. IFN resistance of respiratory
syncytial virus (RSV) of the Pneumovirinae subfamily of para-
myxoviruses, genus Pneumovirus, is mediated by the concerted
action of two nonstructural proteins, NS1 and NS2. In this
case, however, IFN signaling and expression of IFN-stimulated
genes are not significantly affected (7, 47). Intriguingly, both
the NS proteins of RSV (8, 50) and the V proteins of Para-
myxovirinae (44) were recently also shown to be involved in
inhibiting IFN induction, but with different targets, since NS
proteins prevent activation of IRF-3 (8), whereas V proteins
affect activation of NF-B and IRF-3 (44).
In contrast to paramyxoviruses, members of the Rhabdoviri-
dae such as rabies virus (RV) or vesicular stomatitis virus
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(VSV) are sensitive to exogenous IFN and therefore must
prevent IFN induction. For VSV, the lack of IFN induction
was correlated with the activity of the viral matrix (M) protein,
which causes a general shutoff of host-directed gene expression
(1, 18). Compared to VSV, RV is more slowly growing and
much less cytopathic, and a general cell shutoff is not observed,
allowing expression of host cell genes throughout infection.
We therefore reasoned that RV must encode specific mecha-
nisms for preventing IFN induction.
The RV genome comprises five genes, encoding nucleopro-
tein (N), phosphoprotein (P), matrix protein (M), glycoprotein
(G), and polymerase (L) in the order 3-N-P-M-G-L-5. The M
and G proteins are predominantly involved in formation of the
viral envelope. The N, P, and L proteins are components of the
viral ribonucleoprotein, and each of them is essential for ac-
complishing RNA synthesis (13). The P protein is phosphory-
lated by cellular kinases (27) and is present in homo-oligomers.
It associates both with the L protein to function as a noncata-
lytic cofactor for RNA polymerization and with the N protein
to support specific and proper RNA encapsidation in a chap-
erone-like way (11, 12, 33). In addition to full-length P (P1),
amino-terminally truncated products (P2, P3, and P4) which
are translated from internal in-frame AUG initiation codons
by a leaky scanning mechanism have been found in infected cells
and in purified RV (10). The RV P gene contains a second open
reading frame (ORF), termed C in analogy to similar ORFs in
VSV P genes. Whereas VSV C proteins have been shown to be
expressed (51), the existence of an RV C ORF product is unclear.
We here provide evidence that the P protein of RV, in addi-
tion to its above-described functions in RNA synthesis, is re-
sponsible for inhibition of IFN induction in RV-infected cells.
Replicating RV and full-length P1 expressed from transfected
plasmids interfered with phosphorylation of IRF-3 by the up-
stream kinase TBK-1 such that dimerization of IRF-3 and
transcriptional activity was prevented. Although P is crucially
required for viral RNA synthesis, it was possible to generate
replicating infectious RV that could not prevent IFN induction
and that therefore was not viable in IFN-competent cells and
tissues. This was achieved by reducing the expression of P to
levels sufficient for virus replication but insufficient for block-
ing IRF-3 activation. Such viruses are particularly interesting
for development of live vaccines and oncolytic virus vectors.
MATERIALS AND METHODS
Cells and viruses. Vero (African green monkey kidney) and HEp-2 (human
laryngeal epidermoid carcinoma) cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 5% fetal calf serum and antibiotics. HEK
293 (human embryonic kidney), 2fTGH, and U3A cells (40) were propagated in
Dulbecco’s modified Eagle’s medium with 10% fetal calf serum, L-glutamine, and
antibiotics. U3A cells were incubated in the presence of 250 g/ml hygromycin.
The BSR T7/5 cell clone, which constitutively expresses bacteriophage T7 poly-
merase (9), was used for RV rescue from cDNA as described previously (20).
Recombinant RV SAD L16 (48), comprising the sequence of the attenuated
vaccine strain SAD B19 (14), was used as wild-type (wt) RV. SAD eGFP-P is a
recombinant virus encoding an eGFP-P fusion protein (enhanced green fluores-
cent protein [eGFP] fused to the N terminus of P) instead of the authentic P (19).
SAD VB GFP is a recombinant virus containing an extra eGFP gene between the
G and L genes. NPgrL virus is a recombinant RV in which the matrix (M)- and
glycoprotein (G)-encoding genes are replaced by reporter genes encoding eGFP
and DsRed (red fluorescent protein from Discosoma sp.) (21).
cDNA constructs. Mutations in the P protein-coding sequences were intro-
duced into the P expression plasmid pTIT-P (20) by using the Chameleon
mutagenesis kit (Stratagene) according to the suppliers instructions.
For replacement of the P ORF of the full-length cDNA clone pSAD L16 (48),
a pSADPsap subclone was generated, in which the coding region of the P gene
was replaced by a linker comprising restriction enzyme sites in the following
order: SapI-KpnI-NheI-KpnI-SapI. After SapI digestion, ATG and TAA over-
hangs at the stop and start codons of P allow insertion of SapI-digested PCR
products amplified from mutated P-encoding plasmids (primers SADPatg [5-G
ACAGAGCTCTTCGATGAGCAAGATCTTTGTCAA-3] and SADPtaa [5-T
CTCTCGCTCTTCATTAGCAAGATGTATAGCGATCC-3]) without causing
alterations outside the P ORF. In a second cloning step, the plasmids were cut
in the N and M genes, and a DNA fragment containing the modified P ORF was
inserted in the full-length pSAD L16.
A cDNA full-length clone encoding an additional copy of the RV P gene
downstream of the L gene (pSAD PLP; gene order, 3-N-P-M-G-L-P-5) was
generated by insertion of an N/P gene border copy downstream of the L ORF,
followed by a copy of the P-coding sequence. From pSAD PLP, the original P
ORF was deleted by replacement of a region spanning from the N to the L gene
with the corresponding DNA fragment from pSADPsap to generate SAD
PLP (gene order, 3-N-M-G-L-P-5). The sequences of all constructs are avail-
able from the authors upon request. Vaccinia virus-free rescue of recombinant
RV from the cDNAs was performed as described previously (20) by transfection
of 10 g of full-length cDNA and plasmids pTIT-N (5 g), pTIT-P (2.5 g), and
pTIT-L (2.5 g) in 106 BSR T7/5 cells grown in 8-cm2 culture dishes.
To generate a cytomegalovirus (CMV) promoter-controlled P expression plas-
mid, pCR3-P, the P ORF was amplified from pTIT-P by PCR (primers P1Acc65I
[5-TATAGGTACCATGAGCAAGATCTTT-3] and P1NotI3 [5-ATATGCG
GCCGCTTAGCAAGATGTATAGCGATTCAA-3]) and was inserted in the
plasmid pCR3 (Invitrogen). The P gene of bovine respiratory syncytial virus
(BRSV) was excised from pTIT PRSV (9) and was also inserted in pCR3, result-
ing in pCR3-PRSV.
Transfection. For reporter gene assays with infected cells, 1  106 Vero cells
were seeded in 21-cm2 cell culture dishes. After 16 h, 8 g of the reporter
plasmid p125luc, p55C1Bluc, p55A2luc (60) (kindly provided by Takashi Fujita,
Tokyo), or pAP1luc (Stratagene) was transfected using Lipofectamine 2000
transfection reagent (Invitrogen). As an internal control, 20 ng of pCMV-RL
(renilla luciferase) was cotransfected in all experiments. After 6 h the transfected
cells were split and infected with viruses at a multiplicity of infection (MOI) of
3 or stimulated with 5  103 units of tumor necrosis factor alpha (Sigma) when
indicated. After a further 48 h, cell extracts were prepared and subjected to the
reporter gene assay. For transfection of HEK293 cells, the calcium phosphate
precipitation method (mammalian transfection kit; Stratagene) was used. Cells
were seeded into 12-well plates at 4  105 cells/well and were transfected after
16 h with 1 g of p125luc or p55C1Bluc, 2 g of fl-TBK-1, 0.1 g of pCMV-RL,
and 2 g of pCR3 vector. For Western blot analyses, HEK293 cells were trans-
fected in six-well plates (1.2  106 cells/well) with 3 g of fl-TBK-1, 6 g of
pCR3-RVP, or empty vector as indicated. After 24 h, cell extracts were prepared
and were analyzed by nondenaturing polyacrylamide gel electrophoresis (PAGE)
or sodium dodecyl sulfate (SDS)-PAGE and Western blotting.
Luciferase assay. Cell lysates were prepared at the indicated time points and
subjected to reporter gene assay using the dual luciferase reporter system (Pro-
mega). Luciferase activity was measured in a luminometer (Berthold) according
to the supplier’s instructions.
Western blots and antibodies. For native PAGE, cell extracts from infected or
transfected cell cultures were prepared as described previously (31), and 1.5 
106 cells were lysed in 100 l lysis buffer. After centrifugation (14,000 rpm, 4°C,
10 min), 10 l of the lysate was loaded on the gel. For SDS-PAGE, cells were
lysed in cell lysis buffer (62.5 mM Tris, 2% SDS, 10% glycerol, 6 M urea, 5%
-mercaptoethanol, 0.01% bromophenol blue, 0.01% phenol red) at the indi-
cated time points and loaded onto an SDS-10% polyacrylamide gel. Proteins
were transferred to a nitrocellulose membrane (Schleicher & Schuell) with a
semidry transfer apparatus (OWL Scientific). After incubation with blocking
solution (2.5% dry milk and 0.05% Tween 20 in phosphate-buffered saline) at
room temperature for 1 h, membranes were incubated overnight with the re-
spective antibodies. The MxA antibody M134 (23) and the mouse polyclonal
anti-P serum were kindly provided by Otto Haller and Georg Kochs, Freiburg,
and Danielle Blondel, Gif-sur-Yvette, respectively. Primary antibodies to STAT-
1 (Cell Signaling), actin (Sigma), IRF-3 (Santa Cruz Biotechnology), IRF-3
Ser386 (phosphorylated) (IBL) were purchased. Secondary antibodies were con-
jugated with peroxidase, and Western Lightning chemiluminescence reagent
(Perkin-Elmer) was used for detection.
RNA analysis. Total RNA from infected cells was isolated with the RNeasy
minikit (QIAGEN) according to the manufacturer’s instructions. In RNA prep-
arations for reverse transcription-PCR (RT-PCR) analysis, an additional on
column DNase digestion was performed according to the supplier’s instructions.
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Northern blotting and hybridizations with [-32P]dCTP-labeled cDNAs were
performed as described previously (15). Hybridization signals were quantitated
by phosphorimaging (Molecular Dynamics Storm). IFN--specific RT-PCR was
performed on 1 g RNA isolated after 18 h postinfection (p.i.) with the primers
hIFN- (5-CTCCTCCAAATTGCTCTCCTGTTGTG-3) and hIFN-	 (5-
AAGATGTTCTGGAGCATCTCATAGATG-3). As a control, -actin-specific
RT-PCR was performed using the primers actin (5-GGCATCGTGATGG
ACTCC-3) and actin2	 (5 CCGCCAGACAGCACTGTGTTGGCGTA-3).
RESULTS
An RV expressing an eGFP-P fusion protein induces IFN.
Infection of interferon-competent cell lines such as HEp-2 with
the RV SAD L16 does not result in interferon induction. To
identify the responsible viral factors, we screened a series of
recombinant RV mutants derived from strain SAD L16 (48)
for their ability to suppress IFN induction in HEp-2 cells. Due
to the sensitivity of SAD L16 to IFN (47), a more severe
attenuation of growth in HEp-2 cells compared to IFN-incom-
petent BSR T7/5 cells served as a first criterion for the possi-
bility of IFN production. An RV in which eGFP was fused to
the N terminus of the P protein, SAD eGFP-P (19) (Fig. 1A),
fulfilled this criterion, whereas another RV mutant, expressing
eGFP from an extra gene inserted between G and L, did not.
In BSR cells, SAD eGFP-P reached titers of 106 focus-forming
units/ml after 3 days of infection at an MOI of 0,01, whereas
HEp-2 cells virtually did not support virus amplification. Mi-
croscopic examination revealed initial eGFP-P expression in
SAD eGFP-P-infected HEp-2 cells; however, accumulation of
viral N and eGFP-P proteins was observed only in BSR cell
cultures (Fig. 1B), suggesting induction of IFN by SAD eGFP-
P. Notably, infection of HEp-2 cells with an RV lacking both
the M and G genes, SAD NPgrL, (21) led to effective expression
of the viral N and P proteins (Fig. 1B), demonstrating that the
M protein is not required for virus replication in HEp-2 cells.
To confirm that growth restriction of SAD eGFP-P in
HEp-2 cells is correlated to production of IFN, we checked the
presence of IFN- mRNAs by RT-PCR and the biological
effects of IFN by demonstrating expression of ISGs. IFN-
RNA was detectable in SAD eGFP-P-infected cells but not in
SAD L16-infected cells at 24 h p.i. (Fig. 1C). In accordance
with this finding, expression of the IFN-inducible MxA protein
and an up-regulation of STAT-1 levels were observed only in
SAD eGFP-infected HEp-2 cell cultures and not in cultures
infected with wt RV or NPgrL (Fig. 1C). From these results it
appeared that RV P gene products are important in preventing
IFN production in RV-infected cells, whereas the viral M pro-
tein is not required.
Induction of IFN by an RV expressing low levels of P. To
further support the notion that RV P is critical in preventing
IFN production in virus-infected cells, a recombinant RV was
engineered to express low levels of P. To this end, we took
advantage of the typical stop-start mechanism of nonseg-
mented negative-strand RNA viruses yielding a transcription
gradient. In SAD PLP, the viral genome organization was
changed such that the P gene was moved from the second to
the most promoter-distal fifth position (genome organization
NMGLP) (Fig. 2A). As a control, SAD PLP (gene order,
NPMGLP) was generated, retaining the P gene in its original
position but containing an extra P copy downstream of L like
in SAD PLP. Viable virus was rescued from both cDNA
constructs. As revealed by Northern hybridization, much less P
mRNA was transcribed in SAD PLP-infected cells than in
SAD L16- or SAD PLP-infected cells. In contrast, the amounts
of N mRNAs were more similar for all viruses (Fig. 2B). Also,
the amount of P protein was greatly lower in SAD PLP-
infected cells than in cells infected with the control viruses, as
shown by Western blot analyses (Fig. 2B). A decelerated ac-
cumulation of other virus proteins such as N, M, and G and of
viral RNAs further indicated that the reduced levels of P pro-
tein were limiting RNA synthesis of SAD PLP.
Concordantly, growth of SAD PLP in BSR cell cultures
lagged behind that of SAD L16 and SAD PLP; however, final
infectious titers of 107 focus-forming units/ml at 3 days p.i.
were only 10-fold lower than those of wt RV (Fig. 2D). Com-
pared to SAD eGFP-P, however, SAD PLP yielded 10-fold-
higher titers, indicating an RNA synthesis more severely af-
fected by the eGFP-P fusion protein.
To investigate the effect of reduced P levels on the produc-
tion of IFN, HEp-2 cells were infected in parallel with SAD
L16, SAD PLP, SAD PLP, and SAD eGFP-P as a positive
control for IFN induction. Whereas SAD L16 and SAD PLP
rapidly amplified to titers of greater than 106 after 3 days of
infection, SAD PLP and SAD eGFP-P were not able to
productively grow in HEp-2 cells (Fig. 2E). RT-PCR and
FIG. 1. SAD eGFP-P induces IFN- gene expression. (A) Genome
organization of wt SAD L16; SAD eGFP-P, expressing a P protein with
an N-terminal eGFP-moiety; NPgrL virus, with M and G genes re-
placed with eGFP and DsRed genes; and SAD VB eGFP, containing
an extra eGFP gene. (B) Whole-cell extracts of BSR T7/5 and HEp-2
cells were harvested at 48 h p.i. (MOI of 1) and analyzed by Western
blotting for expression of the viral N, P, and M proteins. In contrast to
infection of BSR cells (right panel), SAD eGFP-P produced low levels
of N and eGFP-P protein in HEp-2 cells (left panel). (C) SAD eGFP-
P infection of HEp-2 cells induces transcription of IFN- mRNA as
shown by RT-PCR (right panel). and up-regulation of MxA and
STAT1 proteins as shown by Western blotting (left panel).
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Western blot analyses of ISGs confirmed that this failure was
correlated with the presence of IFN- mRNAs (Fig. 3A) and
with stimulation of MxA and STAT-1 expression. In contrast to
those of SAD L16, proteins of SAD PLP were hardly detect-
able in HEp-2 cells at 48 h p.i. (Fig. 3B). The inability of SAD
PLP to inhibit IFN expression is therefore correlated to a
reduction of P levels below a critical threshold. To further
demonstrate that the IFN-induced establishment of an antivi-
ral state is responsible for the observed growth restriction of
SAD PLP, 2fTGH cells and a mutant of 2fTGH, U3A, which
lack STAT-1 and therefore do not respond to IFN (40), were
infected in parallel. Whereas SAD L16 replicated effectively in
both cell lines, accumulation of SAD PLP proteins was ob-
served only in the nonresponding U3A cells (Fig. 3C).
IFN-antagonistic activity of full-length P (P1). In addition to
full-length P encoded by the P ORF (P1), N-terminally trun-
cated forms of the P protein can be expressed from the RV P
gene, due to ribosomal leaky scanning and internal translation
initiation (10). Since the IFN-inducing phenotype of SAD
eGFP-P could be due to the lack of truncated P products from
the eGFP-P fusion gene, it was important to show IFN-antag-
onistic activity of the full-length P1. To generate an RV en-
coding only full-length P1, SAD P1xxx, the first three internal
methionine codons of the SAD P ORF (codons 20, 53, and 83),
which could serve for translation of P2, P3, and P4, respec-
tively, were changed to isoleucine codons by site-directed mu-
tagenesis. In addition, constructs expressing P1 along with one
of the truncated P products (SAD P12xx, P1x3x, and P1xx4)
were generated. In another construct, SAD PC, the methio-
nine initiation codon of the internal C ORF of the SAD P gene
was destroyed by a T384C base pair exchange, leaving the P
protein sequence unchanged (Fig. 4A).
All mutant cDNAs could be rescued into viable virus dis-
playing the predicted protein expression pattern. Only full-
length P1 was detectable in cells infected with SAD P1xxx, and
P1 along with P2 was detectable in SAD P12xx-infected cells. A
slightly increased expression of P3 and P4 was observed for
SAD P1x3x and SAD P1xx4, respectively, consistent with in-
creased translation initiation at downstream methionine co-
dons when upstream initiation codons are missing (Fig. 4B).
The growth kinetics of the mutants in BSR cells, including
SAD PC, did not greatly differ from that of SAD L16, al-
though the triple mutant SAD P1xxx tended to lag behind at
FIG. 2. The level of P protein is crucial for growth of RV in IFN-
competent cells. (A) Genome organization of recombinant RV. SAD
PLP carries an extra copy of the P gene downstream of L (gene order,
3-N-P-M-G-L-P-5). In SAD PLP, the P gene downstream of N in
SAD PLP was deleted, resulting in a virus with a single P gene copy
downstream of L (gene order, 3-N-M-G-L-P-5). (B) Northern blot
hybridization with N and P gene-specific cDNA of RNA from BSR
T7/5 cells infected for 24 h at an MOI of 1 with the indicated viruses.
SAD PLP virus produces lower levels of P mRNA than SAD L16.
(C) Expression of RV N, P, M, and G proteins was analyzed in
Western blots of cell extracts from BSR T7/5 at 24 h p.i. at an MOI of
1. (D and E) Single-step growth curves were performed on BSR T7/5
cells (D) and on HEp-2 cells (E) after infection with the indicated
viruses at an MOI of 0.01. ffu, focus-forming units.
FIG. 3. The level of P protein is crucial for IFN- gene expression.
(A) SAD PLP effectively induces transcription of IFN- mRNA in
HEp-2 cells as shown by RT-PCR. Mock-infected cells were stimulated
by poly(I · C) transfection. RNA was isolated 20 h after infection at an
MOI of 1. For RT-PCR, primers specific for IFN- or -actin (as a
loading control) were used. (B) SAD PLP infection induces an an-
tiviral response and up-regulates expression of MxA and STAT1 as
shown by Western blotting at 48 h p.i. Only in wt SAD L16-infected
cells were abundant amounts of RV N and P proteins detected.(C) In-
fection (MOI of 1) with SAD PLP of U3A cells lacking STAT-1 leads
to accumulation of viral proteins, in contrast to the case for the pa-
rental STAT-1-containing 2fTGH cells.
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early time points of infection. This indicates some attenuating
effect of the mutations introduced into P. However, the virus
reached comparable infectious titers at 3 days p.i. (Fig. 4C).
Most importantly, all mutants were able to grow productively
in the IFN-competent HEp-2 cells. Some lag phase was ob-
served again for SAD P1xxx; however, the virus caught up and
was amplified to titers similar to those of other P mutants.
Thus, the full-length P1 expressed from SAD P1xxx is active in
preventing IFN induction to an extent that is sufficient to
permit virus growth in HEp-2 cells.
RV prevents phosphorylation of IRF-3 by TBK-1. Induction
of the IFN- promoter is known to require the binding of
transcription factors NF-B, IRF-3, and AP-1 (dimers of
ATF-2 or heterodimers of ATF-2/c-Jun), which are activated
in response to virus infection. To address the mechanisms
utilized by RV to prevent IFN induction, we first made use
of reporter gene assays in which a plasmid-encoded luciferase
gene is controlled by the entire IFN- promoter (p125luc) or
by individual regulatory elements responsive to AP-1 (pAP1luc),
NF-B (p55A2luc), or IRF-3 (p55C1Bluc). Infection of Vero
cells with SAD L16 had very little effect on luciferase expression
from p125luc- and p55C1Bluc-driven reporter plasmids, contain-
ing the native IFN- promoter and the IRF-3-responsive ele-
ment, respectively, compared to mock infection of cells. However,
infection with SAD PLP resulted in 25- and 5-fold increases of
luciferase activity from p125luc and p55C1Bluc, respectively. This
indicated that RV P is able to inhibit transcriptional activity of
IRF-3. In contrast, an inhibition of NF-B or AP-1 was not
apparent. Whereas SAD L16 caused similar three- to fourfold
increases of luciferase activity from p55A2luc and pAP1luc, an
even less effective stimulation was observed in SAD PLP-in-
fected cells (Fig. 5A).
To further address the failure of IRF-3-dependent transcrip-
tion in RV-infected cells, we analyzed the activation status of
IRF-3. C-terminal phosphorylation of IRF-3 by TBK-1 or the
inducible IKK-i is a prerequisite for IRF-3 dimerization, nu-
clear import, association with CBP/p300 coactivators, and ac-
tivation of IFN- gene transcription. The IRF-3 status in ex-
tracts from virus-infected HEp-2 cells was analyzed by native
PAGE. In contrast to mock- and SAD L16-infected cells, in
which only monomeric IRF-3 was detectable, a prominent band
of IRF-3 dimers appeared in cells infected with SAD PLP (Fig.
5B). Western blotting with a serum specific for S386-phospho-
IRF-3 confirmed that only the IRF-3 dimers were phosphory-
lated at S386, which is known as a target residue for TBK-1
phosphorylation (42). Thus, RV has the ability to selectively
block the IRF-3 phosphorylation whereas SAD PLP does
not, because of insufficient expression of P protein.
To verify that RV P is able to directly inhibit TBK-1-
mediated IRF-3 phosphorylation, we expressed the authen-
tic P gene and P1xxx from transfected plasmids and investi-
gated the effect on TBK-1-stimulated expression of luciferase
from the IFN- promoter in p125luc. As a control for the
specificity of inhibition, a plasmid encoding the P protein of
BRSV was used. Transfection of a TBK-1-encoding plasmid
into cells transfected in addition with vector lacking an insert,
or with the BRSV P-encoding plasmid, stimulated luciferase
activity 40- to 50-fold. Cotransfection of pRV-P and pRV-
P1xxx, however, abolished luciferase activity from p125 almost
completely (Fig. 6A, left panel). Similarly, transfection of P
abolished TBK-1-mediated expression of luciferase from
p55C1Bluc containing only the IRF-3-responsive elements.
This occurred in a dose-dependent manner, as evidenced by
cotransfection of TBK-1 with decreasing amounts of P-encod-
ing plasmids (Fig. 6A, right panel). The inability of TBK-1 to
stimulate luciferase expression from p125luc and p55C1Bluc in
the presence of RV P was correlated with the lack of IRF-3
phosphorylation, as visualized in Western blot experiments
with cell extracts from transfected 293 cells (Fig. 6B). Whereas
expression of TBK-1 resulted in appearance of S386-phosphor-
ylated IRF-3 dimers, phosphorylation and dimerization of
IRF-3 were not detectable in cells cotransfected with TBK-1-
and P-encoding plasmids. In summary, these data show that
RV P prevents IFN induction in virus-infected cells by ob-
structing phosphorylation of IRF-3 through its kinase, TBK-1.
DISCUSSION
In this study we present evidence that the phosphoprotein P
of RV is an IFN antagonist preventing transcription of IFN-
in virus-infected cells. Viruses with reduced P expression such
as SAD PLP cannot sufficiently interfere with IFN- tran-
scription in HEp-2 cells. A critical IFN response is therefore
FIG. 4. Mutation of internal AUG start codons does not abrogate
IFN-antagonistic activity of P. (A) Schematic representation of muta-
tions introduced into the P protein. Solid vertical bars represent au-
thentic methionine codons. Lack of the bar indicates substitution with
isoleucine codons. Dotted vertical bars represent the AUG codon of
the hypothetical C of P ORF  1. In SAD PC, the AUG codon was
mutated to ACG. (B) Protein synthesis of RV encoding mutated P
proteins. BSR T7/5 cells were infected with the indicated viruses at an
MOI of 1. Cell extracts were analyzed by Western blotting at 24 h p.i.
P and N proteins were detected by mouse polyclonal anti-P serum and
rabbit polyclonal serum S50, respectively. (C) Single-step growth
curves of RVs lacking short forms of P protein on BSR T7/5 and
HEp-2 cells infected at an MOI of 0.01. RV SAD P1xxx, lacking P2, P3,
and P4, grew productively in HEp-2 cells.
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activated, which prohibits productive virus replication. A sub-
stantial contribution of the M protein to IFN escape of RV, as
observed for VSV (1), could be excluded, since RV replicons
encoding N, P, and L did not induce an IFN response. IFN
induction by SAD PLP was correlated with the activation of
the critical transcription factor IRF-3, whereas the activities of
NF-B and AP-1 were unchanged, demonstrating that the IRF-3
activation pathway is specifically blocked in RV-infected cells.
Activation of IRF-3 in virus-infected cells depends on the
recognition of viruses by cytosolic receptors and on signal
transduction pathways leading from recognition to activation
of IRF-3. Recently, the RNA helicase RIG-I was identified as
key in sensing viral dsRNA of Newcastle disease virus and in
subsequent activation of IRF-3 and NF-B (58). Downstream
signaling by RIG-I required an active helicase function and
caspase recruitment domains (58), suggesting the involvement
of caspase recruitment domain-containing adapter proteins
that relay signals to the IRF-3 kinase TBK-1 or IKK-i.
To circumvent IFN, viruses must either avoid their recogni-
tion and eliciting of an alert or target steps of the excited
signaling pathways. Recognition of influenza A virus RNA and
thus activation of IRF-3 are prevented by the viral NS1 pro-
tein, which has a pronounced dsRNA binding activity and
thereby makes the critical virus pattern inaccessible to dsRNA
receptors (16, 53). Although no direct RNA binding activity
has been reported for RV P, it is an important structural
component of the RV RNP and serves as a chaperone for
proper encapsidation of RNA into N protein. Accordingly, it
could be speculated that a critical level of RV P may be im-
portant for proper masking of viral RNAs in the RNA com-
plex. Although it is formally not excluded that P may improve
such camouflage, the fact that P is active at a downstream step
of the IRF-3 activation pathway (see below) argues in favor of
recognition of cytoplasmic RV RNPs by sensing molecules
such as RIG-I, activation of the pathway, and a downstream
inhibition at the step of IRF-3 phosphorylation. Indeed, acti-
vation of IRF-3 by replicating RNP complexes of VSV has
been demonstrated recently (54).
Signaling pathways triggered by recognition of cytosolic vi-
rus and of dsRNA and lipopolysaccharide by Toll-like recep-
tors 3 and 4, respectively, lead to activation of IRF-3 by two
IKK-related kinases, TBK-1 and IKK-i (22, 30, 41, 49). The
constitutively expressed TBK-1 may be the more important
kinase for IRF-3 activation, since the IFN response of TBK-1
knockout mice is severely affected (30, 41). Activation of cy-
toplasmic IRF-3 involves phosphorylation of multiple serine
residues at the C terminus of the protein which allow dimer-
ization of IRF-3, accumulation in the nucleus, and binding of
DNA in a complex including transcription factors ATF-2/c-Jun
(AP-1) and NF-B and coactivators CBP/p300 (38, 39, 45, 52,
57, 59). Evidence is accumulating that the phosphorylation
status of the Ser386 residue critically determines the transcrip-
tional activity of IRF-3, since TBK-1 can phosphorylate Ser386
and IRF-3 phosphorylated at Ser386 is observed exclusively
within dimers. Moreover, mutation at Ser386 abolishes the
dimerization potential of IRF-3 (42). In RV-infected cells,
FIG. 5. Rabies virus targets the IRF-3 activation pathway. (A) Vero cells were transfected with reporter plasmid p125luc, p55C1Bluc,
p55A2luc, or pAP1luc and infected at an MOI of 3 with SAD L16 or SAD PLP. Cell lysates were analyzed using the dual luciferase reporter
system (Promega) for luciferase activity at 48 h p.i. In contrast to SAD PLP, SAD L16 is able to prevent expression of firefly luciferase from
plasmids containing the IFN- promoter (p125luc) and the IRF-3 binding site (p55C1Bluc). In contrast to IRF-3, the activities of NF-B and AP-1
are not further stimulated in SAD PLP-infected cells compared to SAD L16-infected cells. Incubation of cells with tumor necrosis factor alpha
was used as a positive control. Error bars indicate standard deviations. (B) Dimerization and Ser386 phosphorylation of IRF-3 in SAD
PLP-infected cells. HEp-2 cells were infected at an MOI of 1 and cell extracts were analyzed at 24 h p.i. by native PAGE and Western blotting.
In contrast to SAD PLP, wt SAD L16 prevents IRF-3 dimerization and phosphorylation on Ser386. The same cell lysates were analyzed by
SDS-PAGE for expression of viral N and P proteins.
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IRF-3 is not activated, as demonstrated by reporter gene
analyses using plasmids controlled by the IFN- promoter
(p125luc) or the IRF-3 binding part of the IFN- promoter
(p55C1Bluc). The lack of transcriptional activity correlates
with the absence of Ser386-phosphorylated IRF-3 and of
IRF-3 dimers. In contrast, in SAD PLP-infected cells, IRF-
3-dependent expression of reporter genes was possible, and
Ser386-phosphorylated IRF-3 was readily detectable (Fig. 5).
As predicted, S386 phosphorylation was observed only in
IRF-3 dimers and not in monomers.
How the activity of TBK-1 by TRIF or by putative adapters
of the cytosolic IFN-inducing pathway is regulated is not
known. However, overexpression of TBK-1 in cells is sufficient
for IRF-3 activation (22). We have utilized this feature to
demonstrate that the IFN-inhibitory activity of RV involves a
downstream target of the IRF-3 activation pathway. In addi-
tion, this assay revealed that RV P alone is sufficient for in-
hibiting IRF-3 activation. As a control, the phosphoprotein P
of BRSV was used, which has comparable functions in RNA
synthesis and encapsidation of viral RNA. As we have shown
previously, the BRSV nonstructural proteins NS1 and NS2 are
critical for preventing IRF-3 activation (8), and therefore a
corresponding activity of the RSV P protein appeared unlikely.
In contrast to BRSV P, or empty vector, transfection of ex-
pression plasmids comprising the SAD L16 P ORF led to a
drastic reduction of TBK-1-mediated transcriptional activity.
The same effect was observed after expression of pP1xxx, in
which the initiation codons of P2, P3, and P4 were deleted,
confirming activity of full-length P. Further evidence that P
alone is responsible for the phenotype observed in RV-in-
fected cells was obtained by investigating the IRF-3 phosphor-
ylation and dimerization status after overexpression of TBK-1
in the presence of P. These experiments confirmed that P
precludes the critical S386 phosphorylation of IRF-3 by TBK-1
such that dimerization and transcriptional activity are pre-
vented. Further experiments are needed to reveal the molec-
ular mechanisms involved in blocking IRF-3 phosphorylation.
From preliminary experiments it appears that a direct and
strong interaction of P with either TBK-1 or IRF-3 is unlikely,
since coimmunoprecipitations have been unsuccessful so far.
Distinct colocalization of P and TBK-1 or IRF-3 in virus-
infected cells has also not been observed, suggesting indirect
mechanisms.
Activation of IRF-3 is a key step in initiating an antiviral
innate and adaptive immune response and is apparently non-
redundant in most tissues. The identification of proteins from
negative-strand RNA viruses that interfere with IRF-3 activa-
tion is therefore not surprising. In most cases, small accessory
proteins which are not strictly required for virus replication
and which have “luxury functions” (34) are active as IFN an-
tagonists. As first shown for influenza A virus, the NS1 protein
hides viral dsRNA that could serve as a trigger for IRF-3
activation and IFN induction (53). However, RNA binding-
deficient mutants still have some IRF-3-inhibiting capacity,
suggesting additional activities (16). For the influenza B virus
NS1 C terminus, an activity independent of RNA binding has
been demonstrated, supporting the idea that influenza virus
NS1 holoproteins combine multiple activities in inhibiting
FIG. 6. Expression of P is sufficient to prevent TBK-1-mediated IFN- induction. (A) HEK 293 cells were transfected with expression plasmids
encoding the indicated genes and reporter plasmids harboring the firefly luciferase gene under control of the IFN- promoter and renilla luciferase
controlled by the CMV promoter. Luciferase activities were determined at 48 h posttransfection. Cotransfection of P or of P1xxx with TBK-1
inhibited activation of the IFN- promoter almost completely. The P protein of BRSV (RSV P) was used as a control that is not able to inhibit
TBK-1-mediated activation of the p125luc reporter plasmid (left panel). The inhibition of TBK-1-mediated activation of IRF-3 by RV P is dose
dependent as revealed by luciferase expression from p55C1Bluc (right panel). Error bars indicate standard deviations. (B) Expression of RV P
inhibits TBK-1-mediated dimerization of endogenous IRF-3 and phosphorylation of IRF-3 at Ser386. Cell extracts were harvested at 24 h
posttransfection of TBK-1 or TBK-1 and P-encoding plasmids and were analyzed by native PAGE and Western blotting. Expression of Flag-tagged
TBK-1 (fl-TBK1), RV P, and -actin was confirmed by SDS-PAGE and Western blot analysis of the same lysates.
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IRF-3 (17). Pneumovirus NS1 and NS2 proteins, which are
encoded by two extra genes, and Paramyxovirinae V and C
proteins, which are encoded on P genes, are active in prevent-
ing both IFN response (reviewed in reference 24) and IFN
induction (29, 36, 44). Whereas the RSV NS proteins are
involved in targeting the IRF-3 pathway (8), V and C proteins
appear to prevent activation of both IRF-3 and NF-B (29, 36,
44), suggesting that they target different steps of the pathway.
The present work identifies an essential rhabdovirus protein
as a specific IFN antagonist blocking activation of IRF-3. In-
terestingly, the Ebola virus VP35, which corresponds to the P
protein of other Mononegavirales with respect to RNA synthesis
and RNA encapsidation, has previously been shown to inter-
fere with IFN induction and IRF-3 activation when expressed
from transfected plasmids (4, 5, 28). This suggests that Filo-
viridae target a similar or more upstream target of the pathway.
Our data further indicate that the full-length RV P is active
in preventing IFN induction. A recombinant virus expressing a
P gene in which three internal methionine codons that in the
wt P serve for internal translation initiation were exchanged for
isoleucine codons (SAD P1xxx) was viable in BSR cells. There-
fore, the N-terminally truncated P products are not essential
for virus replication, as indicated previously by the viability of
SAD eGFP-P (19). A slower growth of SAD P1xxx compared
to wt RV may indicate that the functions of the P1xxx protein
in RNA synthesis and assembly are somehow affected by the
three Met-Ile mutations. Importantly, SAD P1xxx was able to
grow in HEp-2 cells, showing that expression of P1xxx is suf-
ficient to counteract IFN in virus-infected cells. On the other
hand, this does not mean that the truncated P products may
not aid P in blocking IRF-3 activation. The major difference
from full-length P is that they do not possess the N-terminal L
binding site (12), but oligomerization and binding to N should
be possible (11). In addition, the binding domains for dynein
light chain-1 (LC-8) (32, 43, 46) and the IFN-induced promy-
elocytic leukemia protein are retained (6). Expression experi-
ments are under way to determine the activity of curtailed P
proteins fragments to identify the minimal domains of P able
to counteract IRF-3 activation.
A more demanding task will be the dissociation of P func-
tions and the identification of mutations that eliminate the
IFN-antagonistic function of P without significantly impairing
its essential roles in virus RNA synthesis and assembly. The
IFN-inducing SAD PLP virus still expresses the authentic P
gene, although at much lower levels. The low levels of P do not
greatly limit gene expression, replication, and growth in BSR
cells (Fig. 2D), but they are not sufficient to inhibit induction of
an IFN response. In case of SAD eGFP-P, both reduced levels
of the P fusion protein (Fig. 1B) and the impediment of P
functions by the N-terminal eGFP moiety may be responsible
for the limited growth and the inability to prevent IFN induc-
tion. Indeed, from previous experiments involving complemen-
tation of P-deficient RV, it appears that the eGFP-P fusion
protein has severe defects in mRNA synthesis, while virus
formation is well supported. In contrast, a protein in which
eGFP was fused to the C terminus of P, P-eGFP, supported
transcription well but had defects in virus assembly (19).
The possibility of generating recombinant RVs that are not
able to prevent an IFN response in infected hosts, such as SAD
PLP, holds promise for the development of safe, attenuated
live vaccines. Since alpha/beta IFN is able to foster the devel-
opment of an adaptive immune response (for a review, see
reference 55), such viruses should induce a potent adaptive
immune response. Indeed, a potent adjuvant function of virus-
induced early IFN in vivo is suggested by the high immunoge-
nicity of viruses lacking critical IFN antagonists, such as influ-
enza virus (25) or BRSV (56). Another approach in which the
identification and knockdown of rhabdovirus IFN antagonists
are important is oncolytic virotherapy (for a recent review, see
reference 37). In contrast to nonmalignant tissue, many tumors
are nonresponsive to IFN. Viruses that both induce the pro-
duction of IFN and are susceptible to its antiviral effects should
therefore preferentially replicate in malignant tissue and may
serve as a basis for development of promising therapeutics.
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Human plasmacytoid dendritic cells (PDC) are key sentinels alerting both innate and adaptive immune
responses through production of huge amounts of alpha/beta interferon (IFN). IFN induction in PDC is
triggered by outside-in signal transduction pathways through Toll-like receptor 7 (TLR7) and TLR9 as well as
by recognition of cytosolic virus-specific patterns. TLR7 and TLR9 ligands include single-stranded RNA and
CpG-rich DNA, respectively, as well as synthetic derivatives thereof which are being evaluated as therapeutic
immune modulators promoting Th1 immune responses. Here, we identify the first viruses able to block IFN
production by PDC. Both TLR-dependent and -independent IFN responses are abolished in human PDC
infected with clinical isolates of respiratory syncytial virus (RSV), RSV strain A2, and measles virus Schwarz,
in contrast to RSV strain Long, which we previously identified as a potent IFN inducer in human PDC
(Hornung et al., J. Immunol. 173:5935–5943, 2004). Notably, IFN synthesis of PDC activated by the TLR7 and
TLR9 agonists resiquimod (R848) and CpG oligodeoxynucleotide 2216 is switched off by subsequent infection
by RSV A2 and measles virus. The capacity of RSV and measles virus of human PDC to shut down IFN
production should contribute to the characteristic features of these viruses, such as Th2-biased immune
pathology, immune suppression, and superinfection.
Successful defense against invading pathogens involves rapid
recognition of conserved danger signals through members of
the Toll-like receptor (TLR) protein family (1) and induction
of cytokines that activate both innate and adaptive immunity.
A principal effector integrating early antiviral and immuno-
stimulatory activities is the alpha/beta interferon (IFN) system,
including the group of IFN- isotypes and IFN- (21). Al-
though most types of cells can produce IFN through recogni-
tion of cytosolic double-stranded RNA (1a, 36, 44), or upon
stimulation of TLR3 and TLR4 through double-stranded RNA
or lipopolysaccharide, respectively (1), the vast amount of IFN
upon entry of bacterial and viral pathogens is produced by a
specialized cell population, plasmacytoid dendritic cells (PDC)
(2, 6). Transcriptional induction of IFN genes is controlled by
interferon regulatory factors (IRFs). IRF-3 mainly regulates
IFN- induction, whereas IRF-7 has the ability to activate
IFN- promoters (22, 25, 45). In contrast to other cell types,
PDC constitutively express high levels of IRF-7 such that ex-
pression of IFN- by PDC is independent of the IFN- recep-
tor-mediated positive feedback via IFN- (3, 13, 16, 18), ex-
plaining in part the promptness of high-capacity IFN-
production.
The TLR repertoire of human PDC is composed of TLR7
and TLR9, both located in the endosomal membrane. As
shown recently, TLR7 and TLR8 recognize viral single-
stranded RNA (8, 12) as well as imidazoquinolines such as
imiquimod and resiquimod (R848) and guanosine analogs (re-
viewed in references 1 and 42). In contrast, TLR9 recognizes
bacterial or viral DNA (1), including synthetic CpG oligode-
oxynucleotides (ODN) (11). Indeed, recent work revealed
IFN- production in PDC after incubation with a variety of
inactivated or live DNA and RNA viruses, including herpes
simplex virus types 1 and 2 (16, 19, 23), murine cytomegalovi-
rus (7), human immunodeficiency virus (46), influenza A virus
(8, 24), Sendai virus (14, 16), and vesicular stomatitis virus (3,
24). For herpes simplex virus (19, 23), Influenza A virus (8, 24),
and vesicular stomatitis virus (24), the critical involvement of
MyD88 adaptor-dependent TLR9 and TLR7 signaling has
been demonstrated.
In addition to perceiving external virus components through
TLR7 and TLR9, human PDC have the means to sense cyto-
solic replicating RNA viruses. As we could show recently, re-
spiratory syncytial virus (RSV) escapes from recognition by
PDC TLRs (14). Nevertheless, infection with a particular lab-
oratory strain of RSV (subtype A, strain Long), or cytosolic
delivery of double-stranded RNA but not of poly(I:C) led to
potent IFN- induction in PDC in a TLR- and protein kinase
R-independent manner (14).
The considerable repertoire of tools for sensing pathogens
combined with a tremendous capacity to produce IFN make
human PDC the key sentinels for exciting a generalized host
alert upon infection. Indeed, activation of PDC by a variety of
pathogens and synthetic TLR agonists profoundly shapes the
host immune system by promoting Th1 immune responses and
* Corresponding author. Mailing address: Max-von-Pettenkofer In-
stitute and Gene Center, Feodor-Lynen-Str. 25, D-81377 Munich, Ger-
many. Phone: 49 89 2180 76851. Fax: 49 89 2180 76899. E-mail:
conzelma@lmb.uni-muenchen.de.
† J.S. and V.H. contributed equally to this work.
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suppressing Th2 immune responses (6, 11, 15, 42). This effect
is exploited in the therapeutic use of TLR7 and TLR9 ligands,
such as R848 and CpG ODN, which are promising as immu-
noprotective agents, vaccine adjuvants, and antiallergens (1,
11, 42).
It may therefore appear from the current literature that
PDC are impeccable in sensing intruders. However, in view of
the key role of human PDC in innate and adaptive immunity,
natural viruses must have evolved tools to counteract IFN
production by PDC. In order to identify such viruses, we scru-
tinized two negative-stranded RNA viruses of the Paramyxo-
viridae family, measles virus (MeV) and RSV, which were
considered successful candidates because of their immune-
suppressive features and Th2-biased immune response (10, 27,
35). Since RSV strain Long was previously identified as an
efficient inducer of IFN in PDC (14), infection of different
human cell types, including PDC, other immune cells, and
fibroblast cell lines, was done as a control. Infection of PDC
with RSV A2 and four primary RSV isolates from hospitalized
children and the vaccine MeV Schwarz effectively and similarly
repressed IFN expression. Most importantly, TLR7- and
TLR9-dependent IFN-inducing pathways stimulated by R848
and CpG ODN were abolished by infection with MeV and
RSV A2. Thus, these viruses can make PDC blind to other
pathogens and therapeutic IFN stimuli.
MATERIALS AND METHODS
Virus and cell culture. IFN-free virus stocks of human RSV strains A2 (ATCC
VR-1540) and Long (ATCC VR-26) were prepared by infection of 70 to 80%
confluent Vero (American Type Culture Collection) cell layers at a multiplicity
of 0.1 in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) in the absence
of fetal calf serum (FCS) as described (34). The inoculum was removed after 1 h
and cells were incubated in DMEM supplemented with 2.5% FCS at 37°C in a
5% CO2 atmosphere. Virus was released by freezing and thawing the cell mono-
layers upon development of extensive cytopathic effects, followed by centrifuga-
tion at 3,500 rpm for 20 min at 4°C. Infectious virus titers were determined on
Vero cells by endpoint dilution and counting of infected cell foci stained for
indirect immunofluorescence with an RSV F-specific monoclonal antibody (Se-
rotec).
Primary human RSV isolates from hospitalized children suffering from bron-
chiolitis or obstructive bronchitis were provided by H. Werchau, Bochum, Ger-
many, and were first amplified by two passages on HEp2 cells (ATCC CCL-23)
before preparation of IFN-free virus stocks on Vero cells as described above.
MeV strain Schwarz was obtained from a commercial batch (Ch.-B: W5663-2)
of measles vaccine Merie´ux (Pasteur Me´rieux MSD, Leimen, Germany); 500
50% tissue culture infective doses were incubated with 2.5  106 Vero cells for
1 h in a 15-ml Falcon tube with 2.5 ml of DMEM without FCS. Cells were seeded
in DMEM supplemented with 2.5% FCS at 37°C in a 5% CO2 atmosphere until
development of an extensive cytopathic effect. A virus stock for infection exper-
iments was prepared from this first passage on Vero cells as described above for
RSV.
For infection of epithelial cell lines HEp2, 293, and A549, 2.5  104 cells were
seeded in DMEM with 10% FCS in 48-well plates and were grown for 16 h at
37°C and 5% CO2. Cell numbers were then determined from three extra wells.
FCS-containing medium was replaced by 200 l of DMEM without FCS and
containing the indicated viruses adjusted to a multiplicity of infection of 3. After
1 h of incubation virus-containing medium was removed and cells were washed
and further incubated with DMEM plus 10% FCS. As a negative control for
infection, cells were incubated in parallel with mock supernatant obtained from
freeze-thaw cell lysates of noninfected Vero cells.
Isolation of human hematopoietic cells. Human peripheral blood mononu-
clear cells were prepared from whole blood of young healthy donors by Ficoll-
Hypaque density gradient centrifugation (Biochrom, Berlin, Germany). PDC
were isolated by magnetic activated cell sorting (MACS) using the BDCA-4
dendritic cell isolation kit from Miltenyi Biotec as described (14). Briefly, PDC
were labeled with anti-BDCA-4 antibody coupled to colloidal paramagnetic
microbeads and passed through a magnetic separation column once (LS column;
Miltenyi Biotec). The purity of isolated PDC (lineage-negative, major histocom-
patibility complex class II-positive, CD123-positive) was between 75% and 100%.
PDC from individual donors were used separately in all experiments and were
not pooled. Contaminating cells represented mainly T cells.
Prior to isolation of monocytes and B cells, PDC were depleted by MACS (CS
column; Miltenyi Biotec). B cells were isolated by MACS using the BDCA-1
dendritic cell isolation kit and B-cell isolation kit, respectively (both Miltenyi
Biotec). Monocytes and T cells were isolated from buffy coats by Ficoll (Lym-
phoflot, Biotech, Dreieich) gradient centrifugation (33) at 1,500 rpm in a
Heraeus Varifuge. T cells were separated from monocytes and B cells by plastic
adherence for 1 h. A fraction of strongly adherent monocytes was separated from
B cells by overnight incubation and rigorous washing three times. Remaining
adherent monocytes were trypsinized and primary cultures of monocytes or T
cells were grown in suspension in RPMI supplemented with 10% FCS at 37°C
and 5% CO2 atmosphere. The purity of primary cell cultures was determined by
fluorescence-activated cell scanning (FACS) analysis using phycoerythrin-la-
beled monoclonal CD3 (Serotec), CD14 (Serotec), and CD19 (Serotec) antibod-
ies. The purity of B cells, monocytes, and T cells was greater than 95%, 95%, and
80%, respectively. Viability was 95% as determined by trypan blue exclusion.
Prior to virus infection, T cells were activated by incubation with phytohemag-
glutinin (5 g/ml, Sigma), while B cells and monocytes were activated by incu-
bation with lipopolysaccharide (100 ng/ml, Sigma) in RPMI with 10% FCS at
37°C and 5% CO2 for 16 h. For infection of 5  104 PDC or 10  104 B cells,
T cells, or monocytes, cells were seeded in 100 l of RPMI (Gibco) plus 10%
FCS into 96-cluster-well plates; 100 l of RPMI plus 10% FCS containing
infectious virus adjusted to yield a multiplicity of infection of 3 was added, and
cells were incubated at 37°C in a 5% CO2 atmosphere.
TLR agonists. R848 was purchased from Invivogen (Toulouse, France). CpG
ODN 2216 (5-ggGGGACGATCGTCgggggG-3; lowercase letters are phospho-
rothioate linkage; capital letters are phosphodiester linkage 3 of the base; italics
are CpG dinucleotides) was kindly provided by Coley Pharmaceutical Group
(Wellesley, Mass.). R848 or CpG ODN 2216 was added to PDC at the indicated
time points at final concentrations of 2 g/ml and 6 g/ml, respectively.
Flow cytometry. Infection of epithelial cell lines and of primary hematopoietic
cells was determined by cell surface staining of viral envelope proteins using 2.5
 105 cells (except for PDC, where 2  104 cells were used), fixed for 5 min with
3% paraformaldehyde at room temperature. After washing with FACS buffer
(phosphate-buffered saline containing 0.4% FCS and 0.02% NaN3), staining for
30 min on ice was performed using the mouse monoclonal antibodies RSV-F
(Serotec) and K83, recognizing MeV H (kindly provided by S. Schneider-
Schaulies, Wu¨rzburg, Germany). As a negative control, mock-treated cells were
stained in parallel. After washing, cells were incubated for 30 min with fluores-
cein isothiocyanate-labeled anti-mouse immunoglobulin antibody (Dianova) fol-
lowed by washing and FACS analysis on a BD Biosciences (Heidelberg, Ger-
many) FACSCalibur (excitation at 488 and 635 nm).
Detection of cytokines. For enzyme-linked immunosorbent assay (ELISA)
detection of human interleukin-8 and IFN-, the interleukin-8 kit and the IFN-
ELISA module set (detection range, 8 to 500 pg/ml) of Bender MedSystems
(Graz, Austria) was used. The IFN- module set ELISA detects most IFN-
isoforms but not IFN-. ELISA for an individual experiment was performed in
parallel with 20 l of cell-free supernatant, each collected at indicated time
points and stored at 20°C. Assays were performed according to the manufac-
turer’s recommendations.
RESULTS
IFN production in virus-infected cell lines. We first com-
pared two widely used RSV subtype A laboratory strains, A2
and Long, and the commercial MeV vaccine strain Schwarz
(Me´rieux) for their capacity to interfere with IFN- induction
in epithelial cells. Human A549, 293, and HEp-2 cells were
equally well infected with RSV A2 and Long, as demonstrated
by expression of the fusion (F) protein on the surface of in-
fected cells (Fig. 1B). However, IFN- production was signif-
icantly lower in RSV A2-infected cells at 12, 24, and 36 h
postinfection (Fig. 1A). This is consistent with previous obser-
vations indicating that nonstructural proteins (NS) 1 and 2 of
RSV A2 are able to counteract IFN induction in A549 cells
(39). Among other IFN antagonistic activities (4, 31), the RSV
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nonstructural (NS) proteins interfere with activation of the
essential IFN transcription factor IRF-3 (5). In contrast to
RSV A2, however, RSV Long induced approximately five
times more IFN-, suggesting that this virus has lost the ability
to effectively counteract IRF-3 activation in virus-infected
cells. Similar to RSV A2, infection by MeV Schwarz did not
lead to IFN- induction considerably exceeding that of mock-
infected cells, confirming potent IFN-antagonistic activity de-
scribed for measles virus (29).
IFN production in hematopoietic cells. To investigate virus-
dependent IFN induction in abundant primary cells of the
human immune system, we isolated T cells, B cells, and mono-
cytes from the peripheral blood of individual healthy donors.
Nonactivated cells were virtually not permissive for infection
with either RSV strain or MeV. Only after activation of T cells
with phytohemagglutinin and of B cells or monocytes with
lipopolysaccharide could infection be demonstrated by appear-
ance of the RSV fusion protein (F) and of MeV hemagglutinin
(H) protein on the surface of cells by FACS (Fig. 2B). In the
hematopoietic cells, a less effective expression of F protein by
RSV Long compared to A2 indicated some growth restriction
of this strain. Nevertheless, and similar to the experiments with
the epithelial cell lines, RSV Long caused substantial IFN-
production in T and B cells and in monocytes, whereas RSV
A2 and MeV completely suppressed IFN production (Fig. 2A).
Notably, cells infected with the latter viruses produced even
FIG. 1. MeV Schwarz and RSV strain A2 but not RSV strain Long are able to inhibit production of IFN- in epithelial cell lines. (A) Human
A549, 293, and HEp2 cells were infected with RSV A2, RSV Long, or the MeV vaccine strain Schwarz. After 12, 24, and 36 h (white, grey, and
black bars, respectively) IFN- secreted into the culture supernatants was determined by ELISA. Results are shown as induction compared to
supernatants of mock-infected cells. (B) Cell surface expression of RSV fusion protein (F) and MeV hemagglutinin (H), determined 36 h
postinfection by FACS with monoclonal antibodies, was used to verify productive virus infection. Error bars indicate the standard deviation in three
independent experiments.
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less IFN- than mock-infected and lipopolysaccharide- or phy-
tohemagglutinin-activated cells, suggesting an inhibition of
TLR4-mediated IFN production.
IFN response of human PDC. To examine whether RSV and
measles virus may also interfere with the activity of PDC,
aliquots of 5  104 freshly isolated BDCA-4-positive periph-
eral blood PDC were incubated with virus-containing cell cul-
ture supernatants at a multiplicity of infection of 3. As
expected from previous work (14), RSV Long was able to
infect PDC, though with a small number of cells displaying
moderate levels of newly synthesized F protein on the sur-
face at 72 h postinfection (Fig. 3C). Infection by RSV A2
was less restricted, as indicated by highly increased numbers
of F-stained cells and a threefold-increased mean F fluores-
cence intensity. Productive MeV infection of PDC was dem-
onstrated by the fast appearance of cells staining for the H
protein, their number reaching more than 90% within 72 h
of infection (Fig. 3C).
FIG. 2. MeV and RSV A2 but not RSV Long inhibit production of IFN- in primary human hematopoietic cells. (A) Freshly isolated T cells,
B cells, and monocytes were either incubated with medium or activated by addition of lipopolysaccharide (LPS) or phytohemagglutinin (PHA) for
16 h, followed by virus infection or incubation with mock supernatant. After 24, 36, and 48 h (white, grey, and black bars, respectively), the amount
of IFN- in supernatants was determined by ELISA. (B) Cell surface expression of RSV F protein and MeV H protein determined by FACS at
48 h postinfection as described for Fig. 1. Error bars indicate the standard deviation of mean in experiments using primary cells from three (T cells),
six (B cells), or seven (monocytes) individual donors.
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As a positive control for IFN- production, PDC were
treated with 4 g of CpG ODN 2216, which strongly activates
PDC through TLR9 binding (20)/ml. Supernatants from virus-
infected, mock-infected, and ODN-treated PDC were assayed
12, 24, and 36 h later for IFN- production by ELISA. Both
CpG ODN 2216-treated and RSV Long-infected PDC pro-
duced huge and comparable amounts of IFN-, with concen-
trations reaching 13.8 ng/ml and 11.6 ng/ml at 36 h, respectively
(Fig. 3A). However, in PDC infected with RSV A2 or measles
virus, IFN- production was suppressed. In particular, MeV
infection allowed not much more IFN to be produced than in
mock-infected cells. Importantly, infection with the different
viruses had no obvious effect on production of interleukin-8,
which is NF-	B dependent (18, 28). Treatment of PDC with
supernatants from either mock-infected or virus-infected cell
cultures led to a similar and approximately 10-fold increase of
interleukin-8 compared to PDC treated with fresh medium
(Fig. 3B). These data confirm the viability of virus-infected
PDC and indicate that RSV NS proteins block IRF-3 and
IRF-7 activation in PDC, whereas the activity of the NF-	B
and AP-1 transcription factors is not affected, as was demon-
strated previously for epithelial cells (5). Similarly, the major
target of MeV appears to be the IRF rather than the NF-	B
activation pathway.
To confirm that natural RSV shares the ability of A2 to
prevent IFN- induction in PDC, four clinical RSV isolates
from children hospitalized with bronchiolitis or obstructive
bronchitis were included in the assay. All four isolates were
able to infect PDC similarly to RSV A2 (Fig. 4C) and sup-
pressed IFN- production equally well (Fig. 4A), while they
did not suppress production of interleukin-8 (Fig. 4B). Thus,
infection of human PDC and potent inhibition of IFN- in-
duction are intrinsic features of clinical human RSV isolates.
RSV A2 but not RSV Long has fully retained this important
wild-type phenotype.
Inhibition of TLR7 and TLR9 signaling. As shown previ-
ously, RSV Long and bovine RSV expressing the F protein
from human RSV Long (34) escape detection by TLRs on
PDC (14). Recognition of double-stranded RNA generated by
replicating virus in the cytoplasm by cytosolic receptors such as
RIG-I and related RNA helicases (1a, 44) is therefore respon-
sible for the observed potent IFN- expression. Since RSV A2
and MeV infection of PDC suppresses IFN- production, it is
suggested that these viruses interfere with the pathway leading
FIG. 3. MeV and RSV A2 but not RSV Long inhibit production of IFN- in infected PDC. Freshly isolated PDC were infected with the
indicated viruses and treated with mock supernatant or supernatant containing 4 g/ml of ODN2216. After 12, 24, and 36 h (white, grey, and black
bars, respectively), secreted IFN- (A) and interleukin-8 (B) were determined by ELISA. Error bars in indicate the standard deviation of mean
of four experiments using PDC from six individual donors (A) or three donors (B). Infection of PDC was assayed by FACS monitoring of cell
surface expression of RSV F and MeV H protein at 36 h (thin line) and 72 h (bold line) postinfection. For a negative control (dotted line),
mock-infected cells were incubated for 72 h.
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from recognition of cytosolic viral double-stranded RNA to
activation of IRF-3.
To assess whether RSV A2 and MeV are also able to inter-
fere with the TLR-dependent IFN--inducing pathways, we
measured the effect of virus infection on TLR7 and TLR9
signaling upon stimulation with known TLR agonists. First, the
response to the TRL7 ligand R848 (resiquimod) was investi-
gated. Stimulation of mock-infected PDC with 2 g of R848
per ml led to production of up to 9 ng/ml IFN- (Fig. 5). Even
higher amounts, up to 15 ng/ml, of IFN were produced in PDC
infected with RSV Long. Since similarly high IFN- levels
were previously observed in the absence of R848 in RSV Long-
infected cells (see Fig. 3), a synergistic effect of the IFN-
inducing virus and R848 stimulation was not evident. In strik-
ing contrast to the situation with RSV Long, R848 treatment of
PDC infected with RSV A2 and MeV did not result in pro-
duction of considerable amounts of IFN-. Thus, RSV A2 and
MeV are able to antagonize TLR7-mediated IFN induction
pathways.
To study the effects of virus infection on TLR9 signaling,
ODN 2216, which is the most potent IFN-inducing CpG ODN
available so far, was used (18). Incubation of mock-infected
PDC with 6 g/ml ODN 2216 stimulated secretion of large
amounts of IFN-, reaching more than 15 ng/ml at 36 h (Fig.
6A). In cells previously infected with RSV Long, similar
amounts of IFN were produced. An additive activation of
IFN- by ODN 2216 and the IFN-inducing RSV Long was
indicated by even higher IFN production at 12 h postinfection.
In striking contrast, IFN secretion was almost completely abol-
ished in cells infected with RSV A2 or measles virus (Fig. 6A).
Thus, RSV A2 and measles virus are able to prevent CpG-
mediated activation of IFN through TLR9.
To assess the capacity of the viruses to shut down TLR9
signaling pathways previously activated by CpG, PDC were
first stimulated by incubation with ODN 2216 for 6 h or 24 h.
The cells were washed and incubated with supernatants from
noninfected (mock) and virus-infected cell cultures (multiplic-
ity of infection of 3). In mock-infected PDC, the 6-h ODN
incubation period resulted in secretion of 2, 4, and 13 ng/ml
IFN at 12, 24, and 36 h, respectively (Fig. 6B, upper panel).
Whereas infection with RSV Long caused slightly increased
levels of IFN-, infection with RSV A2 and measles virus
strongly diminished IFN- secretion turned on during the 6-h
ODN incubation period. Indeed, values were only slightly
greater than previously observed for nonstimulated and mock-
infected PDC (e.g., Fig. 6A). Moreover, virus infection was
able to considerably reduce IFN production even after a 24-h
ODN 2216 stimulation. Compared to mock- and RSV Long-
infected PDC, a reduction of IFN- levels to less than 50% was
observed in RSV A2-infected PDC at all time points moni-
tored (Fig. 6B, lower panel). These results show that previously
activated operational TLR9 signaling can be shut down by both
RSV A2 and measles virus.
DISCUSSION
In summary, we provide the first evidence that viruses can
counteract IFN production by human PDC in vitro. Most re-
markably, this applies to all IFN-inducing pathways so far
known to be active in PDC, including those triggered by cyto-
FIG. 4. Clinical RSV isolates from hospitalized children counteract
IFN- production in infected PDC. PDC were infected with the indi-
cated clinical RSV isolates or RSV Long or incubated with mock
supernatant. After 12, 24, and 36 h (white, light grey, and dark grey
bars, respectively), secreted IFN- (A) and interleukin-8 (B) were
determined by ELISA. Error bars show the standard deviation of the
mean of four experiments using PDC from individual donors. (C) Ex-
pression of RSV F on the surface of PDC as determined by FACS
(mean fluorescence) after 36 h (grey) and 72 h (black) of incubation.
FIG. 5. RSV A2 and MeV infection precludes IFN production
mediated by the TLR7 agonist R848. Human PDC were mock infected
or infected with the indicated viruses for 16 h, followed by addition of
fresh medium or medium containing 2 g/ml of R848. IFN- produc-
tion was determined at 12, 24, and 36 h post-R848 treatment (white,
grey, and black bars, respectively). Error bars indicate the standard
deviation of the mean in three experiments using PDC from five
individual donors.
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plasmic recognition of viral replication, probably through mol-
ecules sensing viral double-stranded RNA, such as RIG-I and
related DexD/H box RNA helicases like MDA5 (1a, 44), as
well as those activated by outside-in signaling through TLR7
and TLR9 (40). In vivo, therefore, RSV and measles virus
should not only avoid an immediate IFN alert caused by them-
selves but also be able to prevent or diminish an IFN and
immune response triggered by coinfecting unrelated patho-
gens, including single-stranded RNA viruses, DNA viruses,
and bacteria. Consequently, infection by RSV and measles
virus should make hosts more permissive to other pathogens.
In addition, an antagonistic effect on the effectiveness of syn-
thetic TLR agonists such as CpG ODN and R848 administered
as immune adjuvants can be predicted.
Intriguingly, deaths from measles are largely due to an in-
creased susceptibility to secondary bacterial and viral infec-
tions, attributed to a prolonged state of immune suppression
(27, 35). One mechanism contributing to immune suppression
is contact-mediated inhibition of T-cell proliferation by mea-
sles virus surface proteins (32). The present findings that hu-
man PDC are highly permissive for infection with measles virus
in vitro and fail to produce IFN upon different TLR stimuli
may further explain how measles virus facilitates bacterial su-
perinfections in vivo and encumbers the development of an
adequate immune response. Of note in this respect is the
typical strong Th2 bias in measles (27). Since IFN- drives the
immune response towards Th1, shutdown of the major human
IFN-producing cells by measles virus may considerably con-
tribute to this feature of measles pathology.
Unlike measles virus, which causes a generalized infection
by targeting mainly cells of hematopoietic origin and therefore
may reach a considerable portion of the PDC population, RSV
infection remains restricted mainly to epithelial cells of the
upper and lower respiratory tract. The finding that clinical
RSV isolates have the capacity to prevent PDC IFN responses,
however, strongly suggests that this feature is also vital for local
infection of the respiratory tract by RSV. Notably, further
immune-relevant features are shared by measles virus and
RSV, including a pronounced in vitro contact inhibition of T
cells by the viral surface proteins (33) and a Th2-biased im-
mune response (10). Although bacterial superinfections in
RSV infection appear to contribute little to the disease in
humans, they are often described for infections of calves with
bovine RSV (see the references in reference 33), a relevant
animal model for human RSV.
In RSV-infected non-PDC cell types, induction of IFN-
and IFN- is prevented by the activity of two unique proteins,
the viral NS1 and NS2 proteins (5, 31, 39, 43). As we have
shown recently, the NS1 and -2 proteins interfere with the
activation of the essential IFN transcription factor IRF-3,
while NF-	B and AP-1 activity is not affected (5). Both cyto-
solic double-stranded RNA-triggered and TLR3- and TLR4-
dependent IFN induction pathways appear to merge in the
phosphorylation of IRF-3 (and IRF-7, if present) by two ho-
mologous kinases, tank binding protein 1 (TBK-1), and the
inducible inhibitor of kappa kinase, IKK-i (1, 9, 26, 38). IRF-3
activation through TLR3 and TLR4 involves the adapter
TRIF, which has been shown to associate with TBK-1 and
IKK-i (reviewed in reference 1). In contrast, TLR7 and TLR9
IFN signaling depends on MyD88 (8, 12, 17), which directly
binds IRF-7 and TRAF6 but not IRF-3 (17).
The observation that RSV Long has lost the ability to coun-
teract both TLR7- and TLR9-dependent and cytoplasmic IFN-
inducing pathways while RSV A2 and all clinical RSV isolates
have retained the full inhibitory set suggests molecular targets
common to TLR-dependent and -independent IFN inducing
pathways, namely, phosphorylation of the IRFs by the different
IRF kinases. This is supported by our experiments with virus-
infected B cells and monocytes stimulated by lipopolysaccha-
ride (in order to render these cells permissive for virus infec-
tion), which indicate that RSV and measles virus not only
FIG. 6. MeV and RSV A2 abolishes ODN-induced IFN- produc-
tion of PDC. (A) PDC were infected with the indicated viruses for
16 h, followed by stimulation with 6 g/ml ODN2216. IFN production
after 12, 24, and 36 h (white, grey, and black bars, respectively) was
measured by ELISA. Error bars indicate the standard deviation of the
mean in three experiments using PDC from five individual donors.
(B) Human PDC were first stimulated by addition of ODN 2216 for 6 h
(upper panel) or 24 h (lower panel). Then, the medium was removed
and the cells were infected with the indicated viruses at a multiplicity
of infection of 3 or mock infected. The effect of the 6-h ODN 2216
stimulus is almost completely abolished by MeV and RSV A2, and
infection after the long 24-h stimulus is still sufficient to diminish IFN
production by approximately 40% and 50%, respectively. Error bars
indicate the standard deviation in experiments using PDC from four
individual donors.
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abolish the TLR7/9 MyD88-dependent signaling to IFN acti-
vation but might also counteract TRIF-dependent TLR4 sig-
naling (see Fig. 2). As the NS proteins of RSV are critically
involved in inhibiting IFN induction in non-PDC and the bo-
vine RSV NS has been shown to prevent phosphorylation of
IRF-3 (5), it will be interesting to determine whether these
proteins are also involved in counteracting TLR-mediated IFN
induction e.g., by preventing activation of IRF-7.
The situation with the IFN antagonists responsible for pre-
venting IFN induction of wild-type measles virus (29) is less
clear. As for other Paramyxovirinae, the V protein of measles
virus interferes with IFN signaling through STAT (30), and a
corresponding activity has been reported for the measles virus
C protein (37). Since PDC are capable of producing IFN-
independently of the IFN- receptor-mediated positive feed-
back via IFN- (3, 13, 16, 18), these viral activities on IFN
signaling are not sufficient to account for the observed effective
IFN- shutdown in PDC. It therefore remains to be clarified
which measles virus factors interfere with IFN induction.
From the present experiment, it appears that measles virus
and RSV have similar targets. Interestingly, measles virus
strain Edmonston, which is closely related to strain Schwarz,
has been shown to activate IRF-3 and to induce IFN in 293
cells (41). Comparison of the sequences of the strains might
help to reveal the genetic basis for interference with IFN in-
duction in fibroblasts and probably in PDC. Further analysis of
the mechanisms used by RSV and measles virus to prevent IFN
production in PDC will not only lead to recombinant vaccine
viruses with abolished or reduced capacity to undermine the
host immune response but may also help to develop tools to
modulate the activities of therapeutic TLR ligands.
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Fluorescent Protein-Tagged Phosphoprotein P Supports
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Rhabdoviruses such as rabies virus (RV) encode only five multifunctional proteins accomplishing viral gene
expression and virus formation. The viral phosphoprotein, P, is a structural component of the viral ribonu-
cleoprotein (RNP) complex and an essential cofactor for the viral RNA-dependent RNA polymerase. We show
here that RV P fused to enhanced green fluorescent protein (eGFP) can substitute for P throughout the viral
life cycle, allowing fluorescence labeling and tracking of RV RNPs under live cell conditions. To first assess the
functions of P fusion constructs, a recombinant RV lacking the P gene, SAD P, was complemented in cell lines
constitutively expressing eGFP-P or P-eGFP fusion proteins. P-eGFP supported the rapid accumulation of
viral mRNAs but led to low infectious-virus titers, suggesting impairment of virus formation. In contrast,
complementation with eGFP-P resulted in slower accumulation of mRNAs but similar infectious titers,
suggesting interference with polymerase activity rather than with virus formation. Fluorescence microscopy
allowed the detection of eGFP-P-labeled extracellular virus particles and tracking of cell binding and temper-
ature-dependent internalization into intracellular vesicles. Recombinant RVs expressing eGFP-P or an eGFP-P
mutant lacking the binding site for dynein light chain 1 (DLC1) instead of P were used to track interaction with
cellular proteins. In cells expressing a DsRed-labeled DLC1, colocalization of DLC1 with eGFP-P but not with
the mutant P was observed. Fluorescent labeling of RV RNPs will allow further dissection of virus entry,
replication, and egress under live-cell conditions as well as cell interactions.
Rabies virus (RV) of the Lyssavirus genus and related mem-
bers of the Rhabdoviridae, such as vesicular stomatitis virus
(VSV, Vesiculovirus genus), are composed of only five multi-
functional viral proteins, namely, nucleoprotein (N), phospho-
protein (P), matrix protein (M), glycoprotein (G), and a large
(L) RNA-dependent RNA polymerase. The viral RNA is en-
wrapped with N and associated with P and L to form a typical
helical ribonucleoprotein (RNP) complex, which is active in
RNA synthesis. During RV assembly, highly condensed RNPs
of the typical rhabdovirus or bullet shape are enwrapped into
an envelope containing the M and G proteins (31, 32). Entry of
rhabdoviruses into cells involves receptor-mediated endocyto-
sis, pH-dependent fusion of the viral and endosomal mem-
branes (21), release into the cytoplasm, and uncoating of RNPs
from M (35) such that gene expression can resume. Although
these basic principles of the rhabdovirus infection pathway
have been known for some time, details of many particular
steps during entry, uncoating, gene expression, and virus egress
await illumination. The possibility of real-time visualization of
the entire infection pathway of rhabdoviruses and of tracking
virus components such as RNPs in living cells is one highly
desirable tool for the study of the rhabdovirus life cycle. A
widely used approach in imaging of proteins or viruses in live
cells is to fuse autofluorescent proteins such as green fluores-
cent protein (GFP) to either the amino or the carboxy termi-
nus of the protein of interest and to examine fluorescence
within the cells over time. However, in view of the multiple
functions of all rhabdovirus RNPs, their multiple interactions
with viral and cellular proteins, and possible structural con-
straints, there may be uncertainty as to the success of this
approach.
We here assessed the feasibility of labeling RV RNPs and
rabies virus virions by N- and C-terminal fusion of enhanced
GFP (eGFP) to the phosphoprotein P. P is not just a structural
component of the RNP but is crucially involved in numerous
events during the virus life cycle, including proper formation of
viral RNPs and virus particles and viral RNA synthesis. In
rhabdovirus-infected cells, P is present in the form of oli-
gomers (20). Binding of P to N is thought to chaperone N such
that it specifically encapsidates viral RNA (9, 23, 26), making it
a suitable template for RNA synthesis by the viral polymerase
complex. In addition, P is an essential cofactor of the polymer-
ase complex itself and directly binds the catalytic L protein (6).
During RNA synthesis, RV RNPs or the polymerase complex
interact with the M protein, which is involved in regulating the
balance of mRNA transcription and RNP replication (17, 18).
Moreover, RV P protein may also be involved in interactions
with cellular factors important for in vivo infection. P was
shown to bind to dynein light chain 1 (DLC1), suggesting a
function in the transport of RNPs by motor proteins (27, 33,
34). In addition, an N-terminally truncated form of P has been
found to enter the nucleus and to colocalize with promyelotic
leukemia bodies (1).
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Since it was not clear whether the fusion of eGFP to the N
or C terminus of RV P affected its essential functions, recom-
binant P fusion proteins were first used for complementation
of a recombinant RV lacking the P gene. Successful comple-
mentation was possible with N- and C-terminally fused P pro-
teins, but differential activity in RNA synthesis and virus for-
mation were noticed. The eGFP-P fusion protein allowed
effective production of fluorescent extracellular virions that
could be detected by conventional epifluorescence microscopy
or laser-scanning microscopy and could be tracked during at-
tachment to cells and internalization. The recovery of a viable
recombinant RV expressing eGFP-P instead of P and its in-
teraction with the cellular DLC1 protein further suggested that
such recombinant viruses represent promising and reliable
tools to study diverse aspects of rhabdovirus biology in living
cells.
MATERIALS AND METHODS
Cells and viruses. Viruses were grown on BHK-21 clone BSR cell monolayers
maintained in Glasgow minimal essential medium supplemented with 10% new-
born calf serum. BSR T7/5 cells constitutively expressing bacteriophage T7 RNA
polymerase (2) was used for recovery of RV from transfected cDNA. BSR cells
that constitutively express the authentic RV P protein were generated by co-
transfection of 2.0 g of p4P plasmid containing the P gene after the simian virus
40 promoter and of 0.2 g of pMamNeo containing the neomycin resistance gene
and subsequent cultivation in the presence of G418 (1 mg/ml). Cells expressing
P fused to the N or C terminus of eGFP (BSR T7-eGFP-P and BSR T7-P-eGFP)
were selected after cotransfection of BSR T7/5 cells with 5.0 g of pEGFP-P or
pP-EGFP and 0.5 g of pTRE-Hyg (Clontech) and subsequent cultivation in the
presence of hygromycin (1 mg/ml). The expression plasmids pEGFP-P and pP-
EGFP are derivates of pEGFP-C3 and pEGFP-N3 (Clontech), with different
linkers of 14 and 16 amino acids, respectively. BSR T7/5 cells that constitutively
express DLC1 fused to the N terminus of a modified red fluorescent protein from
Discosoma sp. (DsRed) were selected after cotransfection of the expression
vector pDLC1-DsRed and pTRE-Hyg and selection as described above for
eGFP-P cells. pDLC1-DsRed was constructed by an insertion of the coding
sequence of DLC1 from human 293 cells into the pDsRed-Express-N1 vector
(Clontech).
Recombinant RV lacking P expression, SAD P, was generated from pSAD
P, which is a cDNA derivative of pSAD L16 (36). A deletion of 934 bp in the
P-gene sequence (SAD B19 [7] nucleotides 1500 to 2434) resulted in the com-
plete deletion of the P-protein-encoding sequence. In SAD eGFP-P, the authen-
tic P coding sequence was replaced with the eGFP-P fusion encoding sequence
from pEGFP-P. For generation of SAD eGFP-PI, the P protein coding sequence
in pTIT-P (16) was mutated with the mutagenesis primer (5-CCAGGAAAGT
CTTCAGCAGCGGCAGCGGCAGCGGCAGCGGGCCGAGAGCTCAAGA
AG-3) using the Chameleon mutagenesis kit (Stratagene) as specified by the
supplier. In pTIT-PI, 8 amino acids (142-EDKSTQTT-149) were thus replaced
by alanine residues, deleting the DLC1 binding motif. The corresponding re-
combinant SAD eGFP-PI was generated by insertion of the mutated P gene
sequence into the pSAD eGFP-P cDNA clone. A detailed description of all
cloning steps and the final sequences are available from the authors on request
by e-mail.
cDNA rescue experiments. cDNA plasmids were transfected into cells after
calcium phosphate precipitation (mammalian transfection kit; Stratagene) as
specified by the suppliers. Vaccinia virus-free rescue of recombinant RV was
performed as described previously (16) by transfection of 10 g of full-length
cDNA and plasmids pTIT-N (5 g), pTIT-P (2.5 g), and pTIT-L (2.5 g) in 106
BSR T7/5 cells grown in 8-cm2 culture dishes. For recovery and subsequent
amplification of the P-deficient RV SAD P, culture supernatants from trans-
fected cells were transferred onto BSR P cells at 3 days postinfection and
incubated until almost 100% of the cells were infected.
Density gradient centrifugation. Supernatants from 3  106 virus-infected
cells were harvested on day 2 after infection at a multiplicity of infection (MOI)
of 1, and the virions were pelleted through 20% sucrose in TEN buffer (50 mM
Tris-HCl, 1 mM EDTA, 150 mM NaCl [pH 7.4]) on a 60% sucrose cushion. The
interphase fraction was diluted in TEN buffer and was loaded on a 12-ml 20 to
40% iodixanol (Optiprep; Axis-Shield) density gradient. After 18 h of centrifu-
gation (Beckman SW28 instrument; 27,000 rpm at 4°C), 12 fractions of 1 ml each
were collected and the quality of the density gradients was controlled by deter-
mination of the refraction index of each fraction. After polyacrylamide PAA gel
electrophoresis and Western blotting, fractions were analyzed with RV N, P, and
M protein-specific sera or with a polyclonal serum recognizing eGFP.
Cell binding and virus uptake. To observe binding of virus to the surface of
cells, BSR T7/5 cells were trypsinized and the suspension was incubated with
virus for 2 h at 4°C. The cells were then pelleted, resuspended in ice-cold
phosphate-buffered saline and transferred onto the slides. After fixation and
counterstaining with propidium iodide, the cells were mounted (Vectashield)
and analyzed by confocal laser-scanning microscopy. To monitor virus uptake,
the cells were incubated at 37°C for 30 min after incubation of cells for 2 h at 4°C.
Fluorescence microscopy. Epifluorescence microscopy was performed on an
inverse Zeiss Axiovert 200M microscope with 20 and 63 (NA 1.4) objectives,
using Zeiss Filtersets (FS) 10 for GFP (excitation, BP450 to 490 nm; emission,
BP515 to 565 nm) and FS 00 (excitation, BP530 to 585 nm; emission, LP615 nm)
for DsRed. Images were taken with a Zeiss Axiocam HRm microscope using the
Axiovision 3.1 software. Confocal laser-scanning microscopy was performed with
the Leica TCS NT laser system, using a Leica DM IRB microscope or with a
Zeiss LSM510 Meta laser system using a Zeiss Axivert200 microscope.
RNA analysis. RNA from cells was isolated with the RNeasy mini kit (Qiagen).
Northern blot analyses and hybridizations with [-32P]dCTP-labeled cDNAs
recognizing the RV N or P gene sequences were performed as described previ-
ously (8). Hybridization signals were quantified by PhosphorImager analysis
(Molecular Dynamics Storm).
RESULTS
Recovery of a P-deficient RV and complementation with
eGFP fusion proteins. To establish a versatile system for as-
saying activities of different RV P constructs, we constructed
an RV cDNA in which the complete P open reading frame was
deleted (Fig. 1A). Rescue of the cDNA into recombinant RV
SAD P was achieved after transfection of BSR T7/5 cells with
plasmids encoding RV N, P, L, and SAD P antigenome RNA
as described previously (16, 36). For further propagation of the
newly generated viruses, supernatants from transfected cells
were then transferred to a cell line constitutively expressing
RV P (BSR-P) that was generated as described in Materials
and Methods. The low levels of P expressed in BSR-P cells (not
shown) supported the amplification of SAD P; however, in-
fectious-virus titers did not exceed 105 infectious units (IU) per
ml of cell culture supernatant (not shown).
To test whether P proteins to which fluorescent eGFP was
fused at the N or C terminus (eGFP-P or P-eGFP, respec-
tively) would support the growth of SAD P and provide a
possibility to label virus RNPs and virus particles, two cell lines
constitutively expressing the fluorescent proteins were gener-
ated. Expression of both fusion proteins led to a diffuse green
cytoplasmic fluorescence with no significant signal in the nu-
cleus of cells (Fig. 1B, bottom). However, when BSR eGFP-P
and BSR P-eGFP cells were infected with the P-deficient SAD
P or the standard RV SAD L16 at an MOI of 0.1, fluores-
cence was concentrated in granular structures similar to the
typical inclusion bodies that are usually observed in RV-in-
fected cells (Fig. 1B, top and middle). Since coexpression of
the RV N and P proteins is sufficient for formation of the
inclusion bodies (5), the appearance of these fluorescent dots
in SAD P-infected cells demonstrated successful viral N gene
expression by the activity of the two fluorescent P fusion pro-
teins. In addition, it indicated typical interaction of eGFP-P
and P-eGFP with N. Indeed, immunostaining with antibodies
recognizing RV N protein revealed colocalization with the
fusion proteins. In wild-type (wt) RV infection, this interaction
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took place in the presence of excess authentic P expressed
from the virus. Moreover, similar to SAD L16, further spread
of SAD P in the cell cultures could be directly observed by
the appearance the autofluorescent inclusion bodies in previ-
ously homogenously fluorescing cells (data not shown). This
suggested that infectious-virus particle formation may also be
supported by the eGFP-P fusions.
The effects of the P fusion proteins on virus gene expression
and protein synthesis were further investigated by Western and
Northern blot analyses (Fig. 2). In both cell lines the cell-
derived GFP fusions with an expected size of approximately 62
kDa were detectable with a serum recognizing RV P protein
(Fig. 2A). Infection with SAD P led to the synthesis of con-
siderable amounts of N protein only in the cell lines expressing
the tagged P proteins. A faint signal for N was also detectable
in noncomplementing BSR T7/5 cells, which could represent
viral input N and newly expressed N protein through primary
transcription of input virus. Notably, although eGFP-P was
apparently present at higher levels than P-eGFP, similar levels
of N protein accumulated in the two cell lines, suggesting a
somewhat higher specific activity of P-eGFP in viral gene ex-
pression (Fig. 2A). This was supported by the finding of lower
levels of cellular P-eGFP mRNA than of eGFP-P mRNA (Fig.
2B, bottom), combined with slightly more abundant N mRNAs
in SAD P-infected P-eGFP cells (Fig. 2B, top). Thus, it ap-
pears that P-eGFP is less impaired than eGFP-P in its function
in viral mRNA synthesis. Moreover, expression of eGFP-P had
a considerable negative effect on RNA synthesis and protein
expression of wt RV, illustrated by reduced N and P mRNA
and protein levels (Fig. 2, right panels), whereas viral RNA
FIG. 1. Complementation of a P-deficient RV in cells expressing
eGFP-tagged P proteins. (A) Genome organization of SAD P, lack-
ing the entire P open reading frame, and the parental SAD L16.
(B) Recruitment of cellular eGFP-tagged P proteins into RV inclusion
bodies. Cells expressing the indicated P fusion proteins were infected
with SAD P or SAD L16. The appearance of fluorescent inclusion
bodies at 1 day postinfection demonstrated nucleoprotein gene expres-
sion from SAD P. Both eGFP-P and P-eGFP proteins also colocal-
ized to inclusion bodies of wt SAD L16. In noninfected cells (n.i.),
diffuse fluorescence was exclusively observed. FIG. 2. Gene expression of SAD P and SAD L16 in eGFP-P and
P-eGFP protein-expressing cells. Cells were infected with the indicated
viruses at an MOI of 0.5 for 2 days and processed for analysis of viral
proteins and RNA. (A) Western blot with a serum recognizing RV N
and P proteins. For SAD L16-infected cells, three times less extract
was loaded. (B) Northern blot hybridization with N- and P-specific
cDNA probes. n.i., not infected.
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synthesis in P-eGFP cells was more similar to that in the
control BSR T7/5 cells.
Incorporation of eGFP-P into virions. Although SAD P
virus gene expression was readily detected in the complement-
ing cell lines, the yield of infectious virus was low, reaching
maximum titers of 7  105 IU per ml of cell culture superna-
tant, i.e., 1,000-fold lower than standard virus SAD L16 titers
in BSR cells. Most interestingly, infectious titers on P-eGFP
cells were the same as or lower than those on eGFP-P cells, in
spite of the obviously more rapid accumulation of viral RNAs
in P-eGFP cells. To study virus formation and incorporation of
the P-fusion proteins, supernatant virions from SAD P-in-
fected cells were enriched 4 days after infection at an MOI of
0.1 by centrifugation through 20% sucrose on a 60% sucrose
cushion. Western blot analysis with sera recognizing GFP or
RV N and P revealed the presence of both P fusion proteins
along with N and suggested the formation of virus particles
containing the P fusion proteins (Fig. 3A). Consistently, super-
natants from eGFP-P cells were found to contain more viral
protein, suggesting that its poor transcription activity is com-
pensated by better permitting particle formation. Further pu-
rification by iodixanol density gradient centrifugation con-
firmed the formation of typical virus particles containing
eGFP-P. A common protein peak of RV N, M, and the cell-
derived 62-kDa eGFP-P protein, which also represented the
peak of infectious virus (not shown), was demonstrated by
Western blot analyses using sera against viral proteins and
GFP (Fig. 3B, fractions 3 to 5). The complemented SAD
P(eGFP-P) virions completely lacked the authentic 37-kDa
RV P protein abundantly present in particles from SAD L16-
infected cells (Fig. 3C). As indicated by the appearance of a
faint band representing eGFP-P in virions from e-GFP-ex-
pressing cells infected with SAD L16, incorporation of eGFP-P
into virions was possible, although at low efficiency, in the
presence of excess amounts of authentic viral P protein (Fig.
3C).
Detection of labeled virus particles by fluorescence micros-
copy. To check whether the amount of virus-incorporated
eGFP-P is sufficient for detection of virions by fluorescence
microscopy, density gradient-purified SAD P(eGFP-P) viri-
ons were transferred to glass coverslips and, without further
treatment, were analyzed by confocal laser-scanning micros-
copy. Bright punctiform green fluorescence was observed, with
individual dots of rather uniform size (Fig. 4A). Such typical
FIG. 3. Incorporation of eGFP-P into RV virions. (A) Supernatants from cells expressing the indicated P fusion proteins and infected for 4 days
with SAD P virus were centrifuged through 20% sucrose and analyzed by Western blotting using sera recognizing eGFP (upper blot) and RV
N and P proteins (lower blot). n.i., not infected. (B) Purification of supernatant virions from SAD P-infected eGFP-P cells in a 20 to 40%
iodixanol density gradient. Fractions were analyzed by Western blotting with sera recognizing GFP (upper blot) or RV N, P, and M proteins (lower
blot). (C) Incorporation of eGFP-P into gradient-purified SAD L16 virions from eGFP-P expressing cells. Fractions were analyzed with RV N, P,
and M protein-specific sera.
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patterns were not observed with purified supernatants from
noninfected eGFP-P-expressing cells (Fig. 4E) or with wt viri-
ons (Fig. 4F), indicating that the fluorescent dots represent
single extracellular, labeled virions. To further characterize the
fluorescent structures observed, immunostaining of the unfixed
and unpermeabilized virions was performed with antibodies
specific for different virus proteins and Cy3-labeled secondary
antibodies. Incubation with an antibody recognizing the viral
surface glycoprotein G resulted in costaining (yellow) of most
of the dots (Fig. 4B). Antibodies to the internal matrix protein
M, which is located underneath the viral lipid bilayer,
costained only a few dots (Fig. 4C), most probably as a result
of disruption of the viral membrane during the course of virus
purification. A similar staining was observed for the nucleo-
protein N, a component of the inner RNP (Fig. 4D). These
data strongly suggest that the punctuate structures observed by
confocal microscopy represented intact fluorescent RV parti-
cles.
Cell binding and uptake of fluorescent virions. To further
investigate the biological behavior of green fluorescent virions,
cell infection experiments were performed. To monitor bind-
ing to target cells, BSR cells grown in suspension were incu-
bated with gradient-purified SAD P(eGFP-P) for 2 h at 4°C,
thereby preventing receptor-mediated endocytosis. Typical
green dots associated with the surface of propidium iodide-
counterstained cells could be visualized by confocal micros-
copy (Fig. 5A, top). The dots were of homogenous size, less
than 1 m, and were present exclusively at the surface of cells.
These dots were not present in preparations of mock-incu-
bated cells (Fig. 5A, bottom), suggesting that they represent
virus particles. Notably, when virus-neutralizing antibodies
were added prior to incubation with the cells, fluorescent sig-
nals were also associated with the surface of cells. However,
the fluorescent structures were much larger (1 m), suggest-
ing that they represent cross-linked virus aggregates (Fig. 5A,
middle).
To further monitor the fate of fluorescent virions during cell
entry, binding assays were performed as above, followed by a
temperature shift to 37°C, which should allow receptor-medi-
ated endocytosis. After 30 min at 37°C, the nonneutralized
green dots were found internalized into intracellular vesicles
(Fig. 5B, top). In contrast, the vast majority of the larger
cross-linked complexes remained bound at the cell surface,
although some of the complexes were also internalized (Fig.
5B, middle). Such temperature-dependent internalization and
accumulation of dots in large vesicular structures indicate that
eGFP-labeled virus particles were internalized by receptor-
mediated endocytosis as described for natural RV.
Recombinant RV expressing eGFP-P fusion protein: live
interaction of eGFP-P with DLC1. Successful complementa-
FIG. 4. Autofluorescence of eGFP-P-containing SAD P virions and coimmunostaining for viral proteins. (A to D) Density gradient-purified
SAD P virions complemented with eGFP-P were adhered to glass coverslips and directly analyzed by confocal laser-scanning microscopy (A) or
were immunostained (red fluorescence) with sera recognizing RV G (B), M (C), or N (D). (E) Negative control: no virus, anti-RV G immunostain.
(F) SAD L16 virions stained with anti-G antibodies. Overlays of the eGFP-P fluorescence (green) and of the immunostainings (red) are shown.
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tion of SAD P in the eGFP-P expressing cell line to yield
fluorescent intact virions led us to construct a full-length RV
cDNA encoding the eGFP-P fusion protein instead of P (Fig.
6A). Successful rescue of viable virus from cDNA in standard
transfection experiments was indicated by the appearance of
the typical fluorescent inclusion bodies in foci of transfected
BSR T7/5 cells at 5 days posttransfection and their further
spread throughout the culture. In standard virus stock prepa-
rations, SAD eGFP-P virus yielded infectious titers of 2  106
focus-forming units (FFU)/ml, which is about 100-fold lower
than those of the parental SAD L16 virus. Infection of cells
and spread in cell culture could be monitored by fluorescence
microscopy (Fig. 6B). Control immunostaining of the RV N
protein revealed that all infected cells expressed eGFP-P pro-
tein (not shown), confirming the absence of virus in which the
GFP sequence had been deleted during virus amplification. In
live cells, green fluorescence was confined to the cytoplasm and
was not observed in the nucleus, as is the case with a virus
expressing GFP from an extra gene (not shown).
Interactions of the virus-derived fluorescent eGFP-P fusion
with other virus proteins were analyzed in more detail by im-
mune staining of the RV N, P, or L protein and examination by
confocal laser-scanning microscopy. Both N and L most exclu-
sively colocalized with eGFP-P in the typical inclusion bodies
FIG. 5. Cell binding and internalization of fluorescent virus. (A) Binding at 4°C of density gradient-purified SAD P(eGFP-P) to the cell
surface. BSR cells were incubated for 2 h at 4°C with virus, fixed, and counterstained with propidium iodide. Small green dots (1 m) were
detectable at the cell surface (top row). Neutralization with anti-G antibodies prior to incubation with cells resulted in larger aggregates (1 m
[middle row]) that were still able to attach. Analysis of multiple sections of cells revealed that fluorescent signals were detectable exclusively at the
cell surface. No comparable signals were obtained in the absence of virus (bottom row). (B) Internalization of bound SAD P virus particles into
large vesicular structures was observed after subsequent temperature shift to 37°C (top row). Most neutralized virus (anti-G antibodies) remained
at the cell surface; however, some virus aggregates were also internalized (middle row). No green fluorescence was observed in cells not infected
with SAD P(eGFP-P) virus (bottom row). All laser scans shown in the figure were made at identical parameter settings.
FIG. 6. Recovery of autonomously replicating RV expressing the eGFP-P fusion. (A) Genome organization of SAD L16 and SAD eGFP-P in
which eGFP is fused to the N terminus of P. (B) Spread of SAD eGFP-P in noncomplementing BSR T7/5 infected at a MOI of 0.001 observed
in live cells by fluorescence microscopy at the indicated time points. (C) Expression of eGFP-P in cells infected with SAD P at a MOI of 1 after
2 days by Western blots with the indicated sera. n.i., not infected.
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FIG. 7. Interaction of eGFP-P with viral proteins (A) and cellular DLC1 (B). (A) SAD eGFP-P-infected BSR T7/5 cells were fixed at 2 days
postinfection, immunostained with sera recognizing the RV N, G, or L proteins (red fluorescence), and analyzed by confocal laser-scanning
microscopy. As a negative control, the infected cells were only incubated with fluorophor-conjugated secondary antibody (first column). (B) A cell
line constitutively expressing DsRed-tagged DLC1 was infected with SAD eGFP-P and a mutant virus lacking the DLC1 binding site, SAD
eGFP-PI. Autofluorescence of eGFP-P (green) and DsRed-DLC1 (red) was observed in live cells 1 day postinfection by conventional epifluo-
rescence microscopy. Whereas DsRed perfectly colocalized with the SAD eGFP-P inclusion bodies (upper lane, arrows), no colocalization was
observed in cells infected with the inclusion bodies of SAD eGFP-PI. Right-hand column, fluorescence and phase contrast.
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(Fig. 7A). As expected, G protein was located predominantly
in Golgi-endoplasmic reticulum compartments and at the cy-
toplasm membrane and did not co-localize with eGFP-P.
RV P protein interacts with cellular DLC1. To check
whether eGFP-P has retained this feature, a cell line express-
ing DLC1 fused to red fluorescent protein DsRed was gener-
ated as described in Materials and Methods and was infected
with SAD eGFP-P virus. At 1 day postinfection, the distribu-
tion of DLC1-DsRed in living cells was analyzed (Fig. 7B, top).
Most eGFP-P inclusion bodies showed red fluorescence, dem-
onstrating interaction of the DLC1 and P subunits of the fusion
proteins. To confirm the specificity of the interaction, an SAD
eGFP-P mutant virus was generated in which the binding motif
for DLC1 was replaced by a stretch of 8 alanine residues, SAD
eGFP-PI. On infection of DLC1-dsRED cells with the mutant,
costaining of inclusion bodies was no longer observed (Fig. 7B,
bottom), demonstrating that eGFP-PI has lost the specific abil-
ity of eGFP-P to bind to DLC1-DsRed.
DISCUSSION
The availability of proteins tagged with GFP or other
autofluorescent proteins, combined with progress in optical
imaging, has recently allowed us to address the dynamics of
many biological processes in living cells (15). This technology is
particularly attractive to monitor virus infection in vitro and in
vivo. Compared to chemical labeling, which allows input virus
to be tracked (11, 22, 28, 37, 38), genetic labeling of virus
proteins allows us to study all aspects of the virus life cycle in
real time. For instance, successful labeling by GFP has been
reported for human immunodeficiency virus, herpes simplex
virus, and rotavirus particles (3, 12, 29). Structural and func-
tional constraints of highly organized viruses, such as rhabdovi-
ruses, however, may preclude the inclusion of entire fluores-
cent proteins or protein domains. We report here the
successful construction of a viable, fluorescent RV which be-
haves like natural virus in many aspects and which allows live
tracking of virus and virus components throughout the viral
live cycle. Of note, even single virus particles were detectable
by conventional live fluorescence microscopy, which is highly
preferable over integrated imaging for kinetic studies.
Several reasons argued for the strategy to select the P pro-
tein for fusion with eGFP. Since P is a component of the viral
RNP, fluorescent P therefore allows tracing not only of extra-
cellular virions but also of RNPs following entry into cells and
uncoating. Of the RNPs, P is of intermediate abundance. With
approximately 450 copies of P present in VSV RNPs (40), it
greatly exceeds the 120 molecules of eGFP required to visual-
ize single rotavirus particles (3). Previously, an elegant study
described successful labeling of the L protein of measles virus
(Paramyxoviridae) by inserting GFP into an internal flexible
loop of the protein and without disrupting its basic functions in
RNA synthesis (14). However, single virus particles have not
been observed, probably due to the lower content of L in
RNPs. Approximately 50 copies of L were reported to be
present in VSV RNPs (40). Approaches to labeling rhabdovi-
rus proteins have so far been confined to the G protein of
VSV. However, GFP fused to the cytoplasmic tail of VSV G
allowed the generation of recombinant virus only when the
authentic G protein was coexpressed (10).
Since RV P is instrumental in several essential virus func-
tions, we first wanted to assess the functions of P proteins with
N- and C-terminal eGFP extensions in virus complementation
assays. We therefore constructed a recombinant P-deficient
RV (SAD P) and a P-cell line in which this virus could be
amplified. The subsequent establishment of cell lines that ex-
press either P-eGFP or eGFP-P fusion proteins allowed ver-
satile testing of protein functions related to virus gene expres-
sion and formation of virions.
RV gene expression could be visualized simply by infection
and subsequent fluorescence microscopy. The redistribution of
the diffuse cytoplasmic green fluorescence into the typical in-
clusion bodies demonstrated successful expression of N from
the SAD P genome (Fig. 1). Moreover, the appearance of
inclusion bodies, first in single cells and later in neighboring
cells, illustrated virus formation and spread (not shown) and
provided strong evidence that both eGFP-P and P-eGFP were
able to support the entire virus life cycle. This was confirmed
by the detection of infectious virions in the cell culture and
their repeated passage in the complementing cells.
Although both P fusion proteins were able to rescue the P
deficiency of SAD P, both were obviously disrupted in P
functions. Moreover, fusion of eGFP to either the N terminus
or C terminus resulted in different phenotypes, as may have
been expected from the complex organization of the RV P
protein and, in particular, the importance of the terminal re-
gions of the P protein. The first 19 residues of P represent a
binding site for L (6), whereas the C terminus of P is involved
in binding to N (5, 6).
It was therefore interesting that SAD P mRNA transcrip-
tion was more effective in P-eGFP-expressing cells than in
eGFP-P expressing cells, in spite of higher levels of the latter
protein (Fig. 2). The decreased efficiency of eGFP-P in gene
expression may therefore be due to steric hindrance, by the
N-terminal GFP, of proper formation of the viral RNA poly-
merase complex, which, in VSV, is thought to contain three P
molecules (19). The interesting observation of impaired gene
expression of SAD L16 in eGFP-P-expressing cells may also be
explained by a dominant negative effect of the eGFP-P fusion
on the polymerase complex. Either incorporation of an
eGFP-P molecule in the multimeric polymerase complex, lead-
ing to reduced activity, or a reduced binding of the viral poly-
merase to N/eGFP-P complexes might be responsible. In ad-
dition, the N-terminal extension of eGFP-P should abolish the
expression of a series of N-terminally truncated P proteins (P2,
P3, and P4) which are expressed in wt RV-infected cells from
the P gene by translation initiation at downstream in-frame
initiation codons (4). However, the recovery of viable SAD
eGFP-P virus illustrated that these truncated forms of P do not
represent essential virus proteins. Moreover, the dominant
negative effect of eGFP-P on RNA synthesis of SAD L16,
which does express the truncated P forms (not shown), strongly
suggests that the intrinsic functions of the eGFP-P full-length
protein rather than the lack of truncated P proteins is respon-
sible for the poor RNA synthesis of SAD eGFP-P.
Compared to eGFP-P, the C-terminally extended P-eGFP
showed less impairment in RNA synthesis; however, it was less
effective in supporting infectious-virus formation. Comparison
of supernatant virions from complementing cell lines indicated
a less efficient release of virus particles from SAD P-infected
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P-eGFP-expressing cells (Fig. 3A). The C-terminal moiety of
RV P is involved in N binding. In particular, the C-terminal
residues aa 268 to 297 were reported to strongly bind N (5).
Thus, the defect of P-eGFP in virus particle formation might
be due to an impairment of N binding. If so, however, it is
notable that this defect in N binding did not greatly affect RNA
replication, which is thought to depend on proper P/N inter-
action and interaction of the P/L polymerase with the RNP
template. The poor formation of virus particles in P-eGFP-
expressing cells is most probably due to its poor activity in
assembly (see above; Fig. 2). In addition, the expression levels
may be limiting, thus contributing to the low-efficiency virus
production.
In the approach of generating fluorescent RV virions similar
to wt RV, the phenotype of eGFP-P with reduced RNA syn-
thesis and reasonable virus formation was preferable to that of
P-eGFP, where viral RNA and protein accumulation was ex-
pected due to more severe defects in virus assembly. There-
fore, eGFP-complemented SAD P virus and recombinant
SAD eGFP-P virus were used for further analysis of fluores-
cent RV. Comigration of eGFP-P with the virion marker pro-
teins N and M in density gradients demonstrated the formation
of typical RV virions and efficient incorporation of the eGFP-
tagged P protein. As already suggested by the occurrence of
strong Western blot signals (Fig. 3B), the level of incorporated
eGFP-P was high enough to enable detection of extracellular
virus particles by confocal laser-scanning microscopy (Fig. 4)
and conventional epifluorescence microscopy (not shown).
Moreover, a series of different experiments demonstrated that
even single virus particles could be identified. Untreated puri-
fied virions appeared as green individual dots of homogenous
size. Staining with antibodies against external (G) and internal
(M and N) virus proteins supported the identity of the dots as
individual virus particles rather than protein aggregates. Vir-
tually all dots stained for the surface G protein; some, in which
the membrane was probably disrupted, stained for M; and
virtually none stained for the RNP protein P. This is in agree-
ment with the proposed structure of RV, with a tight M protein
layer located underneath the lipid envelope, completely pro-
tecting the RNP from access by antibodies (32).
Results of binding and internalization assays also suggest
that we have observed single and intact virus particles which
behave like natural virus. RV enters the cells by receptor-
mediated endocytosis (39). Binding of fluorescent dots of uni-
form size to the surface of cells was demonstrated at low
temperature. In the presence of neutralizing antibodies, fluo-
rescent aggregates of larger and different size were present,
some of which were also bound to the cell surface. Increasing
the temperature to 37°C then allowed internalization of the
individual dots into vesicles, within 30 min, reflecting virus
uptake by receptor-mediated endocytosis (Fig. 5B). Also, some
of the large aggregates formed by neutralizing antibodies were
internalized. These observations are in full agreement with
previous studies showing that binding of antibody-cross-linked
RV to cells is still possible and internalization is not completely
prevented (13). This indicates typical attachment and entry of
SAD eGFP-P into target cells, suggesting that this virus is a
promising tool to further dissect molecular and kinetic details
of RV binding, uptake, membrane fusion, and uncoating.
Further experiments with SAD eGFP-P were aimed at val-
idating whether some prominent function of authentic P in the
interaction with host cell proteins is maintained by eGFP-P.
RV P has been described to efficiently bind DLC1 (27, 34).
Although deletion of the DLC1 binding site of P does not
affect virus transcription and growth in standard cell culture
(30, 33; unpublished data), a role of wt P in the intracellular
retrograde transport of RNPs along microtubules was sug-
gested, with a potentially important impact on the spread and
pathogenesis of RV. To examine the interaction of P with
DLC1 in live cells, a cell line was generated that constitutively
expressed DsRed-labeled DLC1 as well as a SAD eGFP-P
mutant virus in which the DCL1 binding motif was replaced
with a stretch of alanine residues (SAD eGFP-PI; see Materi-
als and Methods). This modification in P did not change the
growth characteristics of the virus in BSR cultures (not shown).
On infection with SAD eGFP-P, DsRed DCL1 colocalized
with viral inclusion bodies. eGFP-P was exclusively responsible
for recruitment of DsRed-DLC1 into the inclusion bodies,
since in SAD eGFP-PI-infected cells, colocalization was never
observed (Fig. 7). The availability of recombinant RV express-
ing fluorescent P now also provides the possibility of directly
monitoring the movement of virus or viral RNPs in more
specialized cell cultures such as neurons, or in vivo, and ad-
dressing the disputed question whether dynein motor transport
of intracellular RNPs or transport of vesicles containing entire
virus makes the greater contribution to the famous retrograde
axonal transport of RV to the central nervous system.
In summary, tagging of the RV P with eGFP-P appears to
allow many aspects of the entire RV life cycle. For instance,
monitoring of RV binding to cells and neurons in vitro and in
vivo may facilitate investigations of the distribution and nature
of RV receptors, virus endocytosis, and membrane fusion. As
viral RNPs are labeled, release of the RNP into the cytoplasm,
uncoating of the RNP from the M layer (35), and onset of
RNA synthesis may be tracked as well. As for studies on the
mechanisms involved in entry, approaches to inhibit virus entry
are more easily done with fluorescent virions and may be
automated in the future. Further work will reveal whether the
assembly and egress of rhabdovirus, which seems to usurp
cellular vesicle transport mechanisms and budding (24, 25),
can also be visualized in live cells.
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